0001193125-12-337716.txt : 20120806 0001193125-12-337716.hdr.sgml : 20120806 20120806160542 ACCESSION NUMBER: 0001193125-12-337716 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120806 DATE AS OF CHANGE: 20120806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABIOMED INC CENTRAL INDEX KEY: 0000815094 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042743260 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09585 FILM NUMBER: 121009889 BUSINESS ADDRESS: STREET 1: 22 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787775410 MAIL ADDRESS: STREET 1: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 10-Q 1 d366941d10q.htm FORM 10-Q Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission file number 001-09585

 

 

ABIOMED, INC.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   04-2743260

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

22 CHERRY HILL DRIVE

DANVERS, MASSACHUSETTS 01923

(Address of principal executive offices, including zip code)

(978) 646-1400

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is, a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   x
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of July 31, 2012, there were 39,527,727 shares outstanding of the registrant’s Common Stock, $.01 par value.

 

 

 


Table of Contents

ABIOMED, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

 

         Page  

PART I - FINANCIAL INFORMATION:

  

Item 1.

 

Financial Statements

     3   
 

Consolidated Balance Sheets as of June 30, 2012 (unaudited) and March 31, 2012

     3   
 

Consolidated Statements of Operations for the three months ended June 30, 2012 and 2011 (unaudited)

     4   
 

Consolidated Statements of Comprehensive Income (Loss) for the three months ended June 30, 2012 and 2011 (unaudited)

     5   
 

Consolidated Statements of Cash Flows for the three months ended June 30, 2012 and 2011 (unaudited)

     6   
 

Notes to Consolidated Financial Statements (unaudited)

     7   

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     15   

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

     20   

Item 4.

 

Controls and Procedures

     21   

PART II - OTHER INFORMATION:

  

Item 1.

 

Legal Proceedings

     22   

Item 1A.

 

Risk Factors

     22   

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

     22   

Item 3.

 

Defaults Upon Senior Securities

     22   

Item 4.

 

Mine Safety Disclosures

     22   

Item 5.

 

Other Information

     22   

Item 6.

 

Exhibits

     23   

SIGNATURES

     24   

ABIOMED, ABIOCOR, cVAD and Symphony are trademarks of ABIOMED, Inc., and are registered in the United States and certain foreign countries. BVS is a trademark of ABIOMED, Inc. and is registered in the United States. AB5000 is a trademark of ABIOMED, Inc. IMPELLA and RECOVER are trademarks of Abiomed Europe GmbH, a subsidiary of ABIOMED, Inc., and are registered in the United States and certain foreign countries.

 

2


Table of Contents

PART 1. FINANCIAL INFORMATION

 

ITEM 1: FINANCIAL STATEMENTS

ABIOMED, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

     June 30, 2012     March 31, 2012  
     (unaudited)        

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 3,989      $ 5,990   

Short-term marketable securities

     77,233        71,233   

Accounts receivable, net

     18,343        20,458   

Inventories

     12,477        11,142   

Prepaid expenses and other current assets

     1,749        1,716   
  

 

 

   

 

 

 

Total current assets

     113,791        110,539   

Property and equipment, net

     6,337        6,378   

Intangible assets, net

     —          115   

Goodwill

     34,741        36,846   

Other long-term assets

     33        33   
  

 

 

   

 

 

 

Total assets

   $ 154,902      $ 153,911   
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

Current liabilities:

    

Accounts payable

   $ 6,294      $ 6,910   

Accrued expenses

     10,134        12,480   

Deferred revenue

     2,687        3,025   
  

 

 

   

 

 

 

Total current liabilities

     19,115        22,415   

Long-term deferred tax liability

     4,890        4,799   

Other long-term liabilities

     377        400   
  

 

 

   

 

 

 

Total liabilities

     24,382        27,614   
  

 

 

   

 

 

 

Commitments and contingencies (Note 9)

    

Stockholders’ equity:

    

Class B Preferred Stock, $.01 par value

     —          —     

Authorized - 1,000,000 shares; Issued and outstanding - none

    

Common stock, $.01 par value

     395        393   

Authorized - 100,000,000 shares; Issued - 39,559,821 shares at June 30, 2012 and 39,323,708 shares at March 31, 2012;

    

Outstanding - 39,497,477 shares at June 30, 2012 and 39,272,754 shares at March 31, 2012

    

Additional paid in capital

     405,688        401,771   

Accumulated deficit

     (270,156     (273,275

Treasury stock at cost - 62,344 shares at June 30, 2012 and 50,954 shares at March 31, 2012

     (1,065     (827

Accumulated other comprehensive loss

     (4,342     (1,765
  

 

 

   

 

 

 

Total stockholders’ equity

     130,520        126,297   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 154,902      $ 153,911   
  

 

 

   

 

 

 

The accompanying notes are an integral part of the consolidated financial statements (unaudited)

 

3


Table of Contents

ABIOMED, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)

 

     Three Months Ended June 30,  
     2012     2011  

Revenue:

    

Product revenue

   $ 38,647      $ 27,166   

Funded research and development

     136        189   
  

 

 

   

 

 

 
     38,783        27,355   
  

 

 

   

 

 

 

Costs and expenses:

    

Cost of product revenue

     7,446        5,891   

Research and development

     6,712        7,324   

Selling, general and administrative

     20,953        18,176   

Amortization of intangible assets

     111        385   
  

 

 

   

 

 

 
     35,222        31,776   
  

 

 

   

 

 

 

Income (loss) from operations

     3,561        (4,421
  

 

 

   

 

 

 

Other (expense) income:

    

Investment (expense) income, net

     (2     4   

Other expense, net

     (4     (81
  

 

 

   

 

 

 
     (6     (77
  

 

 

   

 

 

 

Income (loss) before income tax provision

     3,555        (4,498

Income tax provision

     436        96   
  

 

 

   

 

 

 

Net income (loss)

   $ 3,119      $ (4,594
  

 

 

   

 

 

 

Basic net income (loss) per share

   $ 0.08      $ (0.12

Basic weighted average shares outstanding

     39,144        38,268   

Diluted net income (loss) per share

   $ 0.08      $ (0.12

Diluted weighted average shares outstanding

     41,549        38,268   

The accompanying notes are an integral part of the consolidated financial statements (unaudited)

 

4


Table of Contents

ABIOMED, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)

(in thousands, except per share data)

 

     Three Months Ended
June 30,
 
     2012     2011  

Net income (loss)

   $ 3,119      $ (4,594

Other comprehensive (loss) income

    

Foreign currency translation (losses) gains

     (2,577     1,026   
  

 

 

   

 

 

 

Total other comprehensive (loss) income

     (2,577     1,026   
  

 

 

   

 

 

 

Comprehensive income (loss)

   $ 542        (3,568
  

 

 

   

 

 

 

The accompanying notes are an integral part of the consolidated financial statements (unaudited)

 

5


Table of Contents

ABIOMED, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

 

     Three Months Ended June 30,  
     2012     2011  

Operating activities:

    

Net income (loss)

   $ 3,119      $ (4,594

Adjustments required to reconcile net income (loss) to net cash provided by (used for) operating activities:

    

Depreciation and amortization

     842        1,046   

Bad debt expense

     8        15   

Stock-based compensation

     2,679        2,332   

Write-down of inventory

     252        156   

Deferred tax provision

     90        96   

Changes in assets and liabilities:

    

Accounts receivable

     2,032        847   

Inventories

     (1,982     (1,601

Prepaid expenses and other assets

     (65     220   

Accounts payable

     (300     (1,360

Accrued expenses and other long-term liabilities

     (2,024     (5,443

Deferred revenue

     (333     (270
  

 

 

   

 

 

 

Net cash provided by (used for) operating activities

     4,318        (8,556

Investing activities:

    

Purchases of short-term marketable securities

     (11,500     (5,001

Proceeds from the sale and maturity of short-term marketable securities

     5,500        4,500   

Expenditures for property and equipment

     (470     (472
  

 

 

   

 

 

 

Net cash used for investing activities

     (6,470     (973

Financing activities:

    

Proceeds from the exercise of stock options

     1,228        7,629   

Payments in lieu of issuance of common stock for minimum payroll taxes

     (238     —     
  

 

 

   

 

 

 

Net cash provided by financing activities

     990        7,629   

Effect of exchange rate changes on cash

     (839     220   
  

 

 

   

 

 

 

Net decrease in cash and cash equivalents

     (2,001     (1,680

Cash and cash equivalents at beginning of period

     5,990        5,831   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 3,989      $ 4,151   
  

 

 

   

 

 

 

Supplemental disclosures:

    

Fixed asset additions included in accounts payable

   $ 92      $ 44   

The accompanying notes are an integral part of the consolidated financial statements (unaudited)

 

6


Table of Contents

ABIOMED, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(In thousands, except share data)

Note 1. Nature of Business and Basis of Preparation

Abiomed, Inc. (the “Company” or “Abiomed”) is a leading provider of mechanical circulatory support devices and offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company’s products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting and in accordance with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by GAAP for complete financial statements. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2012 that has been filed with the Securities and Exchange Commission, or SEC.

In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period may not be indicative of results for the full fiscal year.

There have been no changes in the Company’s significant accounting policies for the three months ended June 30, 2012 as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2012 that has been filed with the SEC.

Recently Adopted Accounting Standards

During the first quarter of fiscal 2013, the Company adopted Accounting Standards Update, or ASU, No ASU 2011-05, Presentation of Comprehensive Income. ASU 2011-05 requires entities to present net income and other comprehensive income in either a single continuous statement of comprehensive income or in two separate, but consecutive, statements of net income and other comprehensive income. In December 2011, the Financial Accounting Standards Board, or FASB, issued ASU No. 2011-12, Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05. ASU 2011-12 amended ASU 2011-05 by indefinitely deferring the requirement under ASU 2011-05 to present reclassification adjustments out of accumulated other comprehensive income by a component in both the statement in which net income is presented and the statement in which other comprehensive income is presented. The Company has adopted ASU 2011-05 with retrospective application as required, except for the components of ASU 2011-05 which were indefinitely deferred by ASU 2011-12 and has included in these condensed consolidated financial statements separate unaudited statements of comprehensive income. The adoption of this standard did not impact the Company’s condensed consolidated financial statements other than this change in presentation

In September 2011, the FASB issued ASU No. 2011-08, Testing for Goodwill Impairment. ASU 2011-08 amended current goodwill impairment testing guidance by providing entities with an option to perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The Company adopted ASU 2011-08 during the first quarter of fiscal 2013 and will apply the provisions to its annual impairment assessment to be conducted during the third quarter of fiscal 2013.

 

7


Table of Contents

Note 2. Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted average shares outstanding any potential dilutive securities outstanding for the period. Potential dilutive securities include stock options, restricted stock awards, restricted stock units, performance-based stock awards and shares to be purchased under the employee stock purchase plan. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. The Company’s basic and diluted net income (loss) per share for the three months ended June 30, 2012 and 2011 were as follows (in thousands, except per share data):

 

     Three Months Ended
June 30,
 
     2012      2011  

Basic Net Income (Loss) Per Share

     

Net income (loss)

   $ 3,119       $ (4,594
  

 

 

    

 

 

 

Weighted average shares used in computing basic net income (loss) per share

     39,144         38,268   
  

 

 

    

 

 

 

Net income (loss) per share - basic

   $ 0.08       $ (0.12
  

 

 

    

 

 

 

 

     Three Months Ended
June 30,
 
     2012      2011  

Diluted Net Income (Loss) Per Share

     

Net income (loss)

   $ 3,119       $ (4,594
  

 

 

    

 

 

 

Weighted average shares used in computing basic net income (loss) per share

     39,144         38,268   

Effect of dilutive securities

     2,405         —     
  

 

 

    

 

 

 

Weighted average shares used in computing diluted net income (loss) per share

     41,549         38,268   

Net income (loss) per share - diluted

   $ 0.08       $ (0.12
  

 

 

    

 

 

 

For the three months ended June 30, 2012, approximately 490,000 shares underlying outstanding securities were not included in the computation of diluted earnings per share primarily related to out-of-the-money stock options and performance-based awards where milestones were not met. For the three months ended June 30, 2011, approximately 3,565,000 shares underlying stock options and approximately 837,000 restricted shares were excluded from the calculation of diluted weighted average shares outstanding because the Company incurred a loss in the period, and to include them would have been anti-dilutive.

Note 3. Fair Value Measurements

Fair value is defined as the price that would be received for the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Level 1 primarily consists of financial instruments whose values are based on quoted market prices such as exchange-traded instruments and listed equities.

Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, prepayment speeds, default rates, loss severity, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.

 

8


Table of Contents

Level 3 is comprised of unobservable inputs that are supported by little or no market activity. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.

The following table presents the Company’s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above (in thousands):

 

     Quoted
Prices in
Active
Markets
(Level 1)
     Using
Significant
Other
Observable
Inputs
(Level 2)
     Using
Significant
Unobservable
Inputs

(Level 3)
     Total
Carrying
Value
 

At June 30, 2012:

           

U.S. Treasury securities

   $ 77,233         —           —         $ 77,233   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     Quoted
Prices in
Active
Markets
(Level 1)
     Using
Significant
Other
Observable
Inputs

(Level 2)
     Using
Significant
Unobservable
Inputs

(Level 3)
     Total
Carrying
Value
 

At March 31, 2012:

           

U.S. Treasury securities

   $ 71,233         —           —         $ 71,233   
  

 

 

    

 

 

    

 

 

    

 

 

 

The Company records these marketable securities at fair value and has classified all of its investments as Level 1 since quoted market prices in active markets are readily available.

Note 4. Inventories

The components of inventories are as follows (in thousands):

 

     June 30,
2012
     March 31,
2012
 

Raw materials and supplies

   $ 4,390       $ 3,586   

Work-in-progress

     3,946         4,098   

Finished goods

     4,141         3,458   
  

 

 

    

 

 

 
   $ 12,477       $ 11,142   
  

 

 

    

 

 

 

The Company’s inventories relate to its circulatory care product lines, primarily the AB5000, BVS 5000 and Impella product platforms. Finished goods and work-in-process inventories consist of direct material, labor and overhead. During each of the three months ended June 30, 2012 and 2011, the Company recorded $0.3 million and $0.2 million, respectively, in write-downs of inventory.

From time to time, the Company loans finished goods inventory on a short-term basis to customers for demonstration purposes and this inventory is amortized over a one to five-year life. The Company had $0.3 million and $0.4 million in demo inventory at June 30, 2012 and March 31, 2012, respectively.

 

9


Table of Contents

Note 5. Goodwill

The carrying amount of goodwill at June 30, 2012 and March 31, 2012 was $34.7 million and $36.8 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, or Impella, in 2005. The goodwill activity for the three months ended June 30, 2012 is as follows (in thousands):

 

Balance at March 31, 2012

   $ 36,846   

Exchange rate impact

     (2,105
  

 

 

 

Balance at June 30, 2012

   $ 34,741   
  

 

 

 

Note 6. Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

     June 30,
2012
     March 31,
2012
 

Employee compensation

   $ 5,861       $ 9,272   

Research and development

     1,238         519   

Sales taxes

     1,108         948   

Warranty

     800         726   

Professional, accounting and auditing fees

     383         427   

Other

     744         588   
  

 

 

    

 

 

 
   $ 10,134       $ 12,480   
  

 

 

    

 

 

 

Employee compensation consists primarily of accrued bonuses, accrued commissions and accrued employee benefits at June 30, 2012 and March 31, 2012.

 

10


Table of Contents

Note 7. Stock-Based Compensation

The following table summarizes stock-based compensation expense by financial statement line item in the Company’s consolidated statements of operations for the three months ended June 30, 2012 and 2011 (in thousands):

 

     Three Months Ended
June 30,
 
     2012      2011  

Cost of product revenue

   $ 146       $ 76   

Research and development

     563         500   

Selling, general and administrative

     1,970         1,756   
  

 

 

    

 

 

 
   $ 2,679       $ 2,332   
  

 

 

    

 

 

 

The components of stock-based compensation for the three months ended June 30, 2012 and 2011 were as follows (in thousands):

 

     Three Months Ended
June 30,
 
     2012      2011  

Stock options

   $ 970       $ 903   

Restricted stock

     338         1,156   

Restricted stock units

     1,323         256   

Employee stock purchase plan

     48         17   
  

 

 

    

 

 

 
   $ 2,679       $ 2,332   
  

 

 

    

 

 

 

Stock Options

The following table summarizes the stock option activity for the three months ended June 30, 2012:

 

     Shares
Underlying
Options

(in  thousands)
    Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Term (years)
     Aggregate
Intrinsic
Value

(in  thousands)
 

Outstanding at April 1, 2012

     4,268      $ 10.42         6.03      

Granted

     303        22.44         

Exercised

     (161     7.62         

Cancelled and expired

     (31     9.21         
  

 

 

   

 

 

       

Outstanding at June 30, 2012

     4,379      $ 11.34         6.01       $ 50,278   
  

 

 

   

 

 

       

Exercisable at June 30, 2012

     3,327      $ 10.72         5.29       $ 40,249   
  

 

 

   

 

 

       

Options vested and expected to vest at June 30, 2012

     4,133      $ 11.33         5.89       $ 47,479   
  

 

 

   

 

 

       

The aggregate intrinsic value of options exercised was $2.5 million for the three months ended June 30, 2012. The total fair value of options vested during the three months ended June 30, 2012 was $2.0 million.

The remaining unrecognized stock-based compensation expense for unvested stock option awards at June 30, 2012 was approximately $5.0 million, net of forfeitures, and the weighted-average period over which this cost will be recognized is 2.9 years.

 

11


Table of Contents

The Company estimates the fair value of each stock option granted at the grant date using the Black-Scholes option valuation model. The fair value of options granted during the three months ended June 30, 2012 and 2011 were calculated using the following weighted average assumptions:

 

     Three Months Ended
June 30,
 
     2012     2011  

Risk-free interest rate

     0.78     1.83

Expected option life (years)

     4.33        5.30   

Expected volatility

     56.3     51.6

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on the historical volatility of the Company’s stock and adjusted for factors not reflected in historical volatility that may be more indicative of future volatility. The Company estimates the expected term of options based on historical exercise trends and estimates of future exercises of unexercised options.

The calculation of the fair value of the options is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures, adjusted to the extent historic forfeitures may not be indicative of forfeitures in the future. In addition, an expected dividend yield of zero is used in the option valuation model, because the Company does not pay cash dividends and does not expect to pay any cash dividends in the foreseeable future.

Restricted Stock and Restricted Stock Units

In addition to stock option grants, the Company also has the ability to grant restricted stock and restricted stock units. Similar to stock options, these restricted stock and restricted stock unit grants are subject to certain vesting criteria. The following table summarizes the activity for the three months ended June 30, 2012:

 

     Three Months Ended
June 30, 2012
 
     Number of
Share (in 000’s)
    Weighted Average
Grant Date

Fair Value
 

Outstanding at April 1, 2012

     871      $ 15.76   

Granted

     361        22.40   

Vested

     (209     13.76   

Forfeited

     (18     20.48   
  

 

 

   

 

 

 

Outstanding at June 30, 2012

     1,005      $ 18.47   
  

 

 

   

 

 

 

The remaining unrecognized compensation expense for outstanding restricted stock awards and restricted stock units, including performance-based awards, as of June 30, 2012 was $12.6 million and the weighted-average period over which this cost will be recognized is 2.4 years.

The weighted average grant-date fair value for restricted stock and restricted stock units granted during the three months ended June 30, 2012 and 2011 was $22.40 and $18.49 per share, respectively. The total fair value of restricted stock and restricted stock units vested during the three months ended June 30, 2012 and 2011 was $2.9 million and $1.5 million, respectively.

Performance Based Awards

Included in the restricted stock and restricted stock units activity discussed above are certain awards granted in fiscal years 2012, 2011 and 2010 that vest subject to certain performance-based criteria.

During the three months ended June 30, 2012, performance-based awards of restricted stock units for the potential issuance of 195,188 shares of common stock were issued to certain executive officers and employees, all of which would vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of June 30, 2012, the Company believes it is probable that the prescribed performance targets will be met for these awards and the compensation expense is being recognized accordingly.

During the three months ended June 30, 2011, performance-based awards of restricted stock units for the potential issuance of 284,000 shares of common stock were issued to certain executive officers and members of the senior management of the Company, all

 

12


Table of Contents

of which would vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. During the year ended March 31, 2012, the Company determined that it met the prescribed targets for 184,000 shares underlying these awards. As of June 30, 2012, the Company believes it is probable that the prescribed performance targets will be met for the remaining 100,000 shares, and the compensation expense is being recognized accordingly.

In June 2010, 311,000 shares of restricted stock and a performance-based award for the potential issuance of 45,000 shares of common stock were issued to certain executive officers and members of the senior management of the Company, all of which would vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. During the year ended March 31, 2011, the Company determined that it met the prescribed performance targets and a portion of these shares and stock options vested. The remaining shares will vest upon satisfaction of prescribed service conditions by the award recipients.

During the three months ended June 30, 2012, the Company recorded $0.9 million in stock-based compensation expense for equity awards in which the prescribed performance milestones have been achieved or are probable of being achieved. The remaining unrecognized compensation expense related to these equity awards at June 30, 2012 is $6.8 million based on the Company’s current assessment of probability of achieving the performance milestones. The weighted-average period over which this cost will be recognized is 2.4 years.

Note 8. Income Taxes

Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to tax benefit carryforwards and to differences between the financial statement amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates. A valuation reserve is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The tax benefit associated with the stock option compensation deductions will be credited to equity when realized.

The Company regularly assesses its ability to realize its deferred tax assets. Assessments of the realization of deferred tax assets require that management consider all available evidence, both positive and negative, and make significant judgments about many factors, including the amount and likelihood of future taxable income. Based on the available evidence and uncertainties surrounding the Company’s ability to continue to generate future taxable income, the Company has recorded valuation allowances to reduce its deferred tax assets to the amount that is more likely than not to be realizable as of June 30, 2012 and March 31, 2012.

As of June 30, 2012, the Company has accumulated a net deferred tax liability of $4.9 million which is the result of the difference in accounting for the Company’s goodwill, which is amortizable over 15 years for tax purposes but not amortizable for book purposes. The net deferred tax liability cannot be offset against the Company’s deferred tax assets since it relates to an indefinite-lived asset and is not anticipated to reverse in the same period.

The Company and its subsidiaries are subject to U.S. federal income tax, as well as income tax of multiple state and foreign jurisdictions. The Company has accumulated significant losses since its inception in 1981. All tax years remain subject to examination by major tax jurisdictions, including the federal government and the Commonwealth of Massachusetts. However, because the Company has net operating loss and tax credit carryforwards which may be utilized in future years to offset taxable income, those years may also be subject to review by relevant taxing authorities if the carryforwards are utilized.

During three months ended June 30, 2012 and 2011, the Company recorded a provision for income taxes of $0.4 million and $0.1 million, respectively. The income tax provision for the three months ended June 30, 2012 is primarily due to $0.2 million of income taxes in Germany that the Company does not expect will be offset by the Company’s net operating loss carryforwards in Germany and therefore expects to pay in cash. The Company also recorded $0.2 million in income taxes related to its deferred tax liability on goodwill and alternative minimum tax in the U.S.

Note 9. Commitments and Contingencies

Litigation

From time to time, the Company is involved in legal and administrative proceedings and claims of various types. While any litigation contains an element of uncertainty, management presently believes that the outcome of each such proceedings or claims which are pending or known to be threatened, or all of them combined, is not expected to have a material effect on the Company’s financial position, and results of operations or cash flows. At June 30, 2012, the Company did not have any material pending litigation.

 

13


Table of Contents

Note 10. Segment and Enterprise Wide Disclosures

The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 70% and 68% of the Company’s total consolidated assets are located within the U.S. as of June 30, 2012 and March 31, 2012, respectively. The remaining assets are located in Europe and are primarily related to the Company’s Impella production facility in Germany, and include goodwill and intangibles of $34.7 million and $37.0 million at June 30, 2012 and March 31, 2012, respectively, associated with the Impella acquisition in May 2005. Total assets in Europe excluding goodwill and intangibles amounted to 7% and 8% of total consolidated assets at June 30, 2012 and March 31, 2012, respectively. International sales (sales outside the U.S. and primarily in Europe) accounted for 5% and 7% of total revenue for the three months ended June 30, 2012 and 2011, respectively.

 

14


Table of Contents
ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD LOOKING STATEMENTS

Abiomed’s discussion of financial condition and results of operations may contain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, market acceptance of our new products, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks detailed in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Report. In particular, we encourage you to review the risks and uncertainties discussed under Item 1A of Part I of our Annual Report on Form 10-K, for the year ended March 31, 2012. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Report or to reflect the occurrence of unanticipated events.

OVERVIEW

We are a leading provider of mechanical circulatory support devices and we offer a continuum of care in heart recovery to heart failure patients. We develop, manufacture and market proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Our products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. We believe heart recovery is the optimal clinical outcome for patients experiencing heart failure because it restores their quality of life. In addition, we believe that for the care of such patients, heart recovery is the most cost-effective solution for the healthcare system.

Our strategic focus and the driver of the most recent revenue growth in our business is the market penetration of our Impella 2.5 product, which received 510(k) clearance in June 2008 for partial circulatory support for up to six hours. We received 510(k) clearance in April 2009 for our Impella 5.0 and Impella LD devices for circulatory support for up to six hours. These devices are larger and provide more blood flow to patients than the Impella 2.5.

We received CE mark approval in Europe for the Impella cVAD in April 2012 and we received Health Canada approval for the Impella cVAD in June 2012. The Impella cVAD was commercially available at selected sites in Europe and Canada during the first quarter of fiscal 2013. The Impella cVAD is not currently approved by the U.S. Food and Drug Administration, or FDA, for sale in the U.S. We currently anticipate that the Impella cVAD will receive 510(k) clearance and be commercially available in the U.S. in the second half of fiscal 2013, although there is no assurance if or when clearance will be received.

In addition, we are currently conducting initial patient use trials outside of the U.S. of the Impella RP. The Impella RP is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow and is intended to provide the flow and pressure needed to compensate for right heart failure. This product is not currently available for sale in the U.S.

Revenues from our other heart recovery products, largely focused on the heart surgery suite, have been lower recently as we have strategically shifted our sales and marketing efforts towards our Impella products and the cath lab. We expect revenues from our non-Impella business, including BVS and AB5000, will continue to decrease in fiscal 2012 as we continue to focus on our Impella products.

In November 2011, we announced Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics and potentially improving quality of life. The device is designed with the primary goal of stabilizing the progression of heart failure and/or recovering/remodeling the heart. We recently conducted the initial first in man implant of Symphony outside the U.S. This product is not currently available for sale in the U.S.

For the three months ended June 30, 2012, we recognized net income of $3.1 million. With the exception of fiscal 2012, we have incurred net losses since our inception. Even though we were profitable in fiscal 2012, we may incur additional losses in the future as we continue to invest in research and development related to our products, conduct clinical studies and registries on our products, expand our commercial infrastructure and invest in new markets such as Japan.

 

15


Table of Contents

Impella 2.5

The Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors. The device is designed primarily for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 2.5 device received 510(k) clearance from the FDA in June 2008 for partial circulatory support for up to six hours, has CE mark approval in Europe for up to five days of use and is approved for use in over 40 countries.

The Impella 2.5 catheter can be quickly inserted via the femoral artery to reach the left ventricle of the heart where it is directly deployed to draw blood out of the ventricle and deliver it to the circulatory system. This function is intended to reduce ventricular work and provide flow to vital organs. The Impella 2.5 is introduced with normal interventional cardiology procedures and can pump up to 2.5 liters of blood per minute.

In August 2007, we received approval from the FDA to begin a high-risk percutaneous coronary intervention, or PCI, pivotal clinical trial, known as the Protect II study, for the Impella 2.5. This pivotal study was to determine the safety and effectiveness of the Impella 2.5 as compared to medical management with an intra-aortic balloon, or IAB, during “high-risk” angioplasty procedures. In December 2010, we announced the termination of the Protect II study based on a futility determination at the planned interim analysis regarding the primary end-point, which we view as likely to have resulted from how rotational atherectomy was performed by investigators in the study.

A November 2011 update to the American College of Cardiology Foundation /American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions Guidelines for Percutaneous Coronary Intervention, for the first time, included Impella in both the emergent and prophylactic hemodynamic support settings.

We are currently conducting USpella, the first U.S. multicenter observational registry collecting clinical data and outcomes for patients supported with Impella 2.5 and 5.0 during elective, urgent and emergent procedures. Currently, there are 41 hospitals in the U.S. and Canada contributing data to the USpella registry.

Impella 5.0 and Impella LD

The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. The Impella 5.0 and Impella LD devices received 510(k) clearance in April 2009, for circulatory support for up to six hours and have CE mark approval in Europe for up to ten days duration and are approved for use in over 40 countries.

The Impella 5.0 can be quickly implanted via a small incision in the femoral artery in the groin using a guide wire to reach the left ventricle of the heart where it can then be directly deployed to draw blood out of the ventricle, deliver it to the arterial system and perfuse the heart muscle. This function is intended to reduce ventricular work. The Impella LD is similar to the Impella 5.0 but is implanted directly through an aortic graft. The Impella 5.0 and Impella LD can pump up to five liters of blood per minute, providing full circulatory support.

Impella cVAD

In December 2011, we announced the Impella cVAD, a new higher flow Impella device, which is implanted via a patient’s femoral artery and provides peak flow of approximately four liters of blood per minute. We received CE mark approval in Europe for the Impella cVAD in April 2012 and we received Health Canada approval for the Impella cVAD in June 2012. The Impella cVAD was commercially available at selected sites in Europe and Canada during the first quarter of fiscal 2013. The Impella cVAD is not currently approved by the U.S. Food and Drug Administration, or FDA, for sale in the U.S. We currently anticipate that the Impella cVAD will receive 510(k) clearance and be commercially available in the U.S. in the second half of fiscal 2013, although there is no assurance if or when clearance will be received.

AB5000 and BVS 5000

We manufacture and sell the AB5000 Circulatory Support System and the BVS 5000 Biventricular Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. We believe the AB5000 and BVS 5000 systems are the only commercially available cardiac assist devices that are approved by the FDA for all indications where heart recovery is the desired outcome, including patients who have undergone successful cardiac surgery and subsequently develop low cardiac output, or patients who suffer from acute cardiac disorders leading to hemodynamic instability.

We have developed a Portable Circulatory Support Driver for both in-hospital and out-of-hospital patients. The Portable Driver is designed to support our AB5000 VAD. We received CE mark approval for our Portable Driver in March 2008. In May 2008, we received conditional approval for the Portable Driver under an investigational device exemption, or IDE, to conduct a U.S. patient discharge study at 20 hospitals for 30 patients. In March 2009, we received FDA approval of our PMA supplement for the AB

 

16


Table of Contents

Portable Driver. This clearance allows for commercial shipment of the device to U.S. hospitals for in hospital and transport use. Out-of-hospital use is being studied in the U.S. in a clinical trial, which, when successfully completed, would allow patients to go home while waiting for recovery.

AbioCor

Our AbioCor implantable replacement heart is the first completely self-contained artificial heart. Designed to sustain the body’s circulation, the AbioCor is intended for end-stage biventricular heart failure patients whose other treatment options have been exhausted. Patients with advanced age, impaired organ function or cancer are generally ineligible for a heart transplant and are potential candidates to receive the AbioCor implantable heart. Once implanted, the AbioCor system does not penetrate the skin, reducing the chance of patient infection. This technology provides patients with mobility and remote diagnostics. AbioCor devices have a life expectancy of 18 to 24 months and can only be implanted in normal to larger sized male patients.

We received a humanitarian device exemption, or HDE, supplement approval from the FDA for product enhancement of the AbioCor in January 2008. HDE approval signifies that no comparable alternative therapy exists for patients facing imminent death due to end-stage biventricular heart failure and allows the AbioCor to be made available to a limited patient population. We have no current plans to seek a broader regulatory approval of the AbioCor. We have not had any AbioCor sales since fiscal 2009, and we do not expect revenues from sales of the AbioCor for the foreseeable future as our primary strategic focus is centered on heart recovery for acute heart failure patients.

Critical Accounting Policies

There have been no significant changes in our critical accounting policies during the three months ended June 30, 2012, as compared to the critical accounting policies disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2012.

Recently Adopted Accounting Standards

During the first quarter of fiscal 2013, we adopted Accounting Standards Update, or ASU, No ASU 2011-05, Presentation of Comprehensive Income. ASU 2011-05 requires entities to present net income and other comprehensive income in either a single continuous statement of comprehensive income or in two separate, but consecutive, statements of net income and other comprehensive income. In December 2011, the Financial Accounting Standards Board, or FASB, issued ASU No. 2011-12, Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05. ASU 2011-12 amended ASU 2011-05 by indefinitely deferring the requirement under ASU 2011-05 to present reclassification adjustments out of accumulated other comprehensive income by a component in both the statement in which net income is presented and the statement in which other comprehensive income is presented. We have adopted ASU 2011-05 with retrospective application as required, except for the components of ASU 2011-05 which were indefinitely deferred by ASU 2011-12 and have included in these condensed consolidated financial statements separate unaudited statements of comprehensive income. The adoption of this standard did not impact our condensed consolidated financial statements other than this change in presentation.

In September 2011, the FASB issued ASU No. 2011-08, Testing for Goodwill Impairment. ASU 2011-08 amended current goodwill impairment testing guidance by providing entities with an option to perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. We adopted ASU 2011-08 during the first quarter of fiscal 2013 and will apply the provisions to our annual impairment assessment to be conducted during the third quarter of fiscal 2013.

 

17


Table of Contents

Results of Operations

The following table sets forth certain consolidated statements of operations data for the periods indicated as a percentage of total revenues (which includes revenues from products and funded research and development) for the three months ended June 30, 2012 and 2011, respectively:

 

     Three Months Ended  
     June 30,  
     2012     2011  

Revenues:

    

Product

     99.6     99.3

Funded research and development

     0.4        0.7   
  

 

 

   

 

 

 

Total revenues

     100.0        100.0   
  

 

 

   

 

 

 

Costs and expenses:

    

Cost of product revenue

     19.2        21.5   

Research and development

     17.3        26.8   

Selling, general and administrative

     54.0        66.4   

Amortization of intangible assets

     0.3        1.4   
  

 

 

   

 

 

 

Total costs and expenses

     90.8        116.1   
  

 

 

   

 

 

 

Income (loss) from operations

     9.2        (16.1
  

 

 

   

 

 

 

Other (expense) income:

    

Other expense, net

     —          (0.3
  

 

 

   

 

 

 
     —          (0.3
  

 

 

   

 

 

 

Income (loss) before income tax provision

     9.2        (16.4

Income tax provision

     1.2        0.4   
  

 

 

   

 

 

 

Net income (loss)

     8.0     (16.8 )% 
  

 

 

   

 

 

 

Three months ended June 30, 2012 compared with the three months ended June 30, 2011

Revenues

Our revenues are comprised of the following (in thousands):

 

     Three Months Ended  
     June 30,  
     2012      2011  

Impella product revenue

   $ 34,676       $ 22,192   

Other products

     2,122         3,424   

Service and other revenue

     1,849         1,550   
  

 

 

    

 

 

 

Total product and service revenues

     38,647         27,166   

Funded research and development

     136         189   
  

 

 

    

 

 

 

Total revenues

   $ 38,783       $ 27,355   
  

 

 

    

 

 

 

Impella product revenue encompasses Impella 2.5, Impella cVAD, Impella 5.0, and Impella LD product sales. Other product revenue includes AB5000, BVS5000 and cannulae product sales. Service and other revenue represents revenue earned on service contracts and maintenance calls.

Total revenues for the three months ended June 30, 2012 increased by $11.4 million, or 42%, to $38.8 million from $27.4 million for the three months ended June 30, 2011. The increase in total revenue was primarily due to higher Impella revenue due to greater utilization in the U.S.

Impella product revenues for the three months ended June 30, 2012 increased by $12.5 million, or 56%, to $34.7 million from $22.2 million for the three months ended June 30, 2011. Most of our Impella revenue was from disposable product sales of Impella 2.5 in the U.S., as we focus on controlled rollouts for new sites and increasing utilization of these products through continued investment in our sales force and physician training.

 

18


Table of Contents

Other product revenues for the three months ended June 30, 2012 decreased by $1.3 million, or 38%, to $2.1 million from $3.4 million for the three months ended June 30, 2011. The decrease in other revenue was due to a decline in BVS and AB5000 disposable sales. We expect that BVS and AB5000 revenue will continue to decline in fiscal 2013 as we focus our sales efforts in the surgical suite on Impella 5.0 and LD.

Service and other revenue for the three months ended June 30, 2012 increased by $0.3 million, or 19%, to $1.9 million from $1.6 million for the three months ended June 30, 2011. The increase in service revenue was primarily due to an increase in service contracts, primarily for Impella consoles.

Cost of Product Revenues

Cost of product revenue for the three months ended June 30, 2012 increased by $1.5 million, or 26%, to $7.4 million from $5.9 million for the three months ended June 30, 2011. Gross margin for the three months ended June 30, 2012 was 81% compared to 79% for the three months ended June 30, 2011. The increase in gross margin was primarily due to higher reorders of Impella product disposable pumps and improved manufacturing efficiency.

Research and Development Expenses

Research and development expenses for the three months ended June 30, 2012 decreased by $0.6 million, or 8%, to $6.7 million from $7.3 million for the three months ended June 30, 2011. The decrease in research and development expenses was due to a decrease in clinical trial expenditures as we completed our work associated with the Protect II trial for the Impella 2.5, partially offset by an increase in spending on product development initiatives associated with Impella RP, Impella cVAD and Symphony. Research and development expenses for the three months ended June 30, 2012 and 2011 included $0.9 million and $2.5 million, respectively, in clinical trial costs primarily associated with our Impella 2.5 U.S. trials. We expect research and development expenses to increase slightly in fiscal 2013 as we continue to focus on new product development initiatives associated with Impella RP and Symphony products.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended June 30, 2012 increased by $2.8 million, or 15%, to $21.0 million from $18.2 million for the three months ended June 30, 2011. The increase in selling, general and administrative expenses was primarily due to an increased field headcount as we continued to build out our commercial efforts in the U.S. and increased spending on marketing initiatives as we continued to educate physicians on the benefits of hemodynamic support.

We expect to increase our expenditures on sales and marketing activities in fiscal 2013, with particular investments in clinical personnel with cath lab expertise. We also plan to increase our marketing, service, and training investments to support the efforts of the sales and field clinical teams to drive recovery awareness for acute heart failure patients.

Amortization of Intangibles

Amortization of intangible assets for the three months ended June 30, 2012 decreased by $0.3 million, or 71%, to $0.1 million from $0.4 million for the three months ended June 30, 2011. Amortization primarily relates to specifically identified assets from the Impella acquisition. We fully amortized the remaining net book value of our intangible assets during the three months ended June 30, 2012.

Provision for Income Taxes

During three months ended June 30, 2012 and 2011, we recorded a provision for income taxes of $0.4 million and $0.1 million, respectively. The income tax provision for the three months ended June 30, 2012 is primarily due to $0.2 million of income taxes in Germany that we do not expect will be offset by our net operating loss carryforwards in Germany and therefore we expect to pay in cash. We have also recorded $0.2 million in income taxes related to our deferred tax liability on our goodwill and alternative minimum tax in the U.S.

Net Income (Loss)

During the three months ended June 30, 2012, we incurred net income of $3.1 million, or $0.08 per basic and diluted share, compared to a net loss of $4.6 million, or $0.12 per basic and diluted share, for the three months ended June 30, 2011. The increase in the net income for the three months ended June 30, 2012 compared to the net loss in June 30, 2011 was due primarily to increased Impella sales due to greater demand in the U.S.

 

19


Table of Contents

Liquidity and Capital Resources

At June 30, 2012, our cash, cash equivalents and short-term marketable securities totaled $81.2 million, an increase of $4.0 million compared to $77.2 million in cash, cash equivalents and short-term marketable securities at March 31, 2012. We believe that our revenue from product sales together with existing resources will be sufficient to fund our operations for at least the next twelve months, exclusive of activities involving any future acquisitions of products or companies that complement or augment our existing line of products.

Our primary liquidity needs are to fund the expansion of our commercial infrastructure in the U.S., increase our Impella manufacturing capacity, increase our inventory levels in order to meet increasing customer demand for Impella in the U.S., fund new product development and provide for general working capital needs. Through June 30, 2012, we have funded our operations principally from product sales and through the sale of equity securities. We also generate cash through funded research and development revenue.

Marketable securities at June 30, 2012 consist of $77.2 million held in funds that invest solely in U.S. Treasury securities. We are not a party to any interest rate swaps, currency hedges or derivative contracts of any type and have no exposure to commercial paper or auction rate securities markets. We continue to monitor our cash position closely and currently only invest excess cash in short term U.S. treasury securities.

Cash and cash equivalents held by our foreign subsidiaries totaled $2.2 million and $3.0 million at June 30, 2012 and March 31, 2012, respectively. Our operating income outside the U.S. is deemed to be permanently reinvested in foreign jurisdictions. We do not intend or currently foresee a need to repatriate cash and cash equivalents held by our foreign subsidiaries. If these funds are needed in the U.S., we would be required to accrue and pay U.S. taxes to repatriate these funds.

During the three months ended June 30, 2012, net cash provided by operating activities was $4.3 million, compared to net cash used of $8.6 million during the same period in the prior year. The increase in cash provided by operations was primarily attributable to the net improvement of $7.7 million reflected in our net income of $3.1 million for the three months ended June 30, 2012 compared to our net loss of $4.6 million in fiscal 2012, offset by changes in assets and liabilities used which consist of a $4.5 million decrease in cash used for accounts payable and accrued expenses primarily related to the closeout of the Protect II study in fiscal 2012, a $1.2 million increase in cash provided by accounts receivable due to increases in sales and a $0.4 million increase in cash used for inventories due to an increase in inventory to support growing customer demand for Impella in the U.S. In addition, net cash provided by operating activities was impacted by changes in non-cash adjustments of a $0.3 million increase in stock-based compensation and a $0.1 million increase in write-downs of inventory, partially offset by a $0.2 million decrease in depreciation and amortization expense.

During the three months ended June 30, 2012, net cash used for investing activities was $6.5 million, compared to $1.0 million during the same period in the prior year. The increase in cash used for investing activities was primarily attributable to a $5.5 million increase in net purchases of short-term securities.

During the three months ended June 30, 2012, net cash provided by financing activities was $1.0 million, compared to $7.6 million during the same period in the prior year. The decrease in cash provided by financing activities was primarily attributable to a $6.4 million decrease in proceeds from the exercise of stock options because fewer stock options were exercised in that period, offset by $0.2 million for payments in lieu of issuance of common stock for minimum payroll taxes upon vesting of certain equity awards.

Capital expenditures for fiscal 2013 are estimated to be $3.0 to $4.0 million, which relate primarily to capital expenditures for manufacturing capacity increases for Impella, leasehold improvements and software development projects.

Our liquidity is influenced by our ability to sell our products in a competitive industry and our customers’ ability to pay for our products. Factors that may affect liquidity include our ability to penetrate the market for our products, maintain or reduce the length of the selling cycle, and collect cash from clients after our products are sold. We continue to review our long-term cash needs on a regular basis. At June 30, 2012, we had no long-term debt outstanding.

 

ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Primary Market Risk Exposures

Our cash, cash equivalents and short-term marketable securities are subject to interest rate risk and will fall in value if market interest rates increase. Marketable securities at June 30, 2012 consist of $77.2 million held in funds that invest solely in U.S. Treasury securities. If market interest rates were to increase immediately and uniformly by 10 percent from levels at June 30, 2012, we believe the decline in fair market value of our investment portfolio would be immaterial.

 

20


Table of Contents

Currency Exchange Rates

We have foreign currency exposure to exchange rate fluctuations and particularly with respect to the euro and British pound sterling. Therefore, our investment in our international subsidiaries is sensitive to fluctuations in currency exchange rates. The effect of a change in currency exchange rates on our net investment in international subsidiaries is reflected in the accumulated other comprehensive (loss) income component of stockholders’ equity. Had a 10% depreciation in foreign currency exchange rates occurred relative to the U.S. dollar as of June 30, 2012, the result would have been a reduction of stockholders’ equity of approximately $3.4 million.

Fair Value of Financial Instruments

At June 30, 2012, our financial instruments consist primarily of cash and cash equivalents, short-term marketable securities, accounts receivable, and accounts payable. The estimated fair values of the financial instruments have been determined by us using available market information and appropriate valuation techniques. Considerable judgment is required, however, to interpret market data to develop the estimates of fair value. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

 

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of June 30, 2012. Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2012, these disclosure controls and procedures are effective to provide reasonable assurance that material information required to be disclosed by us, including our consolidated subsidiaries, in reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Evaluation of Changes in Internal Control over Financial Reporting

During the first quarter of our fiscal year ending March 31, 2013, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

21


Table of Contents

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings

We are from time to time involved in various legal actions, the outcomes of which are not within our complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, which, if granted, would require significant expenditures. We record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. We review these estimates each accounting period as additional information is known and adjust the loss provision when appropriate. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated financial statements.

 

Item 1A. Risk Factors

Investing in our common stock involves a high degree of risk. In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part 1, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended March 31, 2012, which could materially affect our business, financial condition or future results. To the best of our knowledge, as of the date of this report there has been no material change in any of the risk factors described in our Annual Report on Form 10-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a) Not applicable.

(b) Not applicable.

(c) The following table provides information about our repurchases of shares of our common stock during the fiscal quarter ended June 30, 2012. During that period, we did not act in concert with any affiliate or any other person to acquire any of our common stock and, accordingly, we do not believe that purchases by any such affiliate or other person (if any) are reportable in the following table.

 

Period

   Total
Number
of Shares
Purchased
    Average
Price Paid
per Share
     Total Number of
Shares Purchased
as Part of
Publicly
Announced Plans
or Programs
     Maximum
Number of
Shares
that May
Yet Be
Purchased
Under the
Plans or
Programs
 

April 1-30, 2012

     —          —           —           —     

May 1-31, 2012

     11,390 (1)    $ 20.89         —           —     

June 1-30, 2012

     —          —           —           —     

 

(1) Represents shares withheld to satisfy minimum tax withholding obligations related to restricted stock units which vested during the indicated period. The shares withheld were recorded as treasury shares.

 

Item 3. Defaults Upon Senior Securities

None

 

Item 4. Mine Safety Disclosures

Not applicable.

 

Item 5. Other Information

None

 

22


Table of Contents
Item 6. Exhibits

 

Exhibit
No.

  

Description

  

Filed with

This

Form 10-Q

    

Incorporated by Reference

 
                

Form

    

Filing Date

    

Exhibit
No.

 
    3.1    Restated Certificate of Incorporation.         S-3         September 29, 1997         3.1   
    3.2    Restated By-Laws, as amended.         10-K         May 27, 2004         3.2   
    3.3    Certificate of Designations of Series A Junior Participating Preferred Stock.         S-3         September 29, 1997         3.3   
    3.4    Amendment to the Company’s Restated Certificate of Incorporation to increase the authorized shares of common stock from 25,000,000 to 100,000,000.         8-K         March 21, 2007         3.4   
    4.1    Specimen Certificate of common stock.         S-1         June 5, 1987         4.1   
  11.1    Statement regarding computation of Per Share Earnings (see Note 2, Notes to Consolidated Financial Statements).      X            
  31.1    Rule 13a-14(a)/15d-14(a) certification of principal executive officer.      X            
  31.2    Rule 13a-14(a)/15d-14(a) certification of principal accounting officer.      X            
  32.1    Section 1350 certification.      X            
101    The following financial information from the ABIOMED, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets as of June 30, 2012 and March 31, 2012; (ii) Consolidated Statements of Operations for the three months ended June 30, 2012 and June 30, 2011; (iii) Consolidated Statements of Comprehensive Income (Loss) for the three months ended June 30, 2012 and June 30, 2011; (iv) Consolidated Statements of Cash Flows for the three months ended June 30, 2012 and June 30, 2011; and (v) Notes to Consolidated Financial Statements.*      X            

 

* The information contained in this exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

 

23


Table of Contents

ABIOMED, INC. AND SUBSIDIARIES

PART II. OTHER INFORMATION

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Abiomed, Inc.
Date: August 6, 2012  

/S/    ROBERT L. BOWEN        

  Robert L. Bowen
 

Vice President and Chief Financial Officer

(Principal Accounting and Financial Officer)

 

24

EX-31.1 2 d366941dex311.htm CERTIFICATION OF CEO PURSUANT TO SECTION 302 Certification of CEO pursuant to section 302

Exhibit 31.1

CERTIFICATIONS

I, Michael R. Minogue certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ABIOMED, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 6, 2012  

/s/ Michael R. Minogue

  Michael R. Minogue
 

Chairman, President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 d366941dex312.htm CERTIFICATION OF CFO PURSUANT TO SECTION 302 Certification of CFO pursuant to section 302

Exhibit 31.2

I, Robert L. Bowen certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ABIOMED, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 6, 2012  

/s/ Robert L. Bowen

  Robert L. Bowen
 

Vice President and Chief Financial Officer

(Principal Accounting and Financial Officer)

EX-32.1 4 d366941dex321.htm CERTIFICATION OF CEO AND CFO PURSUANT TO SECTION 906 Certification of CEO and CFO pursuant to section 906

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. § 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of ABIOMED, Inc., (the “Company”) for the quarter ended June 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned President and Chief Executive Officer, and Corporate Controller, of the Company, certifies, to the best knowledge and belief of the signatory, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Michael R. Minogue

   

/s/ Robert L. Bowen

Chairman, President and Chief Executive Officer     Vice President and Chief Financial Officer
Date: August 6, 2012     Date: August 6, 2012
EX-101.INS 5 abmd-20120630.xml XBRL INSTANCE DOCUMENT 39527727 4151000 1749000 34741000 800000 33000 3327000 130520000 744000 40249000 300000 100000000 5861000 62344 10.72 50278000 39497477 383000 4390000 3946000 77233000 24382000 6294000 2687000 377000 1000000 1108000 -270156000 154902000 11.34 4890000 18343000 12477000 0.01 154902000 1065000 47479000 3989000 39559821 4133000 -4342000 10134000 19115000 4379000 395000 0.01 113791000 4141000 6337000 405688000 11.33 15 1238000 P6Y4D 77233000 77233000 0.70 34700000 0.07 5000000 12600000 1005000 18.47 6800000 5831000 1716000 36846000 726000 33000 126297000 588000 400000 100000000 9272000 50954 39272754 427000 3586000 4098000 71233000 27614000 6910000 3025000 400000 1000000 948000 -273275000 153911000 10.42 4799000 20458000 11142000 0.01 153911000 827000 5990000 39323708 115000 -1765000 12480000 22415000 4268000 393000 0.01 110539000 3458000 6378000 401771000 519000 P6Y11D 71233000 71233000 0.68 37000000 0.08 871000 15.76 45000 311000 31776000 0.0183 -4421000 189000 27166000 -1360000 -81000 -3568000 44000 2332000 -0.12 15000 4000 1046000 P5Y3M18D 7629000 -8556000 -973000 -270000 472000 -1680000 156000 -220000 38268000 -847000 1026000 -4498000 1026000 -0.12 7324000 7629000 0.516 38268000 1601000 -5443000 5891000 27355000 5001000 96000 4500000 -4594000 -77000 18176000 96000 220000 385000 76000 1756000 500000 0.07 903000 256000 1156000 17000 1500000 18.49 284000 837000 3565000 ABMD ABIOMED INC false Accelerated Filer Q1 2012 10-Q 2012-06-30 0000815094 --03-31 35222000 0.0078 <div> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s basic and diluted net income (loss) per share for the three months ended June&#xA0;30, 2012 and 2011 were as follows (in thousands, except per share data):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three Months Ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>June&#xA0;30,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Basic Net Income (Loss) Per Share</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,119</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,594</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average shares used in computing basic net income (loss) per share</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39,144</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38,268</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share - basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.08</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three Months Ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>June 30,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Diluted Net Income (Loss) Per Share</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,119</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,594</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average shares used in computing basic net income (loss) per share</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39,144</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38,268</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Effect of dilutive securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,405</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average shares used in computing diluted net income (loss) per share</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,549</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38,268</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share - diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.08</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 2500000 3561000 136000 38647000 -300000 P5Y3M15D -4000 542000 92000 0.00 P5Y10M21D <div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 2. Net Income (Loss) Per Share</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted average shares outstanding any potential dilutive securities outstanding for the period. Potential dilutive securities include stock options, restricted stock awards, restricted stock units, performance-based stock awards and shares to be purchased under the employee stock purchase plan. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. The Company&#x2019;s basic and diluted net income (loss) per share for the three months ended June&#xA0;30, 2012 and 2011 were as follows (in thousands, except per share data):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three Months Ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>June&#xA0;30,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Basic Net Income (Loss) Per Share</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,119</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,594</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average shares used in computing basic net income (loss) per share</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39,144</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38,268</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share - basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.08</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="80%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three Months Ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>June 30,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Diluted Net Income (Loss) Per Share</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,119</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,594</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average shares used in computing basic net income (loss) per share</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">39,144</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38,268</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Effect of dilutive securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,405</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average shares used in computing diluted net income (loss) per share</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,549</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38,268</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income (loss) per share - diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.08</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">For the three months ended June&#xA0;30, 2012, approximately 490,000 shares underlying outstanding securities were not included in the computation of diluted earnings per share primarily related to out-of-the-money stock options and performance-based awards where milestones were not met. For the three months ended June&#xA0;30, 2011, approximately 3,565,000 shares underlying stock options and approximately 837,000 restricted shares were excluded from the calculation of diluted weighted average shares outstanding because the Company incurred a loss in the period, and to include them would have been anti-dilutive.</font></p> </div> 2679000 22.44 0.08 9.21 8000 -2105000 161000 <div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 3. Fair Value Measurements</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Fair value is defined as the price that would be received for the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories:</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Level 1: Quoted market prices in active markets for identical assets or liabilities.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Level 3: Unobservable inputs that are not corroborated by market data.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Level 1 primarily consists of financial instruments whose values are based on quoted market prices such as exchange-traded instruments and listed equities.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, prepayment speeds, default rates, loss severity, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"> &#xA0;</p> <p style="MARGIN-TOP: 0px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Level 3 is comprised of unobservable inputs that are supported by little or no market activity. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table presents the Company&#x2019;s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above (in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="64%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Quoted<br /> Prices in<br /> Active<br /> Markets<br /> (Level 1)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Using<br /> Significant<br /> Other<br /> Observable<br /> Inputs<br /> (Level 2)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Using<br /> Significant<br /> Unobservable<br /> Inputs</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(Level 3)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total<br /> Carrying<br /> Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">At June&#xA0;30, 2012:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">77,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">77,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="64%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Quoted<br /> Prices in<br /> Active<br /> Markets<br /> (Level 1)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Using<br /> Significant<br /> Other<br /> Observable<br /> Inputs</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(Level 2)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Using<br /> Significant<br /> Unobservable<br /> Inputs</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(Level 3)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total<br /> Carrying<br /> Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">At March&#xA0;31, 2012:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">71,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">71,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company records these marketable securities at fair value and has classified all of its investments as Level 1 since quoted market prices in active markets are readily available.</font></p> </div> -2000 842000 P4Y3M29D 1228000 <div> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The goodwill activity for the three months ended June&#xA0;30, 2012 is as follows (in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at March&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">36,846</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exchange rate impact</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,105</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at June&#xA0;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">34,741</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 4318000 -6470000 -333000 7.62 1 470000 <div> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The components of inventories are as follows (in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>June&#xA0;30,<br /> 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>March&#xA0;31,<br /> 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Raw materials and supplies</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,390</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,586</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Work-in-progress</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,946</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,098</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Finished goods</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,141</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,458</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,477</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,142</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> -2001000 252000 65000 41549000 <div> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes the stock option activity for the three months ended June&#xA0;30, 2012:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="60%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Shares<br /> Underlying<br /> Options</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(in&#xA0; thousands)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Term&#xA0;(years)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Aggregate<br /> Intrinsic<br /> Value</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(in&#xA0; thousands)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding at April&#xA0;1, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,268</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.42</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.03</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">303</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22.44</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(161</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.62</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cancelled and expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(31</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.21</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding at June&#xA0;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,379</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11.34</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.01</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">50,278</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercisable at June&#xA0;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,327</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.72</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.29</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40,249</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options vested and expected to vest at June&#xA0;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,133</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11.33</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.89</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">47,479</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div> <div> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 1. Nature of Business and Basis of Preparation</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Abiomed, Inc. (the &#x201C;Company&#x201D; or &#x201C;Abiomed&#x201D;) is a leading provider of mechanical circulatory support devices and offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company&#x2019;s products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting and in accordance with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by GAAP for complete financial statements. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended March&#xA0;31, 2012 that has been filed with the Securities and Exchange Commission, or SEC.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period may not be indicative of results for the full fiscal year.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">There have been no changes in the Company&#x2019;s significant accounting policies for the three months ended June&#xA0;30, 2012 as compared to the significant accounting policies described in the Company&#x2019;s Annual Report on Form&#xA0;10-K for the fiscal year ended March&#xA0;31, 2012 that has been filed with the SEC.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Recently Adopted Accounting Standards</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">During the first quarter of fiscal 2013, the Company adopted Accounting Standards Update, or ASU, No ASU 2011-05, <i>Presentation of Comprehensive Income.</i> ASU 2011-05 requires entities to present net income and other comprehensive income in either a single continuous statement of comprehensive income or in two separate, but consecutive, statements of net income and other comprehensive income. In December 2011, the Financial Accounting Standards Board, or FASB, issued ASU No.&#xA0;2011-12, <i>Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No.&#xA0;2011-05</i>. ASU 2011-12 amended ASU 2011-05 by indefinitely deferring the requirement under ASU 2011-05 to present reclassification adjustments out of accumulated other comprehensive income by a component in both the statement in which net income is presented and the statement in which other comprehensive income is presented. The Company has adopted ASU 2011-05 with retrospective application as required, except for the components of ASU 2011-05 which were indefinitely deferred by ASU 2011-12 and has included in these condensed consolidated financial statements separate unaudited statements of comprehensive income. The adoption of this standard did not impact the Company&#x2019;s condensed consolidated financial statements other than this change in presentation</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">In September 2011, the FASB issued ASU No.&#xA0;2011-08, <i>Testing for Goodwill Impairment</i>. ASU 2011-08 amended current goodwill impairment testing guidance by providing entities with an option to perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The Company adopted ASU 2011-08 during the first quarter of fiscal 2013 and will apply the provisions to its annual impairment assessment to be conducted during the third quarter of fiscal 2013.</font></p> </div> -2032000 -2577000 3555000 -2577000 0.08 6712000 990000 31000 0.563 39144000 <div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 8. Income Taxes</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to tax benefit carryforwards and to differences between the financial statement amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates. A valuation reserve is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The tax benefit associated with the stock option compensation deductions will be credited to equity when realized.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company regularly assesses its ability to realize its deferred tax assets. Assessments of the realization of deferred tax assets require that management consider all available evidence, both positive and negative, and make significant judgments about many factors, including the amount and likelihood of future taxable income. Based on the available evidence and uncertainties surrounding the Company&#x2019;s ability to continue to generate future taxable income, the Company has recorded valuation allowances to reduce its deferred tax assets to the amount that is more likely than not to be realizable as of June&#xA0;30, 2012 and March&#xA0;31, 2012.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">As of June&#xA0;30, 2012, the Company has accumulated a net deferred tax liability of $4.9 million which is the result of the difference in accounting for the Company&#x2019;s goodwill, which is amortizable over 15 years for tax purposes but not amortizable for book purposes. The net deferred tax liability cannot be offset against the Company&#x2019;s deferred tax assets since it relates to an indefinite-lived asset and is not anticipated to reverse in the same period.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company and its subsidiaries are subject to U.S. federal income tax, as well as income tax of multiple state and foreign jurisdictions. The Company has accumulated significant losses since its inception in 1981. All tax years remain subject to examination by major tax jurisdictions, including the federal government and the Commonwealth of Massachusetts. However, because the Company has net operating loss and tax credit carryforwards which may be utilized in future years to offset taxable income, those years may also be subject to review by relevant taxing authorities if the carryforwards are utilized.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">During three months ended June&#xA0;30, 2012 and 2011, the Company recorded a provision for income taxes of $0.4 million and $0.1 million, respectively. The income tax provision for the three months ended June&#xA0;30, 2012 is primarily due to $0.2 million of income taxes in Germany that the Company does not expect will be offset by the Company&#x2019;s net operating loss carryforwards in Germany and therefore expects to pay in cash. The Company also recorded $0.2 million in income taxes related to its deferred tax liability on goodwill and alternative minimum tax in the U.S.</font></p> </div> 1982000 2405000 <div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table presents the Company&#x2019;s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above (in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="64%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Quoted<br /> Prices in<br /> Active<br /> Markets<br /> (Level 1)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Using<br /> Significant<br /> Other<br /> Observable<br /> Inputs<br /> (Level 2)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Using<br /> Significant<br /> Unobservable<br /> Inputs</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(Level 3)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total<br /> Carrying<br /> Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">At June&#xA0;30, 2012:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">77,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">77,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="64%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Quoted<br /> Prices in<br /> Active<br /> Markets<br /> (Level 1)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Using<br /> Significant<br /> Other<br /> Observable<br /> Inputs</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(Level 2)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Using<br /> Significant<br /> Unobservable<br /> Inputs</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(Level 3)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Total<br /> Carrying<br /> Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">At March&#xA0;31, 2012:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">U.S. Treasury securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">71,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">71,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"> <font style="font-family:Times New Roman" size="2">Accrued expenses consist of the following (in thousands):</font></p> <p style="font-size:12px;margin-top:0px;margin-bottom:0px"> &#xA0;</p> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>June&#xA0;30,<br /> 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1"><b>March&#xA0;31,<br /> 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Employee compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">5,861</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">9,272</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Research and development</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,238</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">519</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Sales taxes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,108</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">948</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Warranty</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">800</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">726</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Professional, accounting and auditing fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">383</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">427</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Other</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">744</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">588</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:1px solid #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">10,134</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">12,480</font></td> <td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="font-size:1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td valign="bottom"> <p style="border-top:3px double #000000">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> -2024000 7446000 38783000 <div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 4. Inventories</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The components of inventories are as follows (in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>June&#xA0;30,<br /> 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>March&#xA0;31,<br /> 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Raw materials and supplies</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,390</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,586</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Work-in-progress</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,946</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,098</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Finished goods</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,141</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,458</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,477</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,142</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company&#x2019;s inventories relate to its circulatory care product lines, primarily the AB5000, BVS 5000 and Impella product platforms. Finished goods and work-in-process inventories consist of direct material, labor and overhead. During each of the three months ended June&#xA0;30, 2012 and 2011, the Company recorded $0.3 million and $0.2 million, respectively, in write-downs of inventory.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">From time to time, the Company loans finished goods inventory on a short-term basis to customers for demonstration purposes and this inventory is amortized over a one to five-year life. The Company had $0.3 million and $0.4 million in demo inventory at June&#xA0;30, 2012 and March&#xA0;31, 2012, respectively.</font></p> </div> 11500000 <div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 9. Commitments and Contingencies</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Litigation</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">From time to time, the Company is involved in legal and administrative proceedings and claims of various types. While any litigation contains an element of uncertainty, management presently believes that the outcome of each such proceedings or claims which are pending or known to be threatened, or all of them combined, is not expected to have a material effect on the Company&#x2019;s financial position, and results of operations or cash flows. At June&#xA0;30, 2012, the Company did not have any material pending litigation.</font></p> </div> <div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 10. Segment and Enterprise Wide Disclosures</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company operates in one business segment&#x2014;the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company&#x2019;s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company&#x2019;s consolidated operating results. Approximately 70% and 68% of the Company&#x2019;s total consolidated assets are located within the U.S. as of June&#xA0;30, 2012 and March&#xA0;31, 2012, respectively. The remaining assets are located in Europe and are primarily related to the Company&#x2019;s Impella production facility in Germany, and include goodwill and intangibles of $34.7 million and $37.0 million at June&#xA0;30, 2012 and March&#xA0;31, 2012, respectively, associated with the Impella acquisition in May 2005. Total assets in Europe excluding goodwill and intangibles amounted to 7% and 8% of total consolidated assets at June&#xA0;30, 2012 and March&#xA0;31, 2012, respectively. International sales (sales outside the U.S. and primarily in Europe) accounted for 5% and 7% of total revenue for the three months ended June&#xA0;30, 2012 and 2011, respectively.</font></p> </div> 90000 5500000 3119000 -6000 20953000 <div> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes stock-based compensation expense by financial statement line item in the Company&#x2019;s consolidated statements of operations for the three months ended June&#xA0;30, 2012 and 2011 (in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cost of product revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">146</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">76</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">563</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Selling, general and administrative</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,970</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,756</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,679</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,332</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 303000 <div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 5. Goodwill</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The carrying amount of goodwill at June&#xA0;30, 2012 and March&#xA0;31, 2012 was $34.7 million and $36.8 million, respectively, and has been recorded in connection with the Company&#x2019;s acquisition of Impella Cardiosystems AG, or Impella, in 2005. The goodwill activity for the three months ended June&#xA0;30, 2012 is as follows (in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at March&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">36,846</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exchange rate impact</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,105</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at June&#xA0;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">34,741</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 436000 -839000 2000000 <div> <p style="MARGIN-TOP: 0px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The fair value of options granted during the three months ended June&#xA0;30, 2012 and 2011 were calculated using the following weighted average assumptions:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="82%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Risk-free interest rate</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.83</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected option life (years)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.33</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.30</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected volatility</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">56.3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">51.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> </table> </div> <div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The components of stock-based compensation for the three months ended June&#xA0;30, 2012 and 2011 were as follows (in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock options</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">970</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">903</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">338</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,156</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">256</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Employee stock purchase plan</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">48</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,679</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,332</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 7. Stock-Based Compensation</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes stock-based compensation expense by financial statement line item in the Company&#x2019;s consolidated statements of operations for the three months ended June&#xA0;30, 2012 and 2011 (in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cost of product revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">146</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">76</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">563</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Selling, general and administrative</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,970</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,756</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,679</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,332</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The components of stock-based compensation for the three months ended June&#xA0;30, 2012 and 2011 were as follows (in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock options</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">970</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">903</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">338</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,156</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock units</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">256</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Employee stock purchase plan</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">48</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,679</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,332</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Stock Options</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes the stock option activity for the three months ended June&#xA0;30, 2012:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="60%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Shares<br /> Underlying<br /> Options</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(in&#xA0; thousands)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Term&#xA0;(years)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Aggregate<br /> Intrinsic<br /> Value</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>(in&#xA0; thousands)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding at April&#xA0;1, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,268</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.42</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.03</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">303</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22.44</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(161</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.62</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cancelled and expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(31</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.21</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding at June&#xA0;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,379</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11.34</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.01</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">50,278</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercisable at June&#xA0;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,327</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.72</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.29</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40,249</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options vested and expected to vest at June&#xA0;30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,133</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11.33</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.89</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">47,479</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The aggregate intrinsic value of options exercised was $2.5 million for the three months ended June&#xA0;30, 2012. The total fair value of options vested during the three months ended June&#xA0;30, 2012 was $2.0 million.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The remaining unrecognized stock-based compensation expense for unvested stock option awards at June&#xA0;30, 2012 was approximately $5.0 million, net of forfeitures, and the weighted-average period over which this cost will be recognized is 2.9 years.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"> &#xA0;</p> <p style="MARGIN-TOP: 0px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company estimates the fair value of each stock option granted at the grant date using the Black-Scholes option valuation model. The fair value of options granted during the three months ended June&#xA0;30, 2012 and 2011 were calculated using the following weighted average assumptions:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="82%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three&#xA0;Months&#xA0;Ended<br /> June&#xA0;30,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Risk-free interest rate</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.83</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected option life (years)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.33</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.30</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected volatility</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">56.3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">51.6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on the historical volatility of the Company&#x2019;s stock and adjusted for factors not reflected in historical volatility that may be more indicative of future volatility. The Company estimates the expected term of options based on historical exercise trends and estimates of future exercises of unexercised options.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The calculation of the fair value of the options is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures, adjusted to the extent historic forfeitures may not be indicative of forfeitures in the future. In addition, an expected dividend yield of zero is used in the option valuation model, because the Company does not pay cash dividends and does not expect to pay any cash dividends in the foreseeable future.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Restricted Stock and Restricted Stock Units</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">In addition to stock option grants, the Company also has the ability to grant restricted stock and restricted stock units. Similar to stock options, these restricted stock and restricted stock unit grants are subject to certain vesting criteria. The following table summarizes the activity for the three months ended June&#xA0;30, 2012:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="67%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three Months Ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>June&#xA0;30, 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number&#xA0;of<br /> Share&#xA0;(in&#xA0;000&#x2019;s)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted&#xA0;Average<br /> Grant Date</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding at April 1, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">871</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15.76</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">361</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22.40</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(209</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13.76</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(18</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20.48</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding at June 30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,005</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18.47</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The remaining unrecognized compensation expense for outstanding restricted stock awards and restricted stock units, including performance-based awards, as of June&#xA0;30, 2012 was $12.6 million and the weighted-average period over which this cost will be recognized is 2.4 years.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The weighted average grant-date fair value for restricted stock and restricted stock units granted during the three months ended June&#xA0;30, 2012 and 2011 was $22.40 and $18.49 per share, respectively. The total fair value of restricted stock and restricted stock units vested during the three months ended June&#xA0;30, 2012 and 2011 was $2.9 million and $1.5 million, respectively.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Performance Based Awards</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Included in the restricted stock and restricted stock units activity discussed above are certain awards granted in fiscal years 2012, 2011 and 2010 that vest subject to certain performance-based criteria.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">During the three months ended June&#xA0;30, 2012, performance-based awards of restricted stock units for the potential issuance of 195,188 shares of common stock were issued to certain executive officers and employees, all of which would vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of June&#xA0;30, 2012, the Company believes it is probable that the prescribed performance targets will be met for these awards and the compensation expense is being recognized accordingly.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">During the three months ended June&#xA0;30, 2011, performance-based awards of restricted stock units for the potential issuance of 284,000 shares of common stock were issued to certain executive officers and members of the senior management of the Company, all of which would vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. During the year ended March&#xA0;31, 2012, the Company determined that it met the prescribed targets for 184,000 shares underlying these awards. As of June&#xA0;30, 2012, the Company believes it is probable that the prescribed performance targets will be met for the remaining 100,000 shares, and the compensation expense is being recognized accordingly.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">In June 2010, 311,000 shares of restricted stock and a performance-based award for the potential issuance of 45,000 shares of common stock were issued to certain executive officers and members of the senior management of the Company, all of which would vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. During the year ended March&#xA0;31, 2011, the Company determined that it met the prescribed performance targets and a portion of these shares and stock options vested. The remaining shares will vest upon satisfaction of prescribed service conditions by the award recipients.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">During the three months ended June&#xA0;30, 2012, the Company recorded $0.9 million in stock-based compensation expense for equity awards in which the prescribed performance milestones have been achieved or are probable of being achieved. The remaining unrecognized compensation expense related to these equity awards at June&#xA0;30, 2012 is $6.8 million based on the Company&#x2019;s current assessment of probability of achieving the performance milestones. The weighted-average period over which this cost will be recognized is 2.4 years.</font></p> </div> 111000 <div> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes the activity for the three months ended June&#xA0;30, 2012:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="67%"></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="12%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Three Months Ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>June&#xA0;30, 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number&#xA0;of<br /> Share&#xA0;(in&#xA0;000&#x2019;s)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted&#xA0;Average<br /> Grant Date</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding at April 1, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">871</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15.76</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">361</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22.40</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(209</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13.76</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(18</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20.48</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding at June 30, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,005</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18.47</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Note 6. Accrued Expenses</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Accrued expenses consist of the following (in thousands):</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"> <tr> <td width="78%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>June&#xA0;30,<br /> 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>March&#xA0;31,<br /> 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Employee compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,861</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,272</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,238</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">519</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Sales taxes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,108</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">948</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warranty</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">800</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">726</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Professional, accounting and auditing fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">383</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">427</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">744</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">588</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,134</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,480</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Employee compensation consists primarily of accrued bonuses, accrued commissions and accrued employee benefits at June&#xA0;30, 2012 and March&#xA0;31, 2012.</font></p> </div> 238000 146000 1970000 563000 0.05 P1Y P5Y 970000 1323000 338000 P2Y10M24D 48000 361000 209000 2900000 13.76 22.40 P2Y4M24D 20.48 18000 195188 900000 P2Y4M24D 184000 100000 200000 200000 490000 0000815094 us-gaap:PerformanceSharesMember 2012-04-01 2012-06-30 0000815094 country:DE 2012-04-01 2012-06-30 0000815094 country:US 2012-04-01 2012-06-30 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember 2012-04-01 2012-06-30 0000815094 abmd:RestrictedStockAndRestrictedStockUnitsMember 2012-04-01 2012-06-30 0000815094 abmd:EmployeeStockPurchasePlanMember 2012-04-01 2012-06-30 0000815094 us-gaap:StockOptionsMember 2012-04-01 2012-06-30 0000815094 us-gaap:RestrictedStockMember 2012-04-01 2012-06-30 0000815094 us-gaap:RestrictedStockUnitsRSUMember 2012-04-01 2012-06-30 0000815094 us-gaap:StockOptionMember 2012-04-01 2012-06-30 0000815094 us-gaap:MaximumMember 2012-04-01 2012-06-30 0000815094 us-gaap:MinimumMember 2012-04-01 2012-06-30 0000815094 abmd:InternationalMember 2012-04-01 2012-06-30 0000815094 us-gaap:ResearchAndDevelopmentExpenseMember 2012-04-01 2012-06-30 0000815094 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2012-04-01 2012-06-30 0000815094 us-gaap:CostOfSalesMember 2012-04-01 2012-06-30 0000815094 2012-04-01 2012-06-30 0000815094 us-gaap:StockOptionsMember 2011-04-01 2011-06-30 0000815094 us-gaap:RestrictedStockMember 2011-04-01 2011-06-30 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember 2011-04-01 2011-06-30 0000815094 abmd:RestrictedStockAndRestrictedStockUnitsMember 2011-04-01 2011-06-30 0000815094 abmd:EmployeeStockPurchasePlanMember 2011-04-01 2011-06-30 0000815094 us-gaap:RestrictedStockMember 2011-04-01 2011-06-30 0000815094 us-gaap:RestrictedStockUnitsRSUMember 2011-04-01 2011-06-30 0000815094 us-gaap:StockOptionMember 2011-04-01 2011-06-30 0000815094 abmd:InternationalMember 2011-04-01 2011-06-30 0000815094 us-gaap:ResearchAndDevelopmentExpenseMember 2011-04-01 2011-06-30 0000815094 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2011-04-01 2011-06-30 0000815094 us-gaap:CostOfSalesMember 2011-04-01 2011-06-30 0000815094 2011-04-01 2011-06-30 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember 2010-04-01 2010-06-30 0000815094 us-gaap:PerformanceSharesMember 2010-04-01 2010-06-30 0000815094 abmd:RestrictedStockAndRestrictedStockUnitsMember 2012-03-31 0000815094 abmd:EuropeMember 2012-03-31 0000815094 country:US 2012-03-31 0000815094 us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember 2012-03-31 0000815094 us-gaap:USTreasurySecuritiesMember 2012-03-31 0000815094 2012-03-31 0000815094 2011-03-31 0000815094 abmd:PerformanceBasedRestrictedStockAndRestrictedStockUnitsMember 2012-06-30 0000815094 abmd:RestrictedStockAndRestrictedStockUnitsMember 2012-06-30 0000815094 us-gaap:StockOptionsMember 2012-06-30 0000815094 abmd:EuropeMember 2012-06-30 0000815094 country:US 2012-06-30 0000815094 us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember 2012-06-30 0000815094 us-gaap:USTreasurySecuritiesMember 2012-06-30 0000815094 2012-06-30 0000815094 2011-06-30 0000815094 2012-07-31 shares iso4217:USD iso4217:USD shares abmd:Year pure abmd:Segment EX-101.SCH 6 abmd-20120630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:calculationLink link:presentationLink link:definitionLink 106 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Nature of Business and Basis of Preparation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Net Income (Loss) Per Share link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Goodwill link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Segment and Enterprise Wide Disclosures link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Net Income (Loss) Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Goodwill (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Computation of Basic and Diluted Net Income Loss Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Net Income or Loss Per Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Marketable Securities Investments (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Components of Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Inventories - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Goodwill - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Goodwill Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Stock-Based Compensation Recognized (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Components of Stock-Based Compensation (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Summary of Restricted Stock and Restricted Stock Units Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Segment and Enterprise Wide Disclosures - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 abmd-20120630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 abmd-20120630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 abmd-20120630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 abmd-20120630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary of Stock Option Activity (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Jun. 30, 2012
Options  
Beginning Balance 4,268
Granted 303
Exercised (161)
Cancelled and expired (31)
Ending Balance 4,379
Exercisable at June 30, 2012 3,327
Options vested and expected to vest at June 30, 2012 4,133
Weighted-Average Exercise Price  
Beginning Balance $ 10.42
Granted $ 22.44
Exercised $ 7.62
Cancelled and expired $ 9.21
Ending Balance $ 11.34
Exercisable at June 30, 2012 $ 10.72
Options vested and expected to vest at June 30, 2012 $ 11.33
Weighted-Average Remaining Contractual Term (years)  
Beginning Balance 6 years 11 days
Ending Balance 6 years 4 days
Exercisable at June 30, 2012 5 years 3 months 15 days
Options vested and expected to vest at June 30, 2012 5 years 10 months 21 days
Aggregate Intrinsic Value  
Outstanding at June 30, 2012 $ 50,278
Exercisable at June 30, 2012 40,249
Options vested and expected to vest at June 30, 2012 $ 47,479
XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
Marketable Securities Investments (Detail) (US Treasury Securities, USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Mar. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities $ 77,233 $ 71,233
Quoted Prices in Active Markets (Level 1)
   
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities $ 77,233 $ 71,233
XML 14 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Jun. 30, 2012
Year
Jun. 30, 2011
Mar. 31, 2012
Income Taxes [Line Items]      
Net deferred tax liability $ 4,890   $ 4,799
Amortization period of deferred tax liability (years) 15    
Income tax provision 436 96  
GERMANY
     
Income Taxes [Line Items]      
Income tax provision 200    
UNITED STATES
     
Income Taxes [Line Items]      
Income tax provision $ 200    
XML 15 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements
3 Months Ended
Jun. 30, 2012
Fair Value Measurements

Note 3. Fair Value Measurements

Fair value is defined as the price that would be received for the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Level 1 primarily consists of financial instruments whose values are based on quoted market prices such as exchange-traded instruments and listed equities.

Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, prepayment speeds, default rates, loss severity, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.

 

Level 3 is comprised of unobservable inputs that are supported by little or no market activity. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.

The following table presents the Company’s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above (in thousands):

 

     Quoted
Prices in
Active
Markets
(Level 1)
     Using
Significant
Other
Observable
Inputs
(Level 2)
     Using
Significant
Unobservable
Inputs

(Level 3)
     Total
Carrying
Value
 

At June 30, 2012:

           

U.S. Treasury securities

   $ 77,233         —           —         $ 77,233   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     Quoted
Prices in
Active
Markets
(Level 1)
     Using
Significant
Other
Observable
Inputs

(Level 2)
     Using
Significant
Unobservable
Inputs

(Level 3)
     Total
Carrying
Value
 

At March 31, 2012:

           

U.S. Treasury securities

   $ 71,233         —           —         $ 71,233   
  

 

 

    

 

 

    

 

 

    

 

 

 

The Company records these marketable securities at fair value and has classified all of its investments as Level 1 since quoted market prices in active markets are readily available.

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\S-#DT9&1D,E\V,S'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT M:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O'!E;G-E#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K5]$971A:6P\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/E-T;V-K0F%S961?0V]M<&5N#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D-O;7!O;F5N='-?;V9?4W1O8VM" M87-E9%]#;VUP93PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-U;6UA#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E=E:6=H=&5D7T%V97)A9V5?07-S=6UP=&EO;G-?53PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-#DT M9&1D,E\V,S'0O:'1M;#L@8VAA2!);F9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA2!296=I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\ M+W1D/@T*("`@("`@("`\=&0@8VQA2!&:6QE3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^06-C96QE2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D("T@,2PP,#`L M,#`P('-H87)EF5D("T@,3`P+#`P,"PP,#`@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ+#`P,"PP,#`\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-#DT9&1D,E\V M,S'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E;G-E*2!I;F-O;64Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\'!E;G-E*2P@5&]T86P\ M+W1D/@T*("`@("`@("`\=&0@8VQA"!P'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'!E;G-E&5D(&%S7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/DYO=&4@,2X@3F%T=7)E(&]F#0I"=7-I;F5S6QE M/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#@E.R!-05)'24XM M0D]45$]-.B`P<'@G/@T*/&9O;G0@6YA;6EC('-U<'!O2!O2!O"<^#0H\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY4:&4-"F%C8V]M<&%N>6EN9R!U;F%U9&ET960@8V]N#L@5$58 M5"U)3D1%3E0Z(#@E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@"<^#0H\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&5R92!H879E M(&)E96X-"FYO(&-H86YG97,@:6X@=&AE($-O;7!A;GDF(W@R,#$Y.W,@$$P.S,P+"`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`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`X)3L@34%21TE. M+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/DEN(%-E<'1E;6)E<@T*,C`Q,2P@ M=&AE($9!4T(@:7-S=65D($%352!.;RXF(WA!,#LR,#$Q+3`X+"`\:3Y497-T M:6YG(&9O6EN9R!A;6]U;G0@87,@82!B87-I2!T:&4@<')O M=FES:6]N3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-#DT9&1D,E\V,S'0O:'1M;#L@ M8VAA"<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D)A28C>#(P,3D[6QE/3-$)TU!4D=)3BU4 M3U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G M/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%PF4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`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`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/DYE="!I;F-O;64-"BAL;W-S*3PO9F]N=#X\+W`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`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\ M='(^#0H\=&0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-#X\+W1D/@T*/'1D(&-O M;'-P86X],T0T/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4 M.B`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`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P M.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[ M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$ M-#X\+W1D/@T*/'1D(&-O;'-P86X],T0T/CPO=&0^#0H\+W1R/@T*/'1R/@T* M/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M M,65M.R!-05)'24XM3$5&5#H@,V5M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY.970@:6YC;VUE("AL M;W-S*2!P97(@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXP+C`X/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,"XQ,CPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^ M#0H\+W1A8FQE/@T*/'`@"<^#0HF(WA!,#L\+W`^ M#0H\=&%B;&4@F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]TF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L6QE/3-$ M)U1%6%0M24Y$14Y4.B`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`@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/DYE="!I;F-O;64- M"BAL;W-S*3PO9F]N=#X\+W`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`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\ M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO M<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\='(^#0H\=&0^/"]T9#X- M"CQT9"!C;VQS<&%N/3-$-#X\+W1D/@T*/'1D(&-O;'-P86X],T0T/CPO=&0^ M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-%149&/@T*/'1D('9A;&EG;CTS M1'1O<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`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`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`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`M,65M.R!-05)'24XM3$5&5#H@,V5M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY.970@:6YC;VUE("AL;W-S*2!P97(@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C`N,#@\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@P+C$R M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF M(WA!,#L\+W1D/@T*/"]T"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY&;W(@=&AE('1H$$P.S,P+"`R,#$R+"!A<'!R;WAI;6%T96QY(#0Y,"PP,#`@2!S=&]C:R!O<'1I;VYS(&%N9"!P97)F;W)M86YC92UB87-E M9"!A=V%R9',@=VAE6EN9R!S=&]C M:R!O<'1I;VYS(&%N9`T*87!P2`X,S'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/DYO=&4@,RX@1F%I6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D9A:7(@=F%L=64@:7,-"F1E9FEN960@87,@=&AE('!R M:6-E('1H870@=V]U;&0@8F4@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,979E;"`Q.B!1=6]T960- M"FUA"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,979E;"`R.@T*3V)S97)V86)L M92!M87)K970@8F%S960@:6YP=71S(&]R('5N;V)S97)V86)L92!I;G!U=',@ M=&AA="!A2!M87)K970@9&%T82X\+V9O;G0^ M/"]P/@T*/'`@#L@5$585"U)3D1% M3E0Z(#@E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@6QE/3-$ M)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`X)3L@34%21TE.+4)/ M5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/DQE=F5L(#$-"G!R:6UA2!C;VYS M:7-T&-H M86YG92UT6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1% M6%0M24Y$14Y4.B`X)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/DQE=F5L(#(-"FEN8VQU9&5S(&9I;F%N8VEA;"!I;G-T6EE;&0@8W5R M=F4L('9O;&%T:6QI='D@9F%C=&]R$$P.SPO M<#X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@5$585"U)3D1%3E0Z M(#@E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@"<^#0H\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@9F]L M;&]W:6YG#0IT86)L92!P28C>#(P,3D["<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E%U;W1E9#QBF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]LF4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0Q/CQB/E5S:6YG/&)R("\^#0I3:6=N:69I8V%N=#QBF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5& M5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY!="!*=6YE)B-X03`[,S`L#0HR,#$R.CPO9F]N M=#X\+W`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`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`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X M.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE M/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0Q/CQB/E5S:6YG/&)R("\^#0I3:6=N:69I8V%N=#QB6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0Q/CQB/BA,979E;`T* M,RD\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`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`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X M03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF M(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^ M)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@#L@5$585"U)3D1%3E0Z(#@E.R!-05)'24XM0D]45$]- M.B`P<'@G/@T*/&9O;G0@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-#DT9&1D M,E\V,S'0O:'1M;#L@8VAA#L@34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CX\8CY.;W1E(#0N#0I);G9E;G1O"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@8V]M<&]N96YT6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%2 M1TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[/"]P M/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0Q/CQB/DIU;F4F(WA!,#LS,"P\8G(@+SX- M"C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DUA6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)' M24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY287<@;6%T97)I86QS(&%N9`T*6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT+#,Y,#PO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`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`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`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`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X- M"CPO='(^#0H\+W1A8FQE/@T*/'`@#L@5$585"U)3D1%3E0Z(#@E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O M;G0@$$P.S,P+"`R,#$R(&%N9"`R,#$Q+"!T M:&4@0V]M<&%N>2!R96-O2P@:6X@=W)I=&4M9&]W;G,@;V8-"FEN=F5N M=&]R>2X\+V9O;G0^/"]P/@T*/'`@#L@5$585"U)3D1%3E0Z(#@E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O M;G0@2!L;V%N2!A="!*=6YE)B-X M03`[,S`L(#(P,3(-"F%N9"!-87)C:"8C>$$P.S,Q+"`R,#$R+"!R97-P96-T M:79E;'DN/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE. M+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY.;W1E(#4N#0I';V]D=VEL;#PO M8CX\+V9O;G0^/"]P/@T*/'`@"<^#0H\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY4:&4@8V%R$$P.S,P+"`R,#$R(&ES(&%S#0IF;VQL;W=S("AI;B!T:&]U#L@1D].5"U325I%.B`Q,G!X)SX-"B8C>$$P.SPO<#X- M"CQT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!B M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED M=&@],T0V."4@86QI9VX],T1C96YT97(^#0H\='(^#0H\=&0@=VED=&@],T0X M."4^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\+W1D M/@T*/'1D/CPO=&0^#0H\=&0^/"]T9#X-"CQT9#X\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C,V+#@T-CPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY%>&-H86YG92!R871E#0II M;7!A8W0\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@R M+#$P-3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T$$P.SPO<#X-"CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^ M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/D)A;&%N8V4@870@2G5N M928C>$$P.S,P+`T*,C`Q,CPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/C,T+#6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO M9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/DYO=&4@-BX@06-C6QE/3-$)TU!4D=)3BU43U`Z(#9P M>#L@5$585"U)3D1%3E0Z(#@E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O M;G0@#L@1D].5"U325I% M.B`Q,G!X)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"="3U)$15(M M0T],3$%04T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`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`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXU,3D\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C$L,3`X/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/CDT.#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY787)R86YT>3PO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY0F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS.#,\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]T:&5R M/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW-#0\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X- M"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@8F=C;VQOF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXQ,BPT.#`\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^ M#0H\+W1A8FQE/@T*/'`@#L@5$58 M5"U)3D1%3E0Z(#@E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@$$P.S,Q+"`R,#$R+CPO9F]N=#X\+W`^#0H\+V1I=CX\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@ M34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY.;W1E(#6QE M/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#@E.R!-05)'24XM M0D]45$]-.B`P<'@G/@T*/&9O;G0@2!F:6YA;F-I86P-"G-T871E;65N="!L:6YE(&ET96T@:6X@=&AE($-O;7!A M;GDF(W@R,#$Y.W,@8V]N$$P.S,P M+"`R,#$R(&%N9`T*,C`Q,2`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T* M/'`@"<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+#PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE M/3-$)U1%6%0M24Y$14Y4.B`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`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXU,#`\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ+#DW,#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO M=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(L-C6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#,S,CPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T* M/"]T"<^#0H\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY4:&4@8V]M<&]N96YT"<^#0HF(WA!,#L\ M+W`^#0H\=&%B;&4@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P+#PO8CX\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`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`] M,T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXR-38\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C0X/"]F;VYT M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$W/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CPO='(^#0H\='(@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\ M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO M<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@8F=C;VQOF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(L,S,R/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@$$P.SPO=&0^#0H\+W1R/@T*/"]T M86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU" M3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E)SX-"CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI M/E-T;V-K#0I/<'1I;VYS/"]I/CPO8CX\+V9O;G0^/"]P/@T*/'`@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG#0IT86)L92!S M=6UM87)I>F5S('1H92!S=&]C:R!O<'1I;VX@86-T:79I='D@9F]R('1H92!T M:')E92!M;VYT:',-"F5N9&5D($IU;F4F(WA!,#LS,"P@,C`Q,CH\+V9O;G0^ M/"]P/@T*/'`@"<^#0HF(WA!,#L\+W`^#0H\=&%B M;&4@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0Q/CQB/E-H87)E6EN9SQBF4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/CQB/E=E:6=H=&5D/&)R("\^ M#0I!=F5R86=E/&)R("\^#0I%>&5R8VES93QBF4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q M/CQB/E=E:6=H=&5D/&)R("\^#0I!=F5R86=E/&)R("\^#0I296UA:6YI;F<\ M8G(@+SX-"D-O;G1R86-T=6%L/&)R("\^#0I497)M)B-X03`[*'EE87)S*3PO M8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0Q/CQB/BAI;B8C>$$P.PT* M=&AO=7-A;F1S*3PO8CX\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY/=71S=&%N9&EN9R!A=`T*07!R:6PF(WA!,#LQ+"`R,#$R M/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT+#(V.#PO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`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`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW+C8R/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/"]T MF4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXY+C(Q/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`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`R,#$R+B!4:&4@=&]T86P@9F%I M$$P.S,P+"`R,#$R('=A"<^#0H\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY4:&4@2`D-2XP(&UI;&QI;VXL#0IN970@;V8@9F]R9F5I='5R97,L(&%N9"!T M:&4@=V5I9VAT960M879E65A6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U14 M3TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*)B-X03`[/"]P/@T*/'`@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>0T*97-T:6UA M=&5S('1H92!F86ER('9A;'5E(&]F(&5A8V@@$$P.S,P+"`R,#$R#0IA;F0@,C`Q,2!W97)E(&-A;&-U;&%T960@ M=7-I;F<@=&AE(&9O;&QO=VEN9R!W96EG:'1E9"!A=F5R86=E#0IA"<^#0HF(WA! M,#L\+W`^#0H\=&%B;&4@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`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`M,65M.R!-05)'24XM3$5&5#H@ M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY%>'!E8W1E9`T*=F]L871I;&ET>3PO9F]N=#X\+W`^ M#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@&5R M8VES97,@;V8@=6YE>&5R8VES960-"F]P=&EO;G,N/"]F;VYT/CPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`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`Q,G!X)SX-"B8C>$$P.SPO M<#X-"CQT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E M)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@ M=VED=&@],T0W-B4@86QI9VX],T1C96YT97(^#0H\='(^#0H\=&0@=VED=&@] M,T0V-R4^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^ M/"]T9#X-"CQT9#X\+W1D/@T*/'1D/CPO=&0^#0H\=&0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^/"]T9#X-"CQT9#X\+W1D/@T* M/'1D/CPO=&0^#0H\=&0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/CQB/E1H$$P.S,P M+"`R,#$R/"]B/CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DYU;6)E M$$P.V]F/&)R("\^#0I3:&%R928C>$$P.RAI;B8C>$$P.S`P,"8C>#(P M,3D[F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E=E:6=H=&5D)B-X03`[079E6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY/=71S=&%N9&EN9R!A="!!<')I;"`Q+`T*,C`Q,CPO9F]N=#X\+W`^#0H\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-2XW-CPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)U1%6%0M24Y$14Y4.B`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`Y/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXQ,RXW-CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5& M5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY&;W)F96ET960\+V9O;G0^/"]P/@T*/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@Q.#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C$L,#`U/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ."XT-SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA! M,#L\+W1D/@T*/"]T"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY4:&4@#L@5$585"U)3D1%3E0Z(#@E.R!- M05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@2X@5&AE#0IT;W1A;"!F86ER('9A;'5E(&]F(')E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DEN8VQU9&5D(&EN('1H90T*#L@5$585"U)3D1% M3E0Z(#@E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@&5C=71I=F4@;V9F:6-E2!T:&4@0V]M<&%N>2X@ M07,@;V8@2G5N928C>$$P.S,P+"`R,#$R+"!T:&4@0V]M<&%N>0T*8F5L:65V M97,@:70@:7,@<')O8F%B;&4@=&AA="!T:&4@<')E6QE/3-$)TU!4D=) M3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`X)3L@34%21TE.+4)/5%1/33H@ M,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D1U2!T:&4@0V]M<&%N>2X@1'5R:6YG('1H90T*>65A$$P.S,Q+"`R,#$R+"!T:&4@0V]M<&%N>2!D971E6QE/3-$)TU!4D=) M3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`X)3L@34%21TE.+4)/5%1/33H@ M,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DEN($IU;F4@,C`Q,"P-"C,Q,2PP,#`@2!T:&4@87=A65A#L@ M5$585"U)3D1%3E0Z(#@E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@ M'!E;G-E(')E;&%T960@=&\@=&AE$$P.S,P+"`R,#$R(&ES("0V+C@@;6EL M;&EO;B!B87-E9"!O;B!T:&4@0V]M<&%N>28C>#(P,3D[F5D M(&ES(#(N-"!Y96%R3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-#DT9&1D,E\V,S'0O:'1M M;#L@8VAA6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/DYO M=&4@."X@26YC;VUE#0I487AE"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$969E`T*8V]N"!B87-I"!R871EF5D+B!4:&4@ M=&%X#0IB96YE9FET(&%S2!W:&5N(')E86QI>F5D+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS M1"=-05)'24XM5$]0.B`Q,G!X.R!415A4+4E.1$5.5#H@."4[($U!4D=)3BU" M3U143TTZ(#!P>"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>0T*F4@:71S(&1E9F5R"!A&%B;&4@:6YC;VUE+B!" M87-E9`T*;VX@=&AE(&%V86EL86)L92!E=FED96YC92!A;F0@=6YC97)T86EN M=&EE2!T;R!C;VYT:6YU92!T;R!G96YE2!H87,@F%B;&4@87,@;V8@2G5N928C>$$P.S,P+"`R,#$R(&%N9"!-87)C M:"8C>$$P.S,Q+`T*,C`Q,BX\+V9O;G0^/"]P/@T*/'`@#L@5$585"U)3D1%3E0Z(#@E.R!-05)'24XM0D]45$]- M.B`P<'@G/@T*/&9O;G0@`T*;&EA8FEL:71Y(&]F("0T+CD@;6EL;&EO;B!W:&EC:"!I28C>#(P,3D[F%B M;&4-"F]V97(@,34@>65A"!P=7)P;W-E"<^#0H\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY4:&4@0V]M<&%N>2!A;F0-"FET"!Y96%R&%M:6YA=&EO;B!B M>2!M86IOF5D(&EN(&9U='5R92!Y96%R&%B;&4@:6YC;VUE+"!T:&]S92!Y96%R69O6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[(%1%6%0M M24Y$14Y4.B`X)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D1U M$$P.S,P+"`R,#$R M(&ES('!R:6UA2!D=64@=&\@)#`N,B!M:6QL:6]N(&]F(&EN8V]M92!T M87AE2!T:&%T('1H92!#;VUP86YY(&1O97,@;F]T(&5X M<&5C="!W:6QL(&)E(&]F9G-E="!B>2!T:&4-"D-O;7!A;GDF(W@R,#$Y.W,@ M;F5T(&]P97)A=&EN9R!L;W-S(&-A2!A M;F0-"G1H97)E9F]R92!E>'!E8W1S('1O('!A>2!I;B!C87-H+B!4:&4@0V]M M<&%N>2!A;'-O(')E8V]R9&5D("0P+C(-"FUI;&QI;VX@:6X@:6YC;VUE('1A M>&5S(')E;&%T960@=&\@:71S(&1E9F5R"!L:6%B:6QI='D@;VX- M"F=O;V1W:6QL(&%N9"!A;'1E"!I;B!T:&4@ M52Y3+CPO9F]N=#X\+W`^#0H\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/DYO=&4@.2X@0V]M;6ET;65N=',@86YD M#0I#;VYT:6YG96YC:65S/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=- M05)'24XM5$]0.B`V<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q% M1E0Z(#(E)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/DQI=&EG871I;VX\+VD^/"]B/CPO M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'@[(%1%6%0M M24Y$14Y4.B`X)3L@34%21TE.+4)/5%1/33H@,'!X)SX-"CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D9R M;VT@=&EM92!T;PT*=&EM92P@=&AE($-O;7!A;GD@:7,@:6YV;VQV960@:6X@ M;&5G86P@86YD(&%D;6EN:7-T2!L:71I9V%T:6]N#0IC M;VYT86EN2!B96QI979E'!E8W1E9"!T;R!H879E(&$@;6%T97)I86P@ M969F96-T(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS(&9I;F%N8VEA;`T*<&]S M:71I;VXL(&%N9"!R97-U;'1S(&]F(&]P97)A=&EO;G,@;W(@8V%S:"!F;&]W M$$P.S,P+`T*,C`Q,BP@=&AE($-O;7!A;GD@9&ED(&YO M="!H879E(&%N>2!M871E'1087)T7S,T.31D9&0R7S8S-S%?-&,U8E]B,C`Y7S`Q8F0X-F9E839F M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S-#DT9&1D,E\V,S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@ M34%21TE.+4)/5%1/33H@,'!X)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY.;W1E(#$P+B!396=M M96YT(&%N9`T*16YT97)P6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!# M;VUP86YY#0IO<&5R871E#(P M,30[=&AE(')E28C>#(P,3D[$$P.S,P+`T*,C`Q,B!A;F0@,C`Q,2P@'1087)T7S,T.31D9&0R7S8S-S%?-&,U8E]B,C`Y7S`Q8F0X-F9E839F M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S-#DT9&1D,E\V,S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/E1H90T*0V]M<&%N>28C>#(P,3D[6QE/3-$ M)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-) M6D4Z(#$R<'@G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1% M4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`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`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DYE="!I;F-O;64-"BAL;W-S*3PO9F]N=#X\+W`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`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X- M"CPO='(^#0H\='(^#0H\=&0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-#X\+W1D M/@T*/'1D(&-O;'-P86X],T0T/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T>6QE/3-$)U1% M6%0M24Y$14Y4.B`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`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T* M/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\ M=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\='(^#0H\=&0^/"]T9#X-"CQT9"!C M;VQS<&%N/3-$-#X\+W1D/@T*/'1D(&-O;'-P86X],T0T/CPO=&0^#0H\+W1R M/@T*/'1R/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T>6QE/3-$)U1%6%0M M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,V5M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY.970@ M:6YC;VUE("AL;W-S*2!P97(@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXP+C`X/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,"XQ,CPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T M9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@"<^#0HF M(WA!,#L\+W`^#0H\=&%B;&4@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]TF4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L6QE/3-$)U1%6%0M24Y$14Y4.B`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`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DYE M="!I;F-O;64-"BAL;W-S*3PO9F]N=#X\+W`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`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@ M$$P M.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\='(^#0H\ M=&0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$-#X\+W1D/@T*/'1D(&-O;'-P86X] M,T0T/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-%149&/@T*/'1D M('9A;&EG;CTS1'1O<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`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`@$$P.SPO<#X-"CPO=&0^#0H\=&0^ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`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`M,65M.R!-05)'24XM3$5&5#H@,V5M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY.970@:6YC;VUE("AL;W-S*2!P97(@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C`N,#@\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B@P+C$R/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H\ M+W1R/@T*/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"CQT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T M9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#L@5$585"U)3D1%3E0Z(#@E.R!-05)'24XM0D]4 M5$]-.B`P<'@G/@T*/&9O;G0@6QE/3-$)TU!4D=)3BU43U`Z(#!P M>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X M03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/CQB/E5S:6YG/&)R("\^#0I3:6=N M:69I8V%N=#QB6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0Q/CQB/BA,979E;`T*,RD\ M+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`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`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`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW-RPR,S,\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P M.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA! M,#L\+W1D/@T*/"]T#L@1D].5"U325I%.B`Q,G!X M)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"="3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`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`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/D%T($UAF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P/@T* M/'`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`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*/'`@$$P.SPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@$$P.SPO=&0^#0H\+W1R M/@T*/"]T86)L93X-"CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M"<^#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@8V]M<&]N96YT6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/ M33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[/"]P/@T*/'1A8FQE M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DIU;F4F(WA!,#LS,"P\8G(@+SX-"C(P,3(\+V(^ M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0Q/CQB/DUA6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@ M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY287<@;6%T97)I86QS(&%N9`T*6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT+#,Y,#PO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T M6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/C0L,30Q/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C,L-#4X/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`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`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\ M+W1A8FQE/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\S-#DT9&1D,E\V,S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R"<^#0H\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY4:&4@9V]O9'=I;&P-"F%C=&EV:71Y(&9O"<^#0HF(WA!,#L\+W`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`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L M;W(],T0C0T-%149&/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T>6QE/3-$ M)U1%6%0M24Y$14Y4.B`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`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T M'0O:F%V87-C3X-"B`@("`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`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;B<@3I4:6UEF4],T0R/C$L,C,X/"]F;VYT/CPO=&0^ M#0H\=&0@;F]W3I4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3I4:6UEF4],T0R/C4Q M.3PO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3I4:6UEF4],T0R/E-A;&5S('1A>&5S/"]F;VYT/CPO<#X-"CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3I4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@3I4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3I4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@3I4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T M'0M:6YD96YT M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;B<@3I4:6UEF4],T0R/C,X,SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@6QE/3-$)VUA3I4:6UEF4],T0R/C6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA M;B<@6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;B<@6QE/3-$ M9F]N="US:7IE.C%P>#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI M9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X-"CQP('-T>6QE/3-$)V)O$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C M,#`P,#`P)SXF(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X-"CQP('-T>6QE/3-$)V)O$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`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`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@ M(S`P,#`P,"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P M,"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H M92!F;VQL;W=I;F<-"G1A8FQE('-U;6UA6QE/3-$)TU!4D=)3BU43U`Z(#!P M>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X M03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0V(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/CQB/E1HF4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXW-CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$)U1% M6%0M24Y$14Y4.B`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`@ M$$P M.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X- M"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#8W.3PO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T M"<^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X- M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^ M#0H\=&0^)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/&1I=CX-"CQP('-T>6QE/3-$)TU! M4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`X)3L@34%21TE.+4)/5%1/ M33H@,'!X)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!C;VUP;VYE;G1S#0IO9B!S=&]C:RUB M87-E9"!C;VUP96YS871I;VX@9F]R('1H92!T:')E92!M;VYT:',@96YD960- M"DIU;F4F(WA!,#LS,"P@,C`Q,B!A;F0@,C`Q,2!W97)E(&%S(&9O;&QO=W,@ M*&EN#0IT:&]U#L@1D].5"U325I%.B`Q M,G!X)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"="3U)$15(M0T], M3$%04T4Z(&-O;&QA<'-E)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(^#0H\ M='(^#0H\=&0@=VED=&@],T0X,B4^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0T)3X\+W1D/@T*/'1D/CPO=&0^#0H\=&0^/"]T9#X-"CQT M9#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^ M#0H\=&0^/"]T9#X-"CQT9#X\+W1D/@T*/'1D/CPO=&0^#0H\+W1R/@T*/'1R M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.TUO;G1H$$P.T5N9&5D/&)R("\^#0I*=6YE)B-X03`[,S`L M/"]B/CPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0Q/CQB/C(P,3(\+V(^/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q M/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/E-T;V-K(&]P=&EO M;G,\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXY-S`\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/CDP,SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$)U1% M6%0M24Y$14Y4.B`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`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY%;7!L;WEE92!S=&]C:R!P M=7)C:&%S90T*<&QA;CPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXR+#8W.3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/"]T"<^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T M9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=CX-"CQP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P>#L@5$585"U) M3D1%3E0Z(#@E.R!-05)'24XM0D]45$]-.B`P<'@G/@T*/&9O;G0@6QE/3-$)TU!4D=)3BU4 M3U`Z(#!P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G M/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`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`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D=R M86YT960\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,P M,SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXR,BXT-#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D5X97)C M:7-E9#PO9F]N=#X\+W`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`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D-A;F-E;&QE9"!A;F0-"F5X<&ER960\+V9O;G0^ M/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B@S,3PO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H\ M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*/'`@$$P.SPO<#X-"CPO=&0^#0H\ M=&0^)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CPO='(^#0H\='(@8F=C M;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D]U='-T86YD:6YG(&%T#0I*=6YE)B-X03`[,S`L(#(P,3(\+V9O;G0^ M/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C0L,S6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,2XS-#PO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXV+C`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`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P/@T*/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D5X97)C:7-A8FQE(&%T#0I*=6YE)B-X03`[,S`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`] M,T1N;W=R87`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`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/D]P=&EO;G,@=F5S M=&5D(&%N9"!E>'!E8W1E9`T*=&\@=F5S="!A="!*=6YE)B-X03`[,S`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`],T1N;W=R87`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`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA! M,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$"<^ M#0H\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY4:&4@9F%I6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/5%1/ M33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[/"]P/@T*/'1A8FQE M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E1HF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!-05)' M24XM3$5&5#H@,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY2:7-K+69R964@:6YT97)E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C`N-S@\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C$N.#,\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B4F(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^ M#0H\='(^#0H\=&0@=F%L:6=N/3-$=&]P/@T*/'`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`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`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!F;VQL M;W=I;F<-"G1A8FQE('-U;6UA6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@34%21TE.+4)/ M5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#$R<'@G/@T*)B-X03`[/"]P/@T*/'1A M8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/"]TF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/CQB/D9A:7(-"E9A;'5E/"]B/CPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]U='-T M86YD:6YG(&%T($%PF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXX-S$\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C$U+C6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/D=R86YT960\+V9O;G0^/"]P/@T*/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C,V,3PO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,BXT,#PO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE M/3-$)U1%6%0M24Y$14Y4.B`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"CQT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^ M#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X- M"CQP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"CQP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L M;W(],T0C0T-%149&/@T*/'1D('9A;&EG;CTS1'1O<#X-"CQP('-T>6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,65M.R!-05)'24XM3$5&5#H@,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY/=71S=&%N9&EN9R!A="!*=6YE(#,P+`T*,C`Q,CPO9F]N=#X\+W`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`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0^)B-X03`[ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*/'`@$$P.SPO=&0^ M#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&-L=61E9"!F7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!;3&EN92!)=&5M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-#DT M9&1D,E\V,S'0O:'1M;#L@8VAAF%T M:6]N('!E'0^,2!Y M96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'!E;G-E7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAAF5D("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQEF5D(%!E MF5D M(%!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$65E(%-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\S-#DT9&1D,E\V,S'0O:'1M;#L@8VAA65E(%-E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$F5D(%!E M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$65E(%-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-#DT9&1D M,E\V,S'0O:'1M;#L@8VAA2!O9B!3=&]C:R!/<'1I M;VX@06-T:79I='D@*$1E=&%I;"D@*%531"`D*3QB'!I'!E8W1E M9"!T;R!V97-T(&%T($IU;F4@,S`L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@ M8VQA'!E8W1E9"!T;R!V97-T(&%T($IU;F4@,S`L(#(P,3(\ M+W1D/@T*("`@("`@("`\=&0@8VQA7,\'0^-2!Y96%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G0@07=A&5R M8VES960@:6X@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XD(#(L-3`P+#`P,#QS<&%N/CPO6EE;&0\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE M($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$F5D('-T;V-K+6)A'!E M;G-E+"!W96EG:'1E9"UA=F5R86=E(')E8V]G;FET:6]N('!E'0^,B!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M, M:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F5D('-T;V-K+6)A'!E;G-E+"!W96EG:'1E9"UA=F5R86=E(')E8V]G;FET:6]N('!E'0^,B!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$F5D('-T;V-K+6)A'!E;G-E+"!W96EG M:'1E9"UA=F5R86=E(')E8V]G;FET:6]N('!E'0^,B!Y96%R'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!3:&%R92!B87-E9"!087EM96YT($%W87)D+"!&86ER(%9A M;'5E($%S65A65A3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\S-#DT9&1D,E\V,S'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!O M9B!297-T'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7S,T.31D9&0R7S8S-S%?-&,U8E]B,C`Y7S`Q8F0X-F9E839F M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S-#DT9&1D,E\V,S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2`H>65A"!P'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5S(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5S(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S&UL/@T*+2TM+2TM/5].97AT4&%R=%\S-#DT9&1D,E\V,S XML 17 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
Goodwill Activity (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Jun. 30, 2012
Goodwill [Line Items]  
Balance at March 31, 2012 $ 36,846
Exchange rate impact (2,105)
Balance at June 30, 2012 $ 34,741
XML 18 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Goodwill - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Mar. 31, 2012
Goodwill and Intangible Assets Disclosure [Line Items]    
Goodwill $ 34,741 $ 36,846
ZIP 19 0001193125-12-337716-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-337716-xbrl.zip M4$L#!!0````(`+J`!D%6QM9QD&@``#]Y!0`1`!P`86)M9"TR,#$R,#8S,"YX M;6Q55`D``Z`C(%"@(R!0=7@+``$$)0X```0Y`0``[%UM<^)(DOY^$?_OHQ'@V>1Y7&:?#[!I]K)0"11.HR3A\\GDQR%>13' M)X.\")-A.$H3\?ED*O*3OW[YS__X]%\(#7SO%_MJ<)F,XD0,+M!7463QR^"/ M2(Q$%A;PIT2^-1(#+XTF8Y$4?QGN`G.+!X+$HGL[/SG[^ M_'DJA@]AAM+R`T^C='PV0&C^9;]5NTDDR/!^PI3^YF0@+ M>'PP!$'.!T3#!&DFTM@-QN>,G%/RO\M/IT_3+'YX+`;_'?T//*QQ!._`-8!_ M`3C1Z<`>C097\M%\<"5RD3V+X>GLDU[NLM$`5)KDGT^60,D_GZ;9PQE\+CV+ M9SHYJ9X\EZ^.-CP/7_VG5-KB>?F'VO,_:?DTMBSKK'QU_FBQ3A$*H+P;CRLO2V\B],QJ$4NH%2\IE-M_G`$2U5D MT\7SI3RYB$X?TN>SV8MGU6IA1/'\;4,1-[\%7FAX/$Z>15XTOZ-ZK>%-29HD MDW&SMH9%=E9,G\09/(3@*9'%T>)]V]]4?P-8UD,8/BW>=!_F=^4;9B\TR`:O MR$_*&]]3OM+P)BG(4-';;#WUL^K%VJ-%XZ.\>K0X@2T^&)2;?'2>EUOA2MP/ MRAUW+D7X?)+'XZ>1W!?EW\(LRM*1:+>WRW<\9N+^\XG<3VB^;TY?\N$>6[^] M59U5L&`?G?M)$1=3-QV/T^2Z2*,_KQ_#3.27DZ+T@.`5!U&:%.*EN))RBG1T M^]UGFD41_(,)UM#?-$TS;Z]OO%OMMD1@4'P+>W^2Q-5[\O(33P9#$<7C<`3K M>?$M.!G$8$#Q\!93BYC&+<4Z]IF-D6TR@ACU?&1Z.$"N:]BNS@,7F_26W'+X M,HV??*$6)X9!C$]G[4!4@&=[[=P-\T<[&/JW M<#01.^+&.YO;OU]XR>$15[(`MP``16V$IJZ`[YEX"N.A__(DDES`FR^+1Y'9>2Z*W)UD M&7S`SLN^-WS/U`(SX+#@1A`@YKL$61;UD$F(:^H6=UW'O,6W^LD7;#"K!KT% MCCKP7])T^#.&XZQOZ+`&FYH9K+ZT3N6? M[)^@O\LG^6#NOX@LBO/P;B2^3<9W(GNS7E9=]ZI*"/,][C$#@?^FB#&F(=@, M.M)98',C(-CQ;.F]2@NFE!CU+7!HS*JIP&GPF(Z&$$A+YUA,>[=7J`6.C6J< MJ+:A2JZ<87#:Q<6X=/7@_`$4N'K(9&*1'Q8B!,CG20R!19%-Q)X8"5D$'75[ MD)8NAK_&$#Z/X@)D[ZOW@IC#@*V]:M'K$#28]MWV;7ZW?9M?0+H`Z4@H32A%MFMRQ&S"D.-J#!&;^Z9FF(Z,4$I#)Q"E:$0YJ[M304T M7!5\U>)K\:T]*1[3+/ZG&';@Z!MB]+8.#0X_K,W^60I3UXM?Q^E#0I5.A;@2 MH[#X$,X!8C=NZO70;2N*.NB;3(3Y))LNZ:=?BVJP588/(G<4SOPM9 M?A)#^UEDX8.8O2*^9W&T:Z*V<3O^?3Q_P`%Q2*#-@T:::S6P MQ4N_I932J453649AEL$,8X.77EM$F44^D+O=BUQ6J<-1(/KKHQF@->LIV68$ M=;2+<_DJ_/D5''H6@S@0>%]/GIY&!X^Y-^9;+L$,:Q8RF`5F8.D6LGW#1P&S MJ:V;9F"Z5G4F,6K5C^!M(-9`_CW-_KQ(0$T1J*EW0'&YC?5FH#71Z_"^AMF? MHI!>]%I`.OX^`49;6X7LPR!*16$#@#K2I=BC=\@(+!\!RR4U:$L2KS@=>5^2 M@W^6P/NZ7IC+:,EBJKMID+V.SQ/W`OX\O!*P@2?]Q0?1((%DIH:O6?:&Y&QI M=7M1.^ MO)=MM@P$(//&6%-BP\T8ZH"OP.G&B1CZ899`5)2#74_&DS++`Q.(H[A_>YF" M/T+$T#"OGY/;H2CNMZQ?]PX>EFO*F:753Y%*VL[RH(^;DW)I`J>4=9(=\BO M@[0VE9!Y8_]OUYC6>#1LP[&A.'ODJE?;$[X,XW1>0[DJ]V$/P]]$+AU]4C9@ M1/"?-ZG\T])A8#\\9.(!-E7_BX:08S.#&0V75N^AH>X;EMZ@U+8-2[AL6**6 M65?J'@U+*V7)BSR?]"R3HJ3L2^.62?"&@FHE^;$-L9<-(8;L9E.J6L=2Q4I8 M-D]\RAQ??GPS"@=BU_3/(>PX/(>`KW^N7^P,\A[&5%#M5U0-=;W MW_/ZM6U87IY]F*Z4V]IT9GP$?+"XV,*8KPMAUK><'":EZZ7SX/*"X\#']18O ML>3+^QD%$JL\@M;U76P^6#]@4D,U-:EI@:>II-57TS=DI09V>;VW9$.#\R*# M#>(DSA_%4+80]^_23G:(8:79N5GT[87U+B[8#]+T:*XT/3:)?^!(]B"2&ULD M[\#['41NUB!W"BZGF'X?A>#J(2J$A.-)NOT^UJ3@G-D-@%0/-EP&!=E M%\/W,!Y>)&[X%!=A_Z@.E,GV4`[.H.[4FL4_=J+T<:OZ1E75I\?,I;87^R6S M[=P>IUD1_[/\>CB&XW08I-F\<.Z""`\':$WX(<)L696:JDJ3&SBP'1_IL!,1 M,P*,K$#7$>:!Q["NN2XWJH82S#^=M19\&6>5,P;.+7_O;O^@_FS13U'I"W]S+MIQ3)L#29 M]<*Q9C"ZSW8SB.[H@69*ZB98F6D'R#$]ABBWN6;[7@")G%0CDRUJ[;J:C@/V M%OZ%&7GAFFE85I?0\:[0RVT&_B>"C0.[XO)>;K0PF;[E/A[`8]/"+[(#U#27 MX#Y-,K'Q2++@(S07SB"3>1[$^#9%CA\P\"H<6\QQ7=OBMV36B*N=&G.'LA:` MFL*`+3S$H(8974X4%TDTFDCS>!M_.O7+WOC#EE1UV%V")W=ND`";S3L MD#CGT:.K9)2;>^SN5>[[+4MS3QE1MNP MNCNM?1!'1G5S+T=&+-]U.*2_<'"`&3F^#V9DVUP/=MYBTR'5V=VG`D M/];-D!:J#*F@M)=#6O:&WZJV1ZHA+;C>9'R\(2U=HRN'M.BF M0C8ZYI"6O1&V*@*1DFA$ZO#>;4A+YZNYWY"6M_<\=@VLG"A"=&(IHU:..%%D M(\2W7_60(TP4Z=K4N#PES(;MUZYOY0!C+MHBW'/,134&1%M%>*09%RJ\P_7Z MD1[.N.AZN\+19Q&#-$:"1YQQT>FBRL`-M+'+C(N#TOT[!5?2_6$%C65\[T;W M[WJ[RCMF9=38N]+]]\;;JJ&F-$_*S34L^&/2_;L&BN6A8IG-0(]$]^\\@(,H M'+\+W;]K9"7=W]!QO56W:[I_YYF$I/N7/7KO0_?O')\AIY61>B'UR'3_SG>F MMB9:/3[=O\LPH'=T_ZX#`4A"+-8OMG_GQT?%]J<0ZM5P'XGMW[DW*MG^U,)- M3=$?@^V_044'[0N<-V%@[90=<`)=/]C^G>\SR?8W+*OQU'L'MG_7>"%E(AKC M9F,4TS';OVMLY<0+K-#CCL[V/X#9MSWF^\GV[WP+:XU'P]'9_IV?\!#%F4IY M8QO9OQL.>;?WJ71QGVHI4U?>D4/>:96NY)!30@W-W)%#WM!;N-(DU[N-+&^J M%%YK&QS')6]W;LV2O(T-97A'3\C;G4=9>CF(QUPIGAR)O-TY/EA<0MB'(V]O M]W)[DK?G.0DC>F<#FCLA;W=>@2K)V_6B[_')V\>+4=^=O-WU@I:$/(U3JZ%. MT25YN^LKF)+:P-=;OS6+4D;V/#4(JOF\C;G5-CN[Y#D+\G@2LO_N_.C)VI<@]F[#RN^Z[_ MP/C?C!I;:N7MU%C'<`/-#1P4.+#3F$,QFW"7JFQK3H`C@/V M[=38MM#QKM`/3(V=@^^8&DLK:JQN]H`:6X/X$*;\YOYC-H6F_5I;\+1/8UW7R(/POV_D6PX?XCVB,(H/J$`A"](=,B`B0 MH7,""^=27=>7^+>RRG?R(2M1V?8MM`KB[')Q`FZUP0D1(&1P+W?,]W@NIRBD*F6V^J M5L4^T$Y;>!,XUB?C2GM7MPC&O*I M'B#&#`/9EEG.38?-Q'P/=%)UG,OJK7F(>6-MT2O=I7"HA$7Y>XSSV[#^;2+) M&04EDKK)-8BNMAV67;5!EHXK(^H?,MF&ITQV7Y&ZH7=T]DQ9']ZICG>T%9,M MZEA76+`-HJNY620[,(0GJG]?)$H'^!&1MB.KEYV4"%-=S<2V`&GH\89P-JUO MZ9E_[.'R0EZ%3,4<-V)8N713[^%W[RQX.UC+TZGCT-&HBWPQ< M%W.3N@Q7/7V(>%2-CD-G,AO?(.N]_=O9\FZ1 MU4DF;<&T.=#[!YB#TZ*4M(CK%"+JK!=\?K_JQ:-)L./%&U M4[S4T+P&Q7]RA&^B'9_3P^AVR(K;:0@Y^*XJKJ#(9+@]G[=\"4MEVKXP*V0"@P>W<;8^D[]I$ MTHOIO2(;X[T5M5>2(.^#^`_Z%9N>XIN4@6*8<=%?'SCE=#1XM()77) MY,K/E+9'U$H3E9_IN2;*4\XR:!M%-`#:EILH[,W^X<>L^LG:+:F)@D-Q`)7O MR&]2._K'),[$VGZ,'N(OV4?U@*X]GC:M_U513E5I_S0A*:L(ZTJ'\"Z8U@TZ MR.)">.G/'@8/LBF:KYGFL!![FXW/!J_-3:1Q`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`KB6Q>YMQWS++-+AD,&HFVV\+ MV(;&')O+23T:^&9/0S:C##R9&8`27!/C\C?WRLYHQ=3;07L7=7!-[TX=1*I# M%J$-_F$4HAO&7@S75@JA4B%X_IN,^^FCF0XXC_4;"('[JF3!<<14.SS'L>0Y ML\T__[D!5(=MFDL<*<[9/GLA")C'B>8B[+@$,=_WP&'"7K`-VW4\PR+4Q0M? M86GU)+Q-VV8W>+%F:6VXO_OAG3L#HOB"=\0+X(S.\,YM':LW^>\'F&*MPPW- M)&!Y<6,<".XA*&B_E2S;.06M]"I[\%W7J'/?7Y+U=-O7&9P0W&,F8EZ@(TMS M#!2X)@3--O5-9Q9+X%D;\''X>IN4]3Z4R@-REG=>P];SSEJOIE;]PJEU?.[E MOPF+>67U]F',NH9OM5VEY\L@RV9$L M"A[>^+GI;)6->Y!#*NV@O'3I)AE6^K%,>1BD[T['6\Y9H8,!M4S MLY7&=9TS&G"*#"(O_7T?+$3'-GRCYT%6K9E4?TT63*K\;M,A8/=1D\JOOQ]. MD_/(@W)UINSA5#D4\?E-%LK[P>OI^"[=8>Y,I0[23"R@6,<^L\$D32;G%4$,'B-BDMZ]<=MOYZGTZ6Q'F548?(!=3F33(PEI2?`O'.Y\9!Q`5 M2U$O+K_ZWN#BFUM)W"3:J^`V^(>A]!'!*-RY&7&-Q!HEV.<:0ZY#8?>X<%PY M-/"0;GEQ7>2Z/2_P9Q'H6CRMD&\+>=<^6W*1JD_QNNQ%TKT3JA M?X@P>P>1Y46C)ON3-DBT*O+-].E05M=23AEJP6?6Y91BK`I7*=M/AMX>'2]O MDY+\B[VK[5$<2=+?D?@/J9K;4;>$&?P*[E:/9#"LZFZZJJZ;V;VY+RMCDL(W MQF9L4]6UO_XBTC9@W@HH*&R3TL[.E+$S,UXR,B(S\HF8FT)#$^1&=JR94:U. MNPY%S#OWUAO2'_]%+S'Q,!\'6X7H1%>69]S*T!8C3Q`1%[IR6HX?,GA,?A`: MLB`GDV_;T$Z+6"*=>0=>9(@EJB1E;XT4#+%DG4NG02P1$\221K-UIARRUQ%+ MOMMC.IRY=-VU8CE6F/P8Y^[W\>BZ#UQKN[[]YXEFB&;V3+G7T@6U80";]*8A MZ)+<$"1-;:EM76FK72UFT\]N]'GH//W\&'VN5O"/*0FC%Y=^N?EJ?/O[[9W0 MOW_X1+3IC\^DW_V?OG![9W;O^I](ZV^?2?)&^[[?O__ZB32F/VX6[8R`D+2I MWOU=7^@97V]_^^,3Z3L3F%!W])E\\R>6=T-"Y]\48VW\MC^FU4H"B_BS-9E^ M_ND'4*E_#LF`I=I9WI`,DXOK'HV(PTX:R0?7#\./!*)XPGQK,O*#:@4"+A*- M04QD`H,9AP2\&_CN/V<>3=HV&I_E1HT@(UG3Z+N39Q`IL4)HPW7]Y[!:^>!X MT(X_"^&5L$;H#YM.HZ7.AE9D??R$1/^"5",=[(_I*UQM(%?7F?B9,'Y]O_W? M[B\VCI+?TA[:-]_,[O?A,[];[\9#]^A"1OHL*8A3*R!'PQI\.4& M]`4<*3><6IAT.O][:@V'Z=_/SC`:?[EI:G^[(9;K/'I?;G##G@9+(HZ"I?\> MII^T&G^[F;,@&F9>>4J:&OA1Y$_FO:A;OSC)XXMT^TN&.\&N\:3?QU.&S08Q M?IB5>$:Y=I.X3Y/[-Y[5K%15?V*!68.(TQ\D]%UG>+/&:%`]4#)XH&W2HF/, MA#C_7]GTKE:Z.+\9`8,Y*/%_,PN,G@$BGU81W_J=+K=7N]F8^^1/UWZ8>X`9+PH M0:23N0OP6[<'C^#)T6R3LFR+;R<@),QMXB9A-N'':@5<4<)\T5U,G2XSX!W5 M<$OC%WFMJ!3MLQX`">_QQ8TR\W\;_?:HA.+@$NWK3S#TI-U97+RO?CL0OHKK;M`&#^(PJW6^WC:\S/GV=K[M6E7'+.OBRTUKJZHN MWE@XS,HIWGY7]_3MRW^:GT*L.$$EWD2#Z'V&.&T.9K[AP33BLL1[?COV^4KJ M.!S?[TD]"+TF*A=>8DKN0N1$T*V:I+6*)FCN5.1J<>1\*[-3D2\7XFZ[1U"M M"+';4%+7X*)!)Q8I*]HRP:6[]Y8"HE%=5KS7N*,@P[(R]&<#E[[+*G9L=SE< M_LO!N8PJ_\)2.38,B.>-\+R1*SQ1+FG>2+7"\T7RHV0\7Z1\C.?Y(H?GBZ05 MH189(]5*G#)">,9(R2DJR'X/SQCA&2-2_P126%;JI5P#MS"S=89M5FJ*0VU:,K,Y7SL M**2&J)R$)Y=6`1XDY`K8DU5^)9F^05=OG@D M/[M#^;*^KZ3^)A:WI%:5)_^6V93RY-_KBWO*D<+*.7>2V&7!)AO"<3P M.%3!$^%`WJ<%=&E@.R$-,]4#;KTH<#P8Q#^.P>K?'S!SK<)"J]65VFU5%5I- MHRDH9JLGM%NB*.A*1U5,T=2Z>BO&.I1.5E[A`$ZLE&C/EKX[IB+A^;%%L8:N MK&K9^IL;1KZQ8BI"B\?0]ODC#.M3R=D*+6NC7IDKEDO#Y!U6*1;]S]S1A0#P M+4U9*<:R8>A[U#I&W/<0=)U=#7@_2O4@@@%>64:OTK'!OLW>'W6#W;/ M>FQXI=;&-SJQ'#3+'1^1D>UH9KE]&DS$$\&Z2K*IZ7*S*QC-KB@H:@>,GF9T ML)R%V6NW%;$E2C%P]X/ZA_Q55,T56_>^5*^8/JQ_<;+BI>\PJ1`Z.EL,9#<) MJQ#2DVE`Q_"#\T3C]V`"WH_ZUH_WI%4W-;G=504-U4;IF::@-^26T&WU.AU1 M;$*C?CINK-3V78E.3HUOKH,=D#49S)JDJX+2[;0$F.02 MEN&4FF)3TQI2]Q!\\RTW*M^Z7^4F%RO`;E`BU4]QL>*R\.SM-+VN6MF&O.Z$ MR0$8'9+!"QGB3,:SL+4SL&H%?D:(]N?5`S5O-AE`>_X(6YKX7G+"1OR%6I+A M#&*LQQCC?.L5C:\CN.S7'OF M6@D#X[NU)/(W#F9C&Y;W0J:@&I$:P#$+@H`V)?R(6VIE-/^":%-:J%>@/N@8=LZG`#%3F0X;' MGQ`'Q`]@?+/`'K/W9MZ0LC%7*W0R=?T7FHQG_@Z9NI97A\F64!629W!EB,7$ MC.(%1E^DP"Q:PP/FA*1J):$IH8EYV M@5^BW[X>Y"!SBE^BYY?HN7B/2Y/BE^CY/8=MO6UXF?.-7Z+/Q_+/+]$7Y2X# MOT1_)8(NPZ45[E1PIZ*(?"N&4Y$O%X*77>`WKTKI#_";5]>W^)?C_A#GW$D< M`%YV82^CP_-&KN1$N:1Y([SL0IZ4C.>+E(_Q/%^$EUW@&2/[OU:0_1Z>,<(S M1KAX><9(@?9WRG!(P?E6YL,=GC%2>,/)O24TI3_Z]OKBG'"FLG',GB7WV2O[%Q-[WP=CL+4/H52M[8.C5 MB#6=!OX/9V)%U'TABMZH(?/F$1+");HO&!HMPT0N@3HB]AY8E2A%=V0!50QR MR**J&.0PW22%GVD"\+H$QS<-H/_`@?X#&J-71GZU`AT*_DB`M@2@A+XD\(H) M;"1#_UO'@4P0()_'#!)PXK@4OO*6QSFA49WT#@`;K%8P.VV54W)-U=0E7I$E M5JT-M%K)?MR2F^S398#+N!4VS%<0(Y>8N88PN@'3,P&8C`%/$Z1&E!:#IIYC M0'I+0)XUQMS(GR-VPD^3:F4)G')`Z0H\97VW![=6CV0KSN\^^-CY`P17;WZ5 MM*;>>!W?^D#\[_"50B)QZ8FTBL@*YG):9>0!E.RT./G_`DWY5ZQL.['!.V93 M[W6DKB`K;6"?8C0%0VXI@M33NCU5[4G-GA27UY"DNJ(<``Y^.L;L!J!.+$N@=6=$13J/MB*Z!R\ZM>E\03ZM^!S,F*YB'PGYP0 MFH%63'!BHM',32N3Y,_X`?-:&TP1G!&7-JU/^68335CMP2>EU-$Q1- M095N=H2NUNS)BMF0&KW&(:C_8NL=8/]E\%.!-X0QIUKY2BWD#=,IYE,-YI[6 M-K?KLI#_;/!/K*8;0J8/Z3+0G1V(J64UQNHT@B@`?UK$&CNM$Z-@B2"8NE3M7(_"&GPQ.[D)E3'4:CC0>2+1($-]A?O)(^9 MSK/M;]L/`G_@!VG%AJ01A*(? MHV,I@,&*]U`6;;+]`]<)V>;)7[/"S`]6Z`6W#\(MS)KK">/7D,Q"-'X3?TC= MV"#X6#2-_1I'_1,:C?VA[_J/R`*L/!'2]/W,/A)V/03_*W@1V#8(>.7I>ZQ3 M)L@A:QM%) MRB.E6I*NADM;3!LY6@,ZJI5GZJ)9)3'W`NK2)UCB"(6&_8ECIVL<,/#[;(#L MP8(MH-U8R`0KTT2,K4L<8;S-3/-XK62#GKJ6#?RP+:QD`N0&N'Y7*VSG:ND; MG.YH#[&I<#:-JXV@/5AZQT6]84OQ\]BQQS"2Q>J=EE*A-@O&UX=P](QX#99A M#U2&[9@/[VB,F8^%>ZX!"QK`1.U:>[)"`#V.T-$*P&3/%W"V;(.:+OE`Z6J- M#:1S"%I(1\"*RH!<')B["U>\Q=KT6/^E@NJ'#$?*G0>/?"Q;-1TUB)SUQ(-QD88 M_5CJ9IDKN3:C_66?$"8#$R/8F#`QGEO*[FRVM>!9HT^,+FC&34TF$@H3T\3B M5=IR<4>=A&-*HUK6?[6QF:6J4JNN*L@YM`-G@/[PP`>O[X/CH4E):O&4M.B. M+AT,GJ(I'#SEZKKE*![O`281!Z+LSSD,S$,:C68?&RPTS3[[&L>IV8GGK M89M*M:8:D7F*G,)E>G[D>5FA=JQ@N!E39'8-OH%150PD"$CVI(*(^WV MX?.0SLF!A#A%I:(HUQG^O]>_UTD_8-N*+U=P!_JB:=_-9DV2Y8-'P-/ZBW9# MJFQWG[D*.I*RRR]GCIV%7DQZZ<(DX1/W;E MQZX7W)`7B[@A7RCY\C,WK@)N13_(X9SCG..<*PKG\HSHV5_< M\JU6XCN\[.IOF-Y]C\]M%W"<*R`T'N(UXKWP^1W>Y)H_<2(\\GFB*=*6%2;7 MN$48`-[^S>!5,!2,S7`N>+D;@M`A`F183Y;COGZQ>AT-*+OQ],V)Z(?**$.&$9F*P-X\X29M(I2-B)X<.\H3'Q@\CY=T[Q+N6;7UM* MEL`=X]^`.SC8`:V7(.L-5I'UYEIB+,`INC^F%`%4^S28B"=""X/_,U53:@A= M6>L)BM)L"H;>4H1VI]&1-:5KBLUFC`7WH/PA?Y5TS>X-5PK'A.F(%)#C-XQ!X_9!^J884(C2`:N M&3'V1(@(#J3L``Y:Z^`LI5;KX"PE[1T3:/)^T-5.0$:L[0=>NWT(OL-Q5-T= MK=92M(+O<.1+D[L)=AO#^*I6'/#6[:BDNIN/#=H/4DV\=/W/:ZQ]PFL77G*9 MW'(;OZ26YK*KI%)K*F+!5\DB6YHKV%E""0&1CQ+$?`Z?.VR:`J-[\JLAB=A-@?X+V8D2\U99S1F#1#D%3 MFHU].+&!HM5=41LS@:A)XW_?>B8=4:SP\XT^46]VVN(;I]$$!1@@R_+*+NDK M=)RXA$FZS53X`B;RS:_-NB:=L(#)0:Q9F9>SR8`&]Z/Y!/Y.'T]4T"-I:9EE MMW>]M1U<^++1`2ZU%-,4%-V0A7:WIPB&HHJZTNYT##W9Q%LJ^;)UU"L[KS&K MPKYOV'_-G``8X,,7TE^VH8EZJV,:@JXWVR#25E2R?E"0*\$4HSI\WG>\OEG/!,ND!H[E)L5/L%:!RR\V MG&6K2ZG)>J-H.UU(W1<,,>JYWA..*9#EB3&S=9YU5DLWO$AE_,1RY.B%MYL M%?B8N`P)*9QO)TGDV;G6%MO6732`%*6:TFP6S<9Q^>XM7Q%\E0U)9/F6;XG6 ML'*D.G'.G60=.R1);/>I>_:L'G.*#&^(_\+3?&``GD7':1VK*3?YRUJ0M/@V MI9C)6SB$IO4KI(QS_PR)BSKDC711O?M745]+"]B$MRYZ5]*4TV\=T7"PISE*APOM9Q`K& M8X7C-_-E/;GKZ/O$$K!$$55%SW#E0(JVI>]LSA1;OHR99!V^G">QI]UM&`U1 M%O2NJ@N**DJ"(35501<-V>B)75/N2+E-[%DKT!W.)A,K@+?B$MTAX9IK2[ M#NN;+`R,P,W9-J=%>W:\!8O!U,X3)'<,()]Y6,55C]3;R`HW\3VR#]/4\.Q3 MEBA>.(%=F>B^T8GE>&OSO0,#",!_F:VB?B,TR8)''UZH%11P5I9!R,;C8T`? MK6@-EC\*'"]T[.SC?[R"RUYZ\UVPT_OER-2*8/).`\==T"K&8<+.**&X.^3Y M..U5:I)6N-/>"YC88IU_-.K%._[@D_?@46CU1N&`?2\DYC.^ENO,WK\'EI4ZI)MG&UL^B@H6JLVA2_E*=<.F2\=)1.I M7I?XC:N+&]KR452B3/,RW/IYE6^7'G^QN'7PIQ=Y+;?C+=C&Q.H9\N944^YY MGO4,66[JU^&GO*MT+WR'KB[SC>_R3UZMWN`Q1FEGL=JH24*#XIQWW. M]XM0KH1?.?/YBS;>7.]])T>E[((9CT@NA&$D2U>"[W$]OHS8J#?Y26KY)Z]: MEZYD-^$:9[$"$8E2./GRB*1H'O;%"2@8OW+FX1=MO$4[-8FONA.LP!8GZ1#Z M8TIM^*-:B7SV?&-]3AZ[G/\T193Y?8*2>3UXFG(E0KWJR:O66X7S;0LEYLO& M+LV:4KR3;AZ[%,T7OS@!!>-7SF*!HHWW:+368T$6LZ"-[5GH>#0,31K:@<.^ M,[PA-.N$]Z.'@(;4BUC#IP9I-$1#;6B&*>BZ:`J*:?0$O==1!;/=E5NZH?4Z MEU/J-V6=[+XI'YF?A! MYI6DB>57/A+@AD5<:@T9EN4TKC\>((.1\;4@@\":OM/%%J`V#E^,K(< M%Z4T!3$@AF^=],<4,:<8*=@#=?UI6"/`C=D(4:B"I,.)%?R)&+8PWFG@T,B" M9N&_AS,;*^U&8PC+L>\A#6%F0_`.75*/G38BW^+>X1DT%]7P3Y>UFHR0#%ZJ M%6?">.$]DO]G[\IZW#:6];L`_8?&(`9R`%%'%*G-00Q0R^08UXY]/79RWPY: M9&O4"44J7&:L_/I;5R>NK[OL)GK/^)-_P:F M+D4P\X,%_HC#+>/%$O\]BSV;]OL$TB,DA-Y#1+$-\0Q^"K,9TUQC@`A&AP`+ M9)PCN0WLY/`GGHGX-VDJ<_FT@6+%Z^J/Z0H>@CMPBV"X`X6%#_NN?R]#9`82 ME@RKZ`[CX%Z0("78"CQ?N(SY#MRD-)4(>YS[,(02HR<$BAKN7_C.RN,+:6?: M@(*8KUSY`([IP*&%0WFQ`&R"G[E,Y@U^DN7@SW@ MQ=(,21UMP%$04_-TTU10\TP;P@*3;%O)&.F+/1X[$M-&8!#4W\WQCYGTN&=+ M$%((<*U.8V=S_@!B$,)#>A&4E![@>(&#WXBQ1PG2_M2\:S)@IPB(O_"S6%)> M"NZ+T>C(?"4,OW1%2%KRBV6];Y`\247DHC`!>!/(C3J"24$4`<476O"S#1:C MMU#H'\0](@`JX9WV?TUFT=WPO+MJH'*!N8*F>'X$8]EN[`A85+B))<`EM!?U M-+[.0Y1V9&B[?D@V'0@Z@=PAT\-ITZR1H2ZH_U:^D5V%HLC)<.['+HP!T@@` MT9"+P/X_4K,DJLB\#LJ$OLC#6=)NOH$`K$C(RHQIJT5;GA?#2!^(N0S>>0MT MUVO@;_\GV_QW!G3#/;AC'E-;_VZ>;TLI1$8X-N=AHATSB1\+9E3<"1N,*9() M)$X^(US?T\06,@R!8E2">NUN,KIHZWFM^.D#AL*T[`"^_CH)&@GV@5P-.`;,FC"*(!J`=>+D0'@P+D MZ+0`'PLA%PX`?\9N%*8R!O>1&-R2MJ4/TP>$H]Q!>C\\ZL,M7&6:Z07>:OUI M8,<*30;4`.AQ`&`A8!1;7@L>",A4^E6OH8)=M.`_HF45X<_SF=+A<*^1H4^7 M,V`#O#1'/[8$5;#!&L!0MFRSS?;MLLUX2&!#V`NV3B(\\!H,+B`6G^Y'A'IM M*R3D4]@/#?7:4=C`UJ'ARTR^_[2Q^0=A4S3`+,=?4A7%RMEZAQ^H0.2R;VOA MRXG&QRJ,(3V9R2",V%\Q1"XJ<$ZD"&(R&D7%```BNIE5<-D9W>S3$H&,'+=U M]ZG!?O7Q_SB,KK4Z#8:SE?CR]V7P40%S(.:PN$1<@`4"A/E*_G1_<9C4TZ(] M1,IY@+XGZ`06*,A_P_,JKD?G1Y:1#Y_\##HO)/W,@3,0!H@L^/?C,/>EM`[8 M-@!%)2QZ]%FH5F*B`6%B'!&J`PPCQC6*/AD&.CP]Q$XB']C`QJ!P>#0"$:]$ M<9MY^VVZQX8^_`_F`9.[M>Z@>A3%*##CXJ]_,[9#8J;<+4E$G4O`LYIG` MF@A7]C"E,<<8!N4*E#B*&H4R;$V6`!,V!,,AX8YR"BC@U\"#D+V+B9LP\7B! ML1C,BPZ]8-ODC\S=IV=;R&EU M#@T\F/H))N8:"5?)^Y?4719\-"G7]F?VOEUN^/G4\A&H,^LO,I$@&^++P`^7 M2ET8QT/O4U;DH7&#B<\8\N6H:"NUY$*,5C;@;6QKUFO(*F)/MGJ6!"&DL;!0H!4#@R4YK"_W MN-I#``J)Q,DFXR<',U8PC\*[P7[`2K>_>W\8NIDX/SW1?>@LK,0)AAA]R@?*`5[(I&B@%`RH6>..'(:PZ!"QHU)EQ]NICP+V0VPE_Z2^5W;$RY_NK MB-[-/O+/S\@N8S#N&L-)1^L:O8EFWH['VJ!E]+5)_W8TTCM]8V3J>"H6LJO3 MZY78]33$;VA7.F+@+T8JW`4S>)>MX8>4YU3WP>,B?"L]/Y#1ZC4NZ<&LX87E M4?`,NVCU%E`#CZ_#IC+EH)Z1Z\>=1:9W;EX9G<[&`6W/Q9'C=?UR-=M9JM?D[T5A+*5'X`M,?L M!RC(6)6"4`^2$_\NSSZZ-Z^Z/;V,X7M)*%,+DL8C+=^K"IPS7'V"0/:UERQ8 MO?ND3(S1TL7YK[9Y\VJ`9Q062#^>GK7S";<6S"U86GLJ)3Q\YRN\9#W" M.B$IIP/6SX2D4N%K3YT*^CQ'.K;-R;@S-GN:/C$-S33-EC8PVEVM:]Y:G=YM M6Q^.+>`5L,HH'VCZ!!2?B:6W$`G^AG&R!:N)A7K;).F!_LU'GPF!^>H#KOB^ MFL5+F'^1P1O\A?\`?]LM;6)T;X&_O9YF#?JF-ARU1D87F*_W>BHX:#4[7>,, M_#V>_*-.'-TXF/-,L'W&\T9UB$2-@0ZZ>\1YH]OIV18Q@0,;9]6^<[>H]`>W M9G\P[&DMTP*,0OKZNJ5KQJ"OMRVCKQN6>5*+RA.GP:E%I=],\G3U&@5%UY'U M3M-'$?\,*U)UC#"FCES)IV@+5(L,!#52W'OPI).5-C`/L%#IF)A:3%>G?/0C0MH#U6HPW MXFH6TQRE+I-%N[`*+P M'LP'(#`F&088'):K*O>'73<4RV-6Q,M?>LE)M5+2):"FAP#;+2@5@H5)E#D) M>Z4ZB(@FNKS)\[!9KUE9$B5,A:,>RG+^6YY+L[XDY7HMKX=39I,ZM*BB_<"E M2^8B,,@".VBHA/?2#Z7*EU$C`QX/1^44U3OUIRC54/^(G?ND[6&*^?8%9JRQ MW?6#V1RP!4`-M?10H4.&B5EA-T2& M@)EOR+J;DG)?ZI*VJE6:CFWD8X-D`5O_5FI$#8)ZAVKT2>,%J`($KV!RZ(7` M?E#2A6?HIJGO_PD@G=RF8'>=4);3"7:9(+4_FR%X\WNPCA`3ZKLFODTUP?N0 MY@)KD+NDJY@-SXM"F@NXX"0>@CK!0C5_8)4MESR!\0`6KT$HDK)0O1;RA4BZ M4RY:$8LU.()"Q.DPG@*$2AZD[AHN_"%L2G)3E]U,.-AEEY;U@*$---1'@9`; MIE!"C,9F)5`Z[+E3L08Q<:;RC8"L@0P=J1SD6D)_7?&+B`R!,BI3*CZJRPGE M?4$".@2V$$%@E0:GH#0QH/-;BZ2(SWP!<1`]-5T!JO^1*&MI5AL`GQ)_CYKN MJ=`I*8=B9YGO/0)Z@8M!`W\+>L/M>0S*@PUY__$?44_`!PF;P\4-0T>-3_J= MX&U(I>I/Q5FIJ&$MT%,VB/U/8`HQKK?^5L7)!-V)=JJM)'92=C\(-6!O"8MP M&%@>826CR"?0;2D>`9A7:";B`04`PU"Y)X;GDQX[.4M;5$S%F+E+GG2+8PTIZ3%-K4*04_NAU30SH,;!X(*>7FA0 MU)O$V.Y*V4;!KLI#;V_FVN5@5!T>5AN!Q)JWB@O@Y>UL-C"[XFRIZON+""CP MR:J$61NZ+Q0FJJ^_61KF)AHW7>T)4C85?DV!"B\F?*)N4X2/Y&VJ/8>OJ)>5 MA_-R6P%I#RY&L(HE"`UL'&%#%5RQQ+N(% M/9+TO"%>GECBVY<2.%3,PW*`!W'I169!]=;-*\#F0U6\`@U'I(W&THWAVD:N M)2]5/4\":=B;=,;C45?K#SJ896F;FM4>&5K7&K='?5T?6;=MX$'OYE7;;'4. MIX\.TU5F3C$7!Z'-VV2%_<[[D+;L6I[SJ^]E';Q4,RY_4W6FA--XT.U-#!U8 M8=RV-=/H&EI_?&MJG>YHW!I/X'^#]NG?1#U7.#3S<75#/6$JTY*TNX2[8^(\ MG8(Q:!"KQ6**.^#"HV)+1?H-2[$%9\I=ZOX(YT)$#98V?-'#Z8<$Z4)*`;T- MS]TK0\\;;6%]"C#T(\;S^5GB+T]WNZWM&;Z?6/&#WW;.\)T?:2H.EC_W'+U[ M\\9Z?P=#V,!JO@S%#83_P*G@YQO0)3SS)UQR+(%D?R^YXZ1_/THGFO]\,VB_ MV'9>?/J%$LAVE MAKEY5,8&H\'0P*0\JD]OVLR7X*5>SMG_;^PG)P1/`_9O->GW`7W_*+WR9:IK MBO*UM^ISQ?+%']]@19CI_]J7^__&&\A\OQ+]A)GYLD#N\A5X^0=JT%B[-,64 M/7T&7KK^VEO&.P3=K@1]Z8+^Y/D'Y;I#@/FM9YBSTIAZS:A4YENHS$<_XFY9 MJ*.D`[A\E18DWU!$5[:CGK5ELSQ5S=@?PU_"5DS?Y+:*HHJBI[KM"<\',+X: M*:@,\S&@),^J7@NS3]TO'B>N<,NV7J_1KG9>_`?LO)AG];4NKTN@_K5CXSWIM51JM2J.51"^P-/J< M);2JZGKQ.E1572N5N:^JKD]8==WU$5E5=JTHJBBJRJY5V?7(UYTU(:]?8T+^ MJN1;U=PJ%:A4X)^N`A7*5V77:R_D5)RK.%=Q[EHX=^)ID>?XMGEMQ\?L_$G+ MMH-8.&_R'Y)OHP634O^VWNEK+T`>:V1V:VM#`37"[;6/4GUA69Z@?^B9Z MP8-[Z6FP^GV)6]HE?RJ!OJ0:-$Y4P\UKO.AE_T5!R$6_B/_69GPAW=7+_8DQ MQ1K::<$+A3I``!B;;2&4?2J-GQRSD[\XIHG@"U_2%]X%\EK;R$O).5!1/[)( MWNN^*-76=Q3BTW^<6E#O]:N"^F:<]+4!\B7%W'L2_JDR*?5*53BK':3HNC5J M/<(ZU^H"&Y\,T2]9-0`QBA*8RNQ?F1Y70C[5$>F#*Q/Q]055=]S%S7BSC?\K MN'H:N-);%5Q]YT(>F-#).M*J0ZI"5?3=7@=+3N%_3O#*-K41\:J*J?^4KORU](I?85)G4D[%O94MRP@ZJV&;E0.[3L5;KMA]J\M'W3UKBSO M_'T.5/[:MUV.,_NN^'9BG_;Q7=6'SC';?-[R'%H3ODM/BRO\=H%'G1DWK[1V MJUT^)_YKZ2QS;>2'T;O9+[[OA'>^ZSPC$PQK.#%TJZ>-\#!YLVT.-&O2'FIM MT^A:G?%D/!G>`A,Z-Z]@F=DML6!MTF6*/H@'X<7/*L\C20%Q&OU>WRC1DDYW M79G5\76K+EC@MNQ.9[H^JVFFWI',_6AI0W'5D=K#7IZ>W`[[H[U\4D' MK/6W;VJWU6F>\%F=F_3"_NI'@IE-W*\F.]J/$&2:>;E=69ZM\^T^YWEPV-;I M>WBB6[U&YV+F)RSBV;@\3#Z#"+_L(X@KVUN0/INH/H7X@LO?TZ<0E[M)TC_[ M8XC+E4OU.<27W'UE.VE]X(]LP4%K)$1;JL@EIR\"_#T3XO8+24U8?3U'? M@7EUZEO)^0N\4&MPN-!\87*^LL#J5GHRG`N'W6/BK(*M)U5GW3S\G>F%J7,E MYR]P3V;GZF'KBK<=RY,16W3B[/L8?>';MMQ<\>WL73)[?>UU8]TW74!BXT3O M<&/RA6%<)=^CY:M#K')XWX0+D^]WY,.^C\WX*LZ=Q8\==7H<;73W7*7K>FWD M+Y;<6R4DM%OZX*>P5,$.A,LCP2*?R2ADM@SL&"[XP8K96-Q>!KX3VU&]YDI/ MA`WX6RYX(-T5;?]G#3O`W`8;_G;'\%^8\6>O%TOANCQ_=`D#SOQ@$399>1E+ MMS_F*3E;A.7));L-4MG=D8&PHZRZT&`NG_H!#>$_B&`NN--DXQ@W?V2"V_-T MB\)H'N#>3`O@X3QDPG/@[1LU0H;5)QH+_J$WZ,&$=<`A&XOD#ONAU31@(.FZ MTO?H9KC29LF%!MP8+@4=X.6N&D`'>PQD)#3'?_1"F$V]EI*V:FX"Y*'.@.?3 MF]O`7[`([@"EJ-?P'V5^N#X'>F9E26:D,60-"^=^$&D@J46]-L6M.%'![#@$ MBQ4!]DL$S!$@DC`*:+X'NDM#/@ MMK82/&"NG(DF^UB8Z)SOD)F9R@R%A/,HO(Q'.[0#Y@!/;U8QZ<>R\/>+=[-K M;E_#4+FUZ#U?X0X^X4??LO^*P2+4X7"(.W?94107V`S7NWFEZQV"XISLHXA9 M[WA;+&1$3UF>,_+I8U;AV7#CTS5;3<9=JST8Z5JG,QYKYF!B:`.C/]*L\;#3 MUL?CT:0UN;AFJT&3%9BE2K$E?I$J[JBU']5^M:U-J93U;._:?_8+:,)_2/S' M&]"*^WR'/9G-^6M(N01859#GNP^`<0!+KKCG+@$6=Q:(M824#^#)R%$*;,M2 M:&F[7"[0P4!H%$@_!JQ=+04XV]_GTA6,(#MC&NW@&W'IX;-,N`+5`Y^-/5L$ M^$,$O@LFS^_53TL`-O@_./RI<*5XP$V`HSF@),[=CR,;$!V?)Y<;QO"?XOP` MYY/I/SMD,N_R:S-KB(U0#2UFDCL2/$J)D@G`AFV+"`@RK M4LF=YG`RM+K#CG8[[/4U\W9B:H-QU]!: M?6-DZ>9XV#5'IV#GC@;)LT*GWFJRA$,*-R?8!P61;RC8[](1+&?7]32Q)CH) MH32I-9T]2T'4-`XQM`]9J$C.#<7\"94Y2+81;+#"%H(J&`JY2[:_`&NW0:OA M!CK5%FR2AVJ;\`">A_C?%F08RWBQ)+6?`=Q0W)?N(\ZEBY``47P0E:*XLMW: M<:K%*HMU)X=KRD\0SXS9^0+'" MT7\1*(A$CM*SW1@L&A)P)06CO&Q`GR3/A8\X[\1GI0A;OHHR6 M5+&7<+/W@GY/E&>WCNQT?#M(W;8X8J\13CVR''@/@@C,YO_9N[+=QI%D^RY` M_T`8-4`U('*X+W.G#9!:"@5,M^O:U37H)X.64A9G*-&7I%Q6?_V-S"0I4ILE M61(7Y6"`+E-<,B,B(Y4438Q2XM#]Z[-("LA[^DR6R@<7@WJ27V M;^1Z$%)V!OD].PG@=A\$Y'I#3P(^LJ_;8YHMSLL]-$9AB$9?9WA9]=U]Z]/" M"PZLBL9>7+V-'>SKK.*F[ITNK&QGZ5(QPFMCG/$1%C*_N3'>^2WNQC79VIHW MM]K:SO;0?A7%\CN*J?C^%415[/+-K2))5J''A2:O]":89?,7O2J1O"3U MYI8OTM6VMGYU1>WC!PP"614LKTMKVZ\RV>CII/OP' M%.+EX,,$YG`'+WBZN?3X=K9XNAO?HV'P/,.'>]]@=Q2,,$,P.O5&1!GH/<=2 M>[QD2P:O]DV;-S7+X75UT)4D614'MG'(1N2BB_>LS`[LO2FQ:S[%,^)?\%@4 M@Y!XNJ+,%R!(B_9P3XO\=C>*84(GZU)\HL]Y\`?G[=@I%Y8!V<.4"9?;(1\R MQV9K(S+92HPUMYDU9\H'L^;4!*2PB.9[8 M?:;`<'%'X>(8[ZBYRC5JI]M*4R*;42:J;N033:]=Q7NFY<.UO$<5BXIIN6:K MJN2HLL,]T\/*)&I8.*]DCNR<2ZV.9=3.R)F>C]"SH=5]X55GIDD36'],;B=@ MF3"VY+EU;,Q3'U[J]>16%BW=@>6>WW MM)YJ\%)?57A5547>4F0=8UELS1C(DM.S'^']-[>*N(+L.6EOBY+\DB!-STL]D7<<3>=5V>[QIJ68?+=K*(9D]?6NHU>-3*`)[58J&6+H6V)XE2(+ M#-TP7!"X$04)X[C5$DA\(-PY84_^=",*I>:*2&I=,+=1:/$-$WCL":$9CI$"VB&$TCSOY"*$?)CX2[F\"K M)TML.`@#MPS#R`]'.WG0E*C=NJ9$X;IY..3I\$3A^@6Q1U4_#'5Y(HE:N M$?]RA;OB!IY/UFB:W,+_:JBG*7>65#M&_?*J-LC37.4ITHY#B;4*="53+O?E MJ.DWMW!%7"DK]S[9LD_28MR-T[75/2RM[F9=-YK@_!'PGSYLE4'7)%],Y4B' MLG9SRYM*D75X2)=.>^SW`T4Q)KG2@["!ZX4_7']^1H*?MBHWTP3C<#2--PVP M&;5G#GC'E"008U=3>U)/[ULF)6O*X@H]]4R=WT8(W/RN!\Q;2U\(C],V1-%\ M2J\5RT6>Z`114K2>K,@V+]D#DU<5>\!;4M_@+5V6'+$GP4@[*)63>%$6(`@: M.^,Y2MAWE'KWC,]DT8@;T=QW!YU+4=(\8>']1"$^^/-)_C]X`*<%H6_+V(=P M#UX(X'P`KRATGZ$=[E)AS3S%N@QQSRB'N'?6SS)2%B/N,>)>1?AC]2/NU5K< M%:+K5?TTYMZ+_LN/\7K%PTI`.-TO/O5MZ!E,-4Y[1<$HN?3)W\KU'@W4J228 M)7.*]M9IQ6-/26I1NL$BB:7;K<\XR73T"_-*9[1@55"NA!5WA5#E MADL6[R'9_()9EFUO:Z*_[6C4#8=]Q4HW]-3?C;@<,!7G]V\V,I4EXSOV,CNO M96?Z[$R_(H?,]3O3;XC@*W2Z7_@62\:W=]H8O)9*$10[USCUW2*7BO9D26&: MK%RQ=L>TE8XXW*,H#KTAS;`.CJFA#JD:YSN*4G+DL^&>J1I:ECI2_=-557P1 MM>JVVBV,8F[J^]5+5^5YI"AG@J7&Q].W`B1XO0S MYK'.">I@RZWF*UDRZJ;D!A$[FT`A9W([3FX?VS+4V_6Q9*&-GME8LM`KGM.: MD:R`2>XD\]K[T+83P\^V8]ORK[RGU>A)=M&U%YZ\@&W/[(H]T^GRHN$,>+4W M&/"VU#5X9>!HAF5U14>L7/)+0^!(I)4GDFFW\M(CBGS*',Y!&#-6?)<5WV5X M/X;W8W@_AO>KF(TPO%_S!,_P?N]N-2L>JF;%=R\8"ZA?+F2F7%9\MQ2_Q(KO MED/;91":*]`R*[[+BN\VV\19\=UKT3,KOLN0(N]\;L8 MGJ;14QG#TUSQ#-8,5`B3W$EFL54\#L*K#/O`;(1A'ZY/ M\`S[\.ZVH.JG]"S7T7GWMNP,OLG*9;F.6*ZCNL:-6*ZC:]`RRW7$2>6T_;):Y#7A4V$HF.![ZHB,'II^$@O$_//R/!WK\=9>+)WK9 M4,INK6D^'PPMBW+Q4LX=QMZK%R\V`L_:K5U)=IJ))[/D@_%DNG@PGDPO!T_& M/GNRSS)DU"4`.B3M'''"2WS<'^"30G\!X[9X/>^Q-_OIY;TG:-IG;[84<1YG MNVNBJ"22J[[F\6\":EH%4-JO*'2?4?%B_PV%0R]:N?HM](:H=@J[,M7=HZGK MS=;&>Q<:$,+Z9>[ZQ1^^HW"ZE-'G!7+#&H[*)BC9?GX.T;,;KRCT*RC.FT7> ML'CYA^O/=PW&QKOOFF$&[N9Q%(/,8&1R;@R#]R7T_&5?);I-V+E+J.^)5C5B M-6I'UJ\D)G=1[9:;8$P4U-J=5[+!>W`K=*%^V-N2U'S&VRH-=?D2NK-DDE2SK5IZ^L5FDG-ZF\^2+I7K;'YA,\B) M=6H(.MN+E>YNF]>C2F\[NNX,A\?1B&8\16\O7LCFCO/.'0J;.AJF4DN02]8I MFSJ:V*,&04.;`-M_5VYEM[]>TCKXT5)NJVQ[:W8PL1I#W@PU92O/L\:0E6MA MOUQ4N^7&D"5!80??S1^\NB"R/49C1[$F=F2C=OB>!NU/FD'`NMP.Y4KD5;$U M?]W:6^FS[R142@AF;$=2#B*GH\BU2T+"=B3OHEH-%DEM_N#5!/E*3A.N<12K ML"-1:Z=?MB.IVPJ[]`[43%X56^'7K;UUBYI0JCOWBJ*8@G0X]/:"=BL. MR'78O&Q)W,'V+F>-ID@*XQ,T;-6#HRE7HM2K'KR:8-9N;5LK-9>[=S$Z:OTB MW6SO4K>U>.D=J)F\*K87J%M[JU[ZUDV3P+1;7IKX!7=LCKA@G-9M@_U+PE#C M?KH1]TD6-&[J^?Y:3=QV*U\4=\L.1^#PA^,@=GUN['KAVN?:K63K-)J'&'JV MN>3NEK>G+12A+;2)PLXM505T$*8IE'!=EQ`-@^<9W)'4>ME4AQAO)V<1(K*? MSQ)A)95ATM21/]UP%&W?9A(QN2\O8?#F34']_H+[I`EBJM9.NS5#,=8)?&., MO'@>HJA#]K)8&S^3_%"\2U-"<2\H]((1%\"?W,^)-YS`;1XHJRNV),"^E_"XHUITMVBW0(M$$S0-:'!C( M!8D64H,^T]P#6,'X=O)GNS6"Y[EYE`X:QW?!@!Z&D\"'UR9/XI=2,YH&(^33 MT;C\'*F`G8[[]"O'#,1VJUC[>NCZP[GOXM_YUD_R_)[LNK8!V[-KMQ&6'7LIHB[0C6QJQZ)N?>B__)CO%[Q ML!)@A=5NA4G"2Q9C.=-!GBB4#8K^6X,B*]70J228)4=8]M9IQ>&K-`Z<[L5\ M;PP;G7P29.:5SA1>N)H8X14J5Q,4L6[*K=E2JI\A6%X#WXT]WXL7S&&=TZ9U MH2Y3+O-3^^I4$DHN-GW<,JJ"<:LPW=J1N!79VW%X:X>ZG%T_(S2FF+UG$P6.K];LB@?N1.4LN=YS-N<7S<-)@>`5M\02^ M%(0>_,XM?2V7O#\)%R1JE$7)^I\H^2C)!N:._C,GX2#<^K$[A#=%8$(@'#3V M:7NAWYL_$4\PI6KJ+G"P9AJ$6$0CN"GV7HE8QG,RW%3O MT-C,:HK1'GPE%1:85AN[>(<2TK@'KRIY[LA?KP0B:>?C-#Z@UO?EK05G&"(ZT,^_0=, M$[]WB,+8!3O$`7\<,AV&'OA6STU"N%DHE86DSPB M_*IOCVINBX-*VR.V)[ENL41G[0"UPYR2B5"3U=N M<>>*+_X^GSZA<-F58%RT+%+R<_ESH4X;M+VP+:E?5;_ZZBTKV)AU9F.Q1E*Q MANNE(=`+^)$![&S>+Q[(XM8[\BYRI'0?)R6+L9UK,7;J^K%6F,:5)&R[J&[+ MI0=J@E'RJ>N'HT/5/5Y?=0/0HIA+NJ, M9OQ9%DOFZ[*J*"=?+"ELL71:1Y2$YY@O.J\ODDK&'#-7=/)5DBBH++OVSMO. MF@_B*NK9E-W^2DFK9DO\E5-2'+'BLI`UFVW/N4KLB*)6-]=<@XFWW'-24U!K ME]>[0?/ME>03*KT#U9)7Y7'66W+3;,U'$^1FY55T6[N5IJ79"J3K<-YLZ,_) MXR\HA#=.<;EC/H%(T^<[G$N`K+LR`$FRH&=)BI*\->W6GHEKN.UY:V!Y(:@? M3%QS*>6EO06Y)=TER$*>I(G)88ZQWMZ!)Z9H2J*D8_/"T*49M\P+0U(UX=-P MI=XV9$7#><1 M=3]/X"@H>R/!XB8.+1T0<&4,MX.%$@]!K*9#C9W0,^!?(N%9T"S0&\"]&YQ> MAO.MLK_I9>,)TS_V'%"=]>ZF$@W&&]1%-9,"F%\"S$WP0-A>%,V)L8(SD"RM M(YDF=2$1H5C`9`6-2=Y!DE'A!RC)(94[>D/#><)?&'MP-:(:0],7/U@@PHV` MZ0#>1J>)G\'<'U$MSE_P^!].//2*II@M`3>]P+=!;T_$-BS@OQGR* MES!X(K!J8HE$E%ES\Y_G8C=\1MAIIE/A%,6I^"/$Y69S_)*-:P+,QT)D_9"; M1MWA,`CQ''^<9ZRT44OG,&K95#MX%7HBHYXB#/.,4K)1A&8>?!X:#&N$U()S M!K3)].E$^H[M<^^8/C&*+;:_X9G,]/-ZP8XVT<=O;CB&J%%:8B27E=;5L=NML&*>'# M[1B)JK;R^K5QV&[M.Q"YC>,04S`/&(B;YR#B(O8?B"MS4+MU\$#DEN.PW=H\ M$*5]!B(=U.\8?Z+!("1F3&4$=IPHA72@0,1-:G%0HE0V2M+[R5#*I`B/PNB( M,'?D&,0Z#&26:;?=GE1XT1Z[6\NK#OB+$-W\2!2M+MHM7P'OEK47_-R>L M:#HQ>B#V=/N]U?7E['`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`&%66465KYX@85;:YNF5464:5;8`9,ZIL\W3*J+*,*EM'NV54 MV<:IE%%EW[V-464WW,RHLL=*JV9+?$:595399AU/,*KL%<^WS:!^,JKL":FR MZP#$B)1+RU"`\33X1&;M M5BHUHL$M\>[*L`FS5B?@X"@M"Y6"])<5.#X3PF$PCV#-%?W",('I(^;!F$"M M'$C@63_+\%F7P/FLP?+(+QE@IY:%ZYN@EW5N4*44LVMP3@AT[-<;Y%M8YY+?B':U2OU9&-#2=TU59OI:., ML,M#>`JB--$1>D5^\(+)9PWU3E4Y!Y65VH6HF)X/GXZDDH$NC8=K/;@^IBFZ M;\FQ"?-8Y_)8DL@\5O/U;-4>.E$M__1O-\2@]P5S3NW MCVT7ZNW[RH4PBQU)87-;<_4K=U2S=F=$#9K5FH&Y9I([R)9DY$[N3$MF<$]HAL:DEDJ\ MHZ+.MG3A\KXIAX_'X>=P_-_"8(C0*+H+TUS$@R#\FB1^OPOOT=71'=X198-7^CU'U@==U="-1_B( M,G215[6>R-NJHO*&80YLK=3;SA/7HF[O-(D6BB9%K2FZ9(BJCE1`+C&>5E(:^*PH)7B%U3Y4VU MU^-5RU9XIS]001Z:9*E.MVM;&ATKZLVM*(A:ZDD.Z%1.%CTT#;[.X,XX"!?Y M3.C?:$;ZH[NO6IKQIDF*KEAKVM8=K&>=[^JR!MIV9-XV#9$7>W:_*SN6;AI+ M=_!-^C/IX3M-O6"G5%%;-^%].B4G)OQ-.ZA3&7%NHX$?WQU3U50\:C5-/6;4 M#@9J3Y/%+B\Y79E7^_T>;_=AU-J&W75ZAB4K72G3XZH7V]R72_17$JW"D#QM M?S.WKF`ME5S"]TD?EJ,JFVLRDKL62`+&O2[CNA-Z7^.M@=CG MS?Z@YZBZJFM]XLQD,N[E/R7Q-UGM+<5T61%V676]@#QQX%VQ`1)#=8##@'=.0>5'4;,?4346WU4Z MW==5V&QH/=7DU=Y`YRW1,?A!U[1TT5;ZII,L1,%WRY:XSPKFW,(J1V%I:OXD M(3\9U#@#_R5T^/B"PO]O[]J:$U6"\%_9RCN!@>&6D[J;'93,7DX3UNN MD(13BA9"HO_^]`P@2$P67<4A\)0(3$/WU]/3E[G\?-OEWD1.DFX9FB[KG(S! M[\:.H7&F@F3.$B3#%BQD.Q;I<1+QS2Y5I7D@?RO$\PQ7;<"V?D^%4(-N3=S\ MV+8GO.WR?3,,*SU.<53!,&U.T1P$,2^@8MB.R"'7U34=@3>G"V7?%[/N^AY# M*;*]4A-0Z3;TK)I6$Q,7Y1)K372K?238,*KM\2D!,%0G1#J)<%H:=TF*]C$D MU]_=*B9(M@7;4A$G"H8"F%@JIVFFQ8F6*JL:LFS=5K)\+?4?24)?1EHC'6G_ MV.O8(JSMBHNZ8YFRBSC%D4&U3<WH`M9&?.7P.4V"ICB:+V.(<5S0XK&B(,RSD@$]D M8\?&@J*8=L44:+BH!9]!3"60FGDQ*<:1;?SNYZ;?)JS`Z*#,Z)Q96MM6[3J< MS&?P]"JK'#68E$K)CQ=YAIB&-%K5,4.HSCO.YW$,=&&`=>,$WBX`5L]R2)Z)P9 M9S69)I[ON=%\1A0QBF>9P#+9326:\TZ\[F'=* M"HA!SX5NG/V"WX%'KCP&?O1E.7D&"_#UXCF.%U<\__KZ>KGT)Y=/\Q?>NO[G M8D@8U)`LZ'C`%\T*4DO_B1B&X6#U*YIZP96_6DR#21#?^.1`TR]>`'?)I*ZO M%T<2DKG>3PY`7,"`AJ;JYL'_=`K/:9PDD!(>Z6'!GR)^(#/#9':X#<)#D(:+?9Y.G;Z3CL(G;IA*4V8+?) MY!'8LG"XDXC1J7IM0JQB)SL)&IU0VF+0Z.!V-WKH(GCI[.RD=T"K#S[ MGDG`[D@*>!NLF_$JF"6S3@)%UWZT!J@@[!Y0Y35*3`(UBD$"I$VQAFD\+;G[ MU^3\BY!F-\?3+F&WO>2.3>PVQWS5JCQGR_AHGKI:6R95YZ6YOO,7\RC^%H1O MW1FZ<3R$[7:Q:WQ64^FD5M"5J1W7BI$_G0;ATU]^Z$=@-$+/\&9@Y,'S'9-J M1[X>O9/Z05=R=UP_R.T?CW33]@[IP,E1;Z=T4*7FRW+JK(F:;T.).%0/?]0\ M_@PGXIK`O[FT'GLJT-7D&\O+L:D6?EV6:D(_1)N:.J MO5`/6*%Q8%E>9+<[.FER61P#L`EI$5&24)]*W0?'(`3,X.FTC"EQ$J"87SL= M/%D$*6AB2R-()XGFBR,'"6>$@N5%B1]`?!`,R53M*7*I9^PA^$B;.M MJ3JC(?IF>RMSO?GW;Z!)@NGU-Q)*;P]%FX>NPT42+^D3Z#=]I_;'W(S_FT?$ MD"Y_/-K^KQBL9KJ5Q7NUXX?1?>2/ETE4>N(S=.22$K&I-CU2$F(@DFJ29\0> MS^CT./6:E\K<=NYT:9Y6U>!5P5O>,5\DVF)3A;!O,O,F,=DA_ MF%X>\/GOE`1I56E?WF:T2B2[!QW=WH]2>>O_G*@7O(","OY)N^_)#(:E>%[8 MK3IO3V6SNSTE:_OA?!:$[Q'>)9N"YMO&`[[T[3M9_]&[.BA MG%4"Y&*-MJ/4I.Y^?W;S'3*IG89__@=02P,$%`````@`NH`&06'5^H:8#@`` MD\(``!4`'`!A8FUD+3(P,3(P-C,P7V-A;"YX;6Q55`D``Z`C(%"@(R!0=7@+ M``$$)0X```0Y`0``[5U;<]LV%G[O3/\#5WW9G:DL7]*T\<3MR+>,9^+((SM- M9U\Z,`G)V%"$%B!MJ[]^#T!2%"6"!$TR(+Q]B6,:E^\[``_..3@`W__VO/"= M1\PXH<')X&!O?^#@P*4>">8G@\^WP_'MV=75X+=?O__N_3^&0^?B_,-XZDP" MGP38N1I>XY"19^ M`X_^.)U^=`[W#ASG(0R7QZ/1T]/3'O;FB`VI;'S/I8N1,QRF'?\>0SQVWNX= M_+SW=N,O4QH%WK'S9N/1&<-QSQY@.G8.]P\.A_N_#/??W!T<'+\Y/#XZ_/=F M:;I<,3)_")U_NO^"POL_#:'&08[KC\Y5X.XY8]]WIJ(H=Z:88_:(O;VD)3\A MZ8!``WXRV.#U?,_\/M?*2N%(T&0$=90OPV3(L-Q:,A M2/CH8.^9>X-?18?O&?7Q%,\$X7"WQR8"3Q=+'@^39`\.SDP&Z7WA"W(?[ M;X_V1?T?SJD;+7`0IC]1X%T$(0E75\&,LH5$/W!$^Y^G5SD:Z)[0!8R(F#IA M,A%'HN!(J\U14^13J/GG;0AS3O0QF5V2`,:+(/^&7@&:K MWY+"#6*X]D#4:#I\P"%QD=\^*7B5`=[8#S$+8.@?<0,6NVVU#G<"DF!G=+%D M^`$''/J(.VV`6MEDZ^#/$'^X].D3OPH\PK`;-D"]VU9CN.>$NS[E$<-"&E$H M-<%D=HHX<<>!=T[\*,3>)QS&\OE(.;_![/8!)FAM'=2@JQ9YKCN8L,TNQIXG M7T+D-U&S+^NE17;7B'W%(;KW\2UV(P:=89@MCYB'8@KQEQ.J:KCEF4@#T:I0 M+X_P'\J@MV;SK:C!%C%O--OR3*ILN446'RCUGHCOMTRAO-DN\+NP$H%UTP+D MM*4648Y=ET78NWA>PM+39%YO-]0BQMN0NE]/A;9X1(L%8JNDJ\E2M-]\EI>VVOEL:EG+U.FD16Y?L/"' ML3=^Q`S-\9CS:"$%R3\#E#N:!@+P)2+L=^1'&,S/N,`'AH*PR;O40M]=S-$I M6`6,N-"\'!,P[K:>?`Y(R%N'7KN8-VO:+G-D<-S8<6-950` MLR4C''\A'LY*M,WNQ3VVXZ!]HB'F=W3M@J^=+'X:<1)@SL\Q=QF)-6+@"2<% M]/P-P!+1$_'T#C^'IS[,K;I":+7OKL5Q@5A`@OG:@>F`M;H+8^3NA)]3VS![ M>4==$UVK_XW7JX.1+._&*,FV1U2GLZX)IY[A*L/0P:"6]F*28MM#JM%7UW13 MK[/3`2WKQ"#!MH>SNJNNR6ZYY["4R[#S1P)T?!E`ZW2<7]9]+X72]MQH`J)K M`64]3V;Y"(EPY,"WY2&71H1T=6_02M;J8/XT!=)S0;4]I]J!T_V"FGB5'=L, M);UT31&$OR#QK@2\V&11H/N%0#WUA%4,81A_;XH?<1!5K$Z*PB9Q@\;:T-:?:.!J,5!6,\$E M#:$H,*__;`+;E3#QY@26\EA;P#)Q\>SZD4C*F,"X M,3L5$#=+&$8(:EBJL0?J>YAQH8[%?G,5[.)JAKF4:\">6(9%68+EP,MJF&`@ M3=%$+U0I[>*RQE#766]**IC`?\.2]:_2."DJ:0CQ$HS\)(2<1I!UK%N=FF88 MT25FX>K&1W%B!JB]I8ACTBHF.$Q!E9``>^F&^X:/"186<8F*B49%$WRT M5Z^>K%=W#",>L57E:UQ0<(UW(Q(W9GGHB+EI@_#?G3!<_I164F+$19J8:&U( M0KQ(Z\\87>QXQ&EG5.6,.I2!B.5!P;?[^P/G26;@R=_AMR4C%):PUP+BJU M)G]HYXNML3!O9TUDXVV1Y:5-696LD+&VR/C28ZW:@,PH6V1[Z;W*A5'8C*]% M[K`>W]W]\(RL12ZR'EEE*DNFK"URF/4XZX2#,_H6*6X]^D71V(QN3F,/7P/? MVGEIF3!>HLO[F$B:OSG*+,S=JZ%,Y)LM1$;R7\EE0]L18%4"6GDE,[E;'$0J M@KG\%MX#9>I6OI0II,)]R.XW44+-%3.3<9,JA4O0-W'.?@0KQ60IKG,4]R2< MXAG-'<:_)H%4"U?BW#KF8M,DWTJLGZYQ^$"]W-5+A6+XE@C,21AP)^-\B@-8 M>=7I3<6E365CQ9*+494G96V7-($X=W>:`FN^C!&4L%K$DSN8QU"2P58A5I8W MDFF3AU(BZ:*2QG*#Z@J]HI*9W`Z.P684VV#GX)/[5.Y3E],HKV.&A0PG"#4M MK^!1S9[=<@;15H`T@^T6^9@G"*3%HU;0A46-8,:^+Y(-8%ECR(=9.?86)"`\ M9-)`+I_,FI6-.FHJXR\?=MDR9:W5F9TV18D"6VH)7[.85N3SZQY!O*V\K](4T1%KCQBAR.GL>3 M*]VA[;RDG4"`E6F&M6A7^8U6[GB7N.]YPRWU>ZQ,M=-DN6O)*'*?>_XV;WNI M.5.TT$NT,D^VC&9!6*%98JRQ72/EISG,')C?AE%QJ459C;]#PJ4A2L5N[248 M9F0>Q/DW[NH.9C='KGSQ`D_^EKR&WG^B>)6N&**..NN;W!I(89>3&3^[\N7+ M>37YF6ZEAJ])N6:2@U463(V9K2N2)IK$TL5T]XM1O;E,YP:#U(13+9*4\#F. M?ZJ6U3I-F+SVI=YV=U4M,TS@W7$)2MZ+S4BFDH6ZA@D&%[,9S/3)[.+9?4#! M'$_A=9@$Q5-(0:E6$X;2*G*3_BK82DQ7)UA4U.L7F^S\6VU"&U5[PVDKCSX] M_[7VUZMOUVG<;#]DL95=KTUVNUX_V.2^4J?)9/=#=*99)&<34Q$7GE'4IJ?5 MF-%+MKZ`R8;/Z9-J62LH:,B#%PO.#:./!.S!TY7XM--5D.0`!_/DJT;JJ5>C M@1[QBX/N#?@5-=`C?FO=_%)^10W\'6%27FZ4WK=.QRZ8;L7?,U6@UZO;"U;* MZUQTJ:D;,'0EE8NQ)S=<12`?`%VC4$A\-9G5&<':[1AB^T@X>$V7E)W3Z#Z< M17YJS*J)J:L827!;?^$@_Y7-0O2*PF9#<"\(5FR%(;75O96I`AT)J'"]M_(0 M?4<"*C3XK#R[V51`]>([5I[OK&\4Y\YQZQD[EJ;N-!--?8O"ROM:6IY`)7:E MXGH7.V=1B5?VVO8:FTF@=)?`RBO9FLFCW':W<@NVF4!4CH"59SV:B:(HXFCE MT8^F*J-BB]3*TR!-IX;.QI?BM,BK7F(K-EGL3%1M6R1Z.S:*,S+_9[+:V1^W M,X._?:G4VI.V,NF_;:'M;%XW.S;U;;/#LD]S"L,L"I,SBF"J$5><4R5^%&(O MY^'<8";-.1/)8U^D++$W?H3!FN-/T>(>LP2D!,4G4V M9B*47HAU,E.AK<.XI)4>,=T!)^=H/9Z*-HRJHQ<.[*9.JBDQ*P,478E)1WG8 ME.Z;*?2UTIZP3;6=W?QH^%O(&=*B2.OF*5KCZR(-!`YQ=#]S.DPF*UV*ZQ,> ML">/L%4E+.4+__TEPPJ,4_1TC4+,"/+EM=?1!+=_MNC?8E-/$G[*+VCJQAE[>I&3D$MECY=83S%\D)L[=E37<_<9WEK MO@@5E8Q=6BBOW'`)%YM@V]\1*2125Y(9?$!/W3JRDN)%? MP4>KKMDO>57-M5Q&6O6[9J5YJB6$^LK42NNUUH2H?,VMS`BI)P(]_6!E/D@M M05090%:F@M220-7BW2SQPY1G(+])LI/A-,4NG0?D+VB\-T',8J1F\=V*2<96 M";B)'-)^>'S%TNJAH[RUNS'F\.)*.7*QOWU'SQ(`^!(1)C__,YG%@N;RCC#3 M4W0]!XN!1T)\=? MB(>S$OU!_8F&F-_1]<>,UM?6\-.(DP#6RG/,74:628ZQV,L$978#'*"0A',' MW9^"C_.U7_C3SXVE&W"VP;P3IJJ133@UV+4.VYC*/95K*=0^RG8=>,\`]U2T M94C[*-DTEMU[P98`[:-XF_B$(?QR*#.9GE/2$9#).7#&>G M0=9'R_HY*@W)]'%\UA9K[U\)\3U>$F<`B9.\\I[^.89"%KS.B>4]Q4MQ$BZ8 MUP+\?B2`W,.4@E_^!U!+`P04````"`"Z@`9!5#D1.6DF```?&`,`%0`<`&%B M;60M,C`Q,C`V,S!?9&5F+GAM;%54"0`#H",@4*`C(%!U>`L``00E#@``!#D! M``#M/=MRY+:5[ZG*/_0J+[M5T6@T8SOQE">IUFVBVAFUJJ6QDWUQ422ZQ9A- M*B"I4?OK%R"[>6L`!$B0`"CD(;9;N)QS`)[[.?CI[R^;8/8,8.Q'X<>CTS=O MCV8@="//#]'<_OSJ^OC_[^MS_^X:?_.CZ>75Y\FB]GBS#P0S"[/OX" M$NB_S/[I@@!`)P&S>^'/Z MES<_5/ZRC-+0^S#[KO+3.01.MK.'0/HP>_?V]-WQV[\>O_WN_O3TPW?O/KQ_ M]W_5T='3%OKKQV3VW^[_H,%OOS]&,TYKJ/YY=AVZ;V;S()@M\=!XM@0Q@,_` M>[-;*=@A.4/T#../1Q6\7AY@\":"ZQ.T]ON3_<"C/_YAE@_^\!+[M0G?WN^' MGY[\\\OG._<1;)QC/XP3)W1K$_%BI*FG/_[XXTGVU^IH!(>7%,.K8'U_DO\Q M'QW['^)LS\^1FQ&2`YT9=03^K^/]L&/\TS$ZC_>G;UYB[^AO>,.?8!2`)5C- M,H@_)-LG\/$H]C=/`3C:_?8(P>KCD?.P\?#AO'O[P_NW>/Z?+B(WW8`PV?_3 M";W+,/&3[76XBN`F@_YHAM?_NKRNH>$\^-$&G1^^:,GNUI[@@2=<:Y[TA7R) M9OYZEZ`;BO=8K*[\$)VN[P2W49Q]-^>!$\?^R@>>*`*^:0^H MJ4M*!_[K,B7UW M'GH7?I`FP+L!24Z?SU$]DAX'>1)$+:C020]RM)A'+N MNC`%WN7+$Q(]?>YU#EL_.:@G<:!WZOXOK;P(K#\1) MR/O*82J4M66>1[K9.'"[VVKQA-?O?\N9JPY^FR1S&9%-).+V"\#6,_#FSP`Z M:S"/XW23$3+^BD"YC\Z=P$T#I,-=.3[\V0E2@-3/?,`GZ(1)GV])PMY#W-$E MT@J@[Z+ELS-!REWCEZ^AG\02KZ_@AE+E/E;R[IV7`>1^R\HR3PZLL18WS[P" M`#Y!/P:_^!XH1\C&KO..<@RTFR@!\7U4F."%D16?I;$?@CB^`+$+_9PCAAXV M4A"?OT5@8>\)_O4>O"1G`;I;HD20NO?0Y+AT8.B'Z\*`&0!K^A;*D+O'=HZP M8M9]HZ$1+=A_Y?,:X"39VRA%4O:)\FPV-,)[RW!;PC#`H3)W48FB["/EV&MH M=/=6YZ`'RMI$(8*RC[-]JZ&1;9CG2)1G;N?//D(GR!QH@YYSM^VU)(KLN]$' MB*$)5.Z\6-4])-B00[9MG,29$I&9NK?.-ILUP/WI"XCFA))]I^2`,[Q`W5F5 M`^L,C%V&1A$1?^/G40GT89]'88)4;X`&#D<(+@:+9;N(I.,4H//;`RDF#1`RZP^GCP!IM'#_L#&H^>TA(LQV.-V#S`*`@F+6I`\+XB):` M;OH`C@O*B$%*6F`'KU?DG^'TLQK,Z",#H8==R?FO>"F9J4$9``@$]"'7]@UP M-E4$B<3*4(R!^V8=/9]XP#_!W`O_RW&>O7:Z2YCZ$_KIUSG:VL/;7P7.>K]< MX#R`X./1X=]/!H?G/(4X!><*\3$G^!=PX&7H72!N1P"-.G1X*/=GEN]]"Z`? M>5?HMY@`)GWLV'!B&O%!68X<#\;*M4>?&;A&$HX%*''X>-#FYTB_G.1QX\%W MCY9E@)7]>7AH,H:&]+!,R2:`4__[2/!LSQ$!((YN>.#E?\&6!M?!N-'@0PIM M%&;QL\QPB1=I@O-U<2(U'5C6I+$@O]AI,A08+ZJJRO#07/D!@.?HNUM'D'[* M]5%CP;8$:S].<"SXQME0/XWFL.&A^PS63I#O/7_Q20RX.6)XF.ZA@V_QW7;S M$`4$B.I_+^`IU;8YK$.&=+[],COUC\]RV+H`?@QZ/3 MMV_?O$7_0Z,SC?8#-M^`]_$H@2DH?T1&+5(U+X/,ZD.JD'2!Z"0^ M'KT[FJ4QPB-ZRF.W0]&A80STH4A=5NT)\N;M*2:'T9@UM.H2M7?&HT91@$H4 MWT\&Q0.MN43RNXDA63-A2C2_-Q[-ANPH4?O!>-3(BD2)X5\F@N&!NEZB^%?C M4:3[.THL?S0>2Z(^7B!X^G8B"+(-MQ)?10H.T4?:Q)IHLN_1/+`.RDNJZ@P/ MO.A-A"@63?WD]H:K*#X_G=2=PT,ZC#E+,3N;8RLG?LAHG,;':\=YRFTR$"3Q M_I>F<;;[^=>YZT9IF,2WSA;?FAU/:UAJ+8.[FY']X5X"%_C/&)H;D/!!3YRB M"`><4E%)H6A%@#)>$?3I)LN4]VBEH;B,#]%XL;IW7N@X":VB!-,BJ_K6\;WK M\-QY\A.GZTT'!AS%"% MP4X39AY!& M3"L,UIUNE>^70K;J",40(KF4,?K'*$`V=HQ%;M*,RG)/TQ&7%J6)>[IBW-CR M3Q.[\1`,?NKKH+>2NKJP"<^:H0*#S-#>R9$VE8,\5AG4(MH28X(*^&_A3GMK M5:U)(Q5!_.3X^Y*??<4/CTW,,U,-1M$3@,GV-G#R0GK$OI^PZ4777IA35."P M1*S$#X&W+Y"N>-!PMTW7IV'",5$%/H5O_"!"TX"?,%`IO*3,2,H@-7!R:FR: MZ&C"6IEF>M@]!$ZR<,'#]*RO;$X@A;BW=1YQ@W/W)L@:!SF)L?1SZW M@_(0MQ1<2?CHE[C'CP]%52^1TR]E3Y2S5+'1+S>/*\9218HSK%'@_$Z_1"AA MG)DF<8FI[H*"`U-VVD&!ZGO=Y04'JG7/;HF:[N*!`S4NP[;$6'ZRTI(!^F>$R*,#R?):XZY:1$7E\]J@_RK-&E#CEY_DZ)M984T%?_:H_LD53I9N9QB:F^ MUJ`PIK0\WQ)9(X0W![*TE*P24R.$-`>F[/-4)(X/:IW;PRQU)EP/;DRPU%F, M($TO5GG`^EJ%?)CQRZL29T768FOU$SLVIW$)%,]ABB@2Q"0#G6O8NZ%YF*.L M\QJ)E8CI7P7XRR$ MUZ]:M?[@IMI"%03+`F9@>]F'5+ZWF&]+KUVASE1<>I,7H<_3Y!'=B]_+8Z1C M5+E< M#V;X\@3197VF.OOK.J%Y^(WJFW?4$47*!ZIOBA$?GD2M5GDYCRYQ3$7.Y-S; M/P\2`$,G\9^!DH:'&_SFTPYFS$A4$=A!/?N:S\#(9*8]*Y7Y-&JFG3EE,NA M8O?J:HZTL9J<-H@6Y>6DT*\^1@F42/?*/[APG8.RNX`TB*GCM8*^11"WSU/2 MLJ@.$N/>D$8J:[(D>H5:)JEIDA,#9'7A2NP+\`R"*&OJP$:#/4<-%ED./1:$ MG_`S(;3;5#CT.4FM!5E0_948/!)K1O%2$;(<)K0H\]SL^@'L0T MH74>'V*4[!<3^N/Q(2CH2#2A5UZWDRTRA$SHB-?K;.GN<.4-\5YY*BNME86B M/@A-,%H>76;-F$HFG]E]! MIIG.O7^GN6K9JJ-\KZ>@Y#(`/S9A-#]^!0ET4>18\GZNL?QHFB69K<1,F_0();WM*<%[S3U>#&]?H;!3&>N?I@198#0LA1EE"!X_[=`K$J MO[99:C!!0LOUG9WN7DU0I&)!GZ&D)GBU0OQ\L;I\<1^=<`V6B.DO0O(5HJ`D MM,14?)Z]:EMKG^!UV'B>A4+F]GEZ85.^VRB,4&6J-C@UGI79OV182/S:ZUG\ M^(HLJP9C,R)9` M%M+.FS=WD3$*P1<'_@82;&'<`3>%K`O'-U<+K-!E0=']VPQ"_$NQS0+N;\U5!''75J0N@`5<@J<4NH]( MP5ZL*IU/#_MI]%Q,TU<%_5#H4Y3DF.P2M8&'(VW( MX&$Y*2F#;2[/=+J"W*5/3WF:@!/LPWO7X2J"F]PUS59.>&>KBSH/&2VLO\', MB``H3T;1B%!L)FI"6L=8E**Q:A.2/<:B$@.(!X?8%.#%-$SH8!7-AUJL2(32G%E$X`O#&-"!>]0GT@1PC>AVG<`(@A% MR4TH&)9-HX/HN?KBX==7\M$]B-:P:-H<=B:43?E(<2946JHB[EYDK.4BPQI7ZC>:N=1;NHC%EW?^''6-M"T./P?YKLGKO( M>DWB!T[R1H4U=7[?KE%%6?XTGL+-JF+/T0&+L1_TE0ZYX`DT9TE)=#W< M9/\]'DB7:DHKS[2!X2.E'')-F4I1]N1*V0PHK2#VTZ5UTRU=4Q1\NJZF#>;V M83TQ/+5[6(]+,Q#IAJYQQ(I3"G.U8]/7J]X!RZX-X#7.\Y9%!1[6;D(VM[Q; MP=$Z7N.,[0YT:'\E0%4&]D$T1%2C+U):6K7L"49*NA"+4VSJG*(@$^V#KT=Y M%D*K+U'$J-38LZ@VBU&-@[!0QA:PZ@:<>YZ?0U=QG"IIV8EHZN$OPG^N)"Q= MOKA!BE#/W\NJN#B;EW"^P3G5%'M"SMHJK*F>D)]MR0L0/!EC[*@/!6^<#2!Z MF+BG30B77]]9;ZCUAD[(&XI.*Y-EH0MR2^M+395K]E^@C%8!^1(@9=!WL8F( MT]Z9<)/'JFED4%8T,$$F#!Q>QP,K)PV2NI(WHGRMI5NV,G#-E6--Z88DF`:4 MXZA2YA3@M3QV&C,SP9/8!6$2-S'!2]@%5PJ_5^X,M,XQ55XB27:P\F#+*_$E M24=S%`F[(]L[3;6,B;K@2!5YU2?;)V)+=K7N(>5CM#_`%.)B( MWB)<8NI!'$<,O9LHA/O_Q'&$F.9J&&8/4ZG$ZC@G;WVEU#G;%O_Z#Q]`Q'D> MMY_!,P@8SD_.R4KQN@X1UX\S8$Z9QC9KAE(,=G-@7>2=;KL@'[VQ-,6/>*/[YD\:NU[?2!S_N_M/: MM)C^>G637.)*I@$W1_C'8,;?U?='5]#*;)&^PG M&90FHL:!X3,PZ)-X=/K5?^O?&%\4:BARGAN4ZV M&Y$J)"-=?;QN:MT;^3YZ0:M0D`'J2`W&%S\&,4SYW(7-SBHU6/:1:+1:7]2V\ MO)TB22JW33&Y&H="I0)=SF(JYOBA(**J4=2Q:M7U\AVX%E6]&&B^FBXKDOWB M;](-,Q!<'Z,$2L0=6Z&LC5$!9?;:4?F%(-Y&`94P4$EM&N[TR\B?*?^N##IV MO5QEA/805C-5QC#->.1,89K11\K!DC?;&F-`=:%7?M#?)1,^4Q*^5 MFV-\]DJ;SF9PW@@W?@0QICS-8VIN/\Z([($F<7`^AY$T]1@QHJJ\")D2&26H M*K5(<%V_5NZTD8!1W:X1;4ZGQDV#78+?_""0W,-)O2]$CKZ])P]%V2[^+,4K M4IQ%Z%V'";IL/A(_>4X>I^=&<(7QH*9Z=P1F:^T_&<.^ZG8_"FU;Y*"F:H-U M)^$A1U!NB_'IM>+?I[Z:_*LL^2X.,'\.;&NE\C!262YL-#E-'Z<2VGOHA'&0 MOWA4/N?9`CIEDM9R>LR.9D6`MR`8HV*>-GKLNC?J_:VU5Z*A-D&]08@P&FD' MLE&BL0CU/MJ).<#X7^-C,QC#$TCFKHN8A9>]KA?W22GOT2LW!Z%2#7>.7_>C M]XBFCE?2Z3>'YA9&*Q#'V8%>`4X4:).D>`QV>RQ!#'`M%'YD$!G%[(2>`[$4\%(W M^<6!2/=#7Q@&T0E:[@/77*L*2BF!X/@:"+40U/LY0>NM&\$$1+G.=EZ/VR*D MHZDW`8>Z`*TR47GRSG"H\PD!G0/W_0C09C\I?WUN,,S;--H2\[],#',NI/^J MJ5](3`TUW#V4];H_@GL0(')DGLDE<*-UZ/^.%E?A<0FRQ7=O+528+F;GGA^-4^E_N`'SV=P]>')!S1VT?]STO+TV>=XS1 M:.T!+7L7N(SZ9501POKVP:H;(#*D(C+Q!R\^OAUK-^+S^_5D!+J&V"V,XPAE;QZS<2! M6F1"!'(L\E`\`29$'!61J.EV4!]?5$\J/N^A:.:(HBJ&=+-QX';G.,\YQ]3Z M?$W+FUF*V>[WG,^+UG=]+;TI-)#;0A@2%I93Y=\5COS;CN?K-42W.`'7(>+S M2)US\Y?7'W!&B4OL=S+TELKNR4,[3@\4G"Y?D%+LQ_B>U[$Z9=V?838TZCL[ M1.W4VD[,\@QNB$6<-2[+^[C_!/%90I=MA`M.X.SS2I/RA3Y=Y^FK15P$IZ M`F6BK22,\M@FE$0`M?#5L6[0D`X[KGUUI!#M/$_[IPH#>DA M.*Y<((RD,\%EH8+2HF`82>NZQT,%F04@&(?;M@$L+DG?=6*Y0\"A+$OY.HY3 MX%VDR,19YR>=X197(NX%:Z-Z$,07LNE_0Z6W28J[ZYOR1TU&EA==)^F!!%1[3X"N*>&ISQJIRX[<9B2>=32V>)*48E7?5+ M21XSR6H@1MQT[Y?DUK5;NB)R#Y3_5=);4:-V7>FM)KI5'L<$51&N=3MX5"91LZ+-_23F[YG0)M4<$A.2HW5^\<8\`O-G M:RA_=&=H74XDQCR0'L$.O10G\$X_9X?>)R`S`%:>@GZN$+-/03"T7AZ$?LJV MV0@'YJI]$GT#?ELCP8_=X%4)EXQN]C'R05HW2% MO0Z.)7(L2BL*RX-Y'8Q,Q<'(3%\NSXN/O^GT1.G<\_PYR(7TQHV7H@GL'KD%27K(S,'[";*/D72"K/[9+OSW#[38IZN;F# M+*#=3W@^UI;7M8B5JN,A,8H^A>@#V/XW2S M=WSE-N:%_^Q[`.DDWKT?3B(C&9?S"C-2[BV-I&F M=18T&"MLV4U+RNG]SH[J5W;8YC!AX.M[2$:#RDU;G3O]ZERU-*%\8;3*R==U3(H?:DZYJ1+69@D'3#L.>GJ%C5$I41#)UWD,@Q'X/<3 MJ7_7SCCBRG?M3[K*2-$AL#W0.M<7F4IQ>@7M!`O`B316%\-ZI:UI5.84OKXN M-6V)$CKWEQG#'4UY$;1PX>I'Z3S?_N& M6L::N_A+?H[0E^0'Z%Z,G5G3V%EMAAT)T"\@>8P\S'-HJ33C[*DS94CYTL/O M9_S7M_3CWZX@P%WE`)+/R5C?'G%?FS70+18\*L?I[X#A^I`G>_9A&Y!@Z MAY/5TGT@/5/G8/,T+CI-,54>D6[-D!I-SY*61::H@4"ZV3APNUCQ>7CF;N(_ M(RRFV$S`NAXZFC.VF-46LPX2'MOU:RMCZZ/7#FQCG>L5IWX8]!HD_VJ@$_SLHP,/T!$"[+9S4_1SV`P#1!4X9K`?;VQ@NQK6J^N@<_NN"$_[H%:\V<:H^L4=M M2INB^NN+5G/68+'"_G0GW.:7B'2N],'2 M8>+GVT_@6@-G:='WUV"M9^U#FE<;\3BRJ^@%?9^BP^#ZQ(\@S`%)("X MT&'-5]S6(+^P2_"$U=AP71$T9]O='SD;&'"OI`3C'("2_$[`KI>@CC<:>F&/ MK%3X27>#YM`5FJKF_40G`4TJ,T(3]/&OR;/Y:DM61/FLP0:I).PY/C3UEBM' M2D0;[Z;[0?5+81="BF#;Z9P/+HX;T>)2_B(-/?5/0`I3DOOXO^,)^K_[TI%A M7>KL"^^*=IL)J[-/O.]1\SF,E/O,QSCUGLX"$R*=T6D4U MP4*7M,JU7+X,!3GH=LE2&#-H<1,E(+Z/KOS0"5W?"0JLX[,T1A<\CB]`[$(_ M@Q!]P&=.[,>+U2T$,;[A^-=[M/T9LF=_4]$_M@.49!N^PT)32>"GN42](T3OQ"NP>[@(TH79*C=_^'U:Q`_1R%;P=*E^ MZ<`0J;'XD=*L6$>I\*8#0^:"]/%6%%M1;$6Q%<6O1A0S6*>5N&9(W`SIV.2< MOPE+KB(NTCP^K.VZ2.N]\(,TV3T;U*:W=%W-RFPKLZW,GHS,[LQ4K$372J(7 M#3PJ^?P2[&B]Y'EWCLPF#YE!L^=8K<3*9BN;K6P>4#:W,"TK@ MBP5:X:^5\+\.G]$_(K@MA;^UOBOU[`SJD'DUY^W:!$/8+=.M;+:RV4R2O-9`UEEZ%IKL_0'Z;^'"& ME;]6_EKY.QGYRV0.5OYJ)7_GKHNNH[=[Q2">AU[V,F/EJ8K>-C'M$;Y..]?Y M7H^%;!&TEGJ%E[`NW6VV2RE MS[[NC;`R3FWQSHB>@',G:Q^H*6^D+9Z6GS%$1;`.X`?/9=0#GR((,%_=MB MM01NM`[]W]&!9T^.9Q^,0(,YR?NII5X&_D,3_"6($^B[B)O<)0C&>>@U?OF* M&%X\=Q/_&5T"0:?3`%MJ0,.#*Y`!O<@$2"]*=5E8%WI4.6H5;%PQGG\G<9QN M\M\ZTZ;')M;2L9:.M70F8^D,J!0HMX$&,0>E:.%&/$4G>'^ZBW0CGJ7K3(T^ M`MV(Q^BZ4$:R^JS\M3KK;JF7XZ/1X-YYL75^Q&8X#.J0=47F%.O?L%:"M1*L ME3!H,QP6RU*NZ%OI6Y6^2*W:^$F>R!@B)2O$3P0#-$A"C8$(H@/KD)F](3$VD1&QPSK9"V M0MH*Z`L``00E#@``!#D!``#M?6USY#ARYO>+\'_`S3G",Q%2=Y'U/MZU0VIUCV5W MM]J2>M9['1<35!4D<:>*K"59:LF__@B`9/$%($$21*(TCK!WU!*1R$SD\^`M M`?SI7Y^W&_2$@]#UO3__8+T9_8"PM_+7KO?PYQ^^WIR>W;R[O/SA7__E'_[7 MG_[WZ2EZ?_'+V36Z\C:NA]'EZ2<XS^J\5WN#`B3"Z=9Y]S]^^H(_.'=Z$ MZ*/K_7[GA/@$D?]=(]]#_W5^_1'9;RR$'J-H]_/;M]^_?W^#UP].<.I3N6]6 M_O8M.CU-Z_R5:?34_C$E;!S!-TZ:W>H+/- M!EV33T-TC4,Q[/';],,?_N%_ M(?;QS\^A6RCP?9Q^;KW]KT\?;U:/>.NX`=>DAKCUQDD-_R?Y]0^( M?/3U^C*30B7LP[?[\/3!<79,R(8$82KJA[=,/?I+$I<%!?%SA+TUD]@.NR536O1/>48&IRB16W^)-E!EQRJ+72HU/?OW; MV6H5!WX4?G%>G+L-?K!O&R,EK=N7,OXM(!ZN\0J[3T2CSSB20P6W"``V>'I(!M/"GE@E MA!RDH5B<&4#I:V$1+D$F[01YF&N:;MC411\//$*'M(.0<[==4V",9N,1A07Y M#:DEV./U^^<=]D(VGURUWMGLWE!VWB($KC.!MW[ M`7)0B'<.'5"OG!T=SL;_1^J,AX$1)IX@E=Z[7CPH)(5V?NC2S^YP]!UC]NV* MQ53\QX#^[<>DCT'?W>C1]9!EHZWO18\AD?6"G2`>^<=*![2POR,#^G@6@%8O MJPW^B1KD^=YI*C63YMS'FN>$$71DXGYZ,PCK\"A53QRD1$M;.ZT&Q?4@6A'* MU80.5:%OI#)$:_M_>GE8CUMLGEL@6+D_^1&N[NDTH$$0T3:G7>,(2/"]WN$/ M7PFYV+,L>S(J0C*//^AQ3W_3"K#"-;#J;X\?.9O![9G)VJ-Q\%:/FM+(K<8% M@*#_$OCW."2+9,[F`Y9$OJB0?O@+-)&<'4QFDU*WG)>'B$`CF$"!E90.\G). MR,"3S";(0(V,T)S]VJ7_N,=&`*LA,CGHJG.3RID16<2-[7F,N_4+_(0W_HX, MJY/.G@^@UL6!9D$RNLF%G3T>+Y*Y3PJN5#@-MYSX=-1W,BC8F@;^JDVWN*:? M\4V'H9DAS:>$4VCQ]4$L]/"^#8++@WII1P'UZOOM?D,V+>B,XYV_W07X,5;- M?<*7WLK?XH]^&'[&T=7]K?,L[G9:2=';[[=137*$.5K.QAE@4_G)M+Q0`V)5 M(%('72"]NB<;EV"C@Z%\89=]P1:D5@5?Q/-7Z(%"EV`OC1Q:NQ`$U^LU7:5S M-E\<=WWIO7-V;CSK$@6&X&N=..6K(!F#$VN2XC&3@XB@&'\H$06$N?YVV26[ M=L0NUR/KM2*[M"&J/LP*R*EQ!`Q"_K8/(](5A[?^-2;&NG1_Y(#B6_^=$S[& MLX0G=XW7YR]?0QPK?I4N5Y^M(O>)SLW/[L(H<%;"6?`056G%IGK])>>B]C3; M<3PH@6Y]E*E!>]5\+QO_D>B"4F70^0LBZA`JR!1"!XW0MU0GSN/O>#W[* M[>TXF8X_PS+6<+`OTMU`C0K"E1LJ'*]O'IT`GY/T.C+PB4<]='T@FS=R">46XV98Z;R%_]?LIR+E:`H M;Q6P!=S*.ZD[$D.\>O/@/[U=8Y>!,/ZAC+WX5[^=Q?RQ)ASR8>,\E%JU^G<- M"*I4*A4MD^5\;J?C\[0T(L7U`J&7]K:<]D-'N#`L2!#S#03I,;8D$^2_*6:N M[B^]*/:O>[?!9V&(HU!$4/6%=/80M9I(3]Z6LS3H#^+("M!!(&(2@3H$95;: M%2O]^WBPF%GI"*W4UB-(!62A)VCVCII-HEP]7W#@^NL/?G"![W$0#\'?Q;W0 M`RX#1KZ<]FTA":4D`VN9Y<(5`HM)1;%8E,I%B6#-VT"*3:TRA6Y3&_9]%-M; MY8P=LS>FCG5J;N0\9UF-\<22Y/J%/\'M!K6`ZF$;2-9O(/VT%[EK=[./IYKX M!J_V`9UPOG]>;?;QG/1#;#H9_>ZCA`7?.X$73TW#V`XZ/HYMVXN3/Y3(UMGK MJU!8$@+V;+E,()^K%1VJ16F]B%2,CV')MYDK(A MPJFC:#HP34=V-BNR29,,1*AF\=^_8W*H+O[!><*!\X!1R`3X^XB<>2,'$4&' M*"JQ6!C)*&N=(Z2H\Q>^@+-G5S@/&;#&XZ&S.C-DYP;SI:66Y,Y?D$C4-Z(8 MU!*^&:ZVZUPM]L^1$)P,DA727F.CF$.&GYTMOO"WCEN>DTD7`Z>E@R[26:K3 M63VW$)'H&Q-J%"]TL[4.W"?-QL*"O!JAS4@MN0D$;K7+E?J7)5LLS(WFLW$Z MPQAPC;'Q+$=KE>G!C5LBUX1E0_'R8-=E0)61V91X4OQ(>Z2VRD:8+!>3V2(? ML?"9&9VM8&1]<_/^]@8^?&OS%*HFPH5SPV&BPC?:@[G=&;3Q:%F,Y4$3]N58 MN(,%.3).3V.;0LIUYWLJYH+'M!13E[^%BO%V6636>&I9O%@WA+][&$5I_%TA M\&&SU^I"2H@`>';_[@3KV[B6ND6WPCPU,9-INF%'2B-2''8!JJL1 MMK01VF*<%RR%V*[8JF0?OI+K=18$L?OH%2CG+X=TL"_."_D5U>+]W_=N]'+I MQ?BB^^(A/11R^^AX5_0N%;*8=.\'6W*AWBW9Z:/GOE817M_ZY_AL]>CBI\-% MO,=CJ.9+(EF.J]I)G$KW>9:J;:1;GUT M/G`CU6=J'$=+Y;=PR;56U/L/L:*QS!/D1L@-R:F".WKS$[W-BFSM[N+/5X%[ M%_MYEVN#B*H4HN_N9D,@LH6YJ`V:NLNY)\"1`#'6/-^'KH?#\(+&"=7XS%O' M5KKAU?V7.'K2KDAT%5T/01I'K>VUDUV#':>3N;0*E*N#WD=`:R$;M/EZ`.\= MT^,3RE>?G8C8=)_.(3SU";],#/O_0'03Y@79'?T*@/CE-2H]GK%W2 M1N&E1U>LUN?[Z+,?_15'Y-RI('*DBVM$N*Q.DC$\FBRF#->)8)27C%+1<5Q' M*!:.8NGT!#4,E(Y+;AG4> MO:U<"(/9D%R*0OY#QAQ/SH:,-LZB=TX0O+C>PZ_.9B\Z5"A75BM:)122O5%C M-+-3J(;L"B#Z0TXP.HM0*AI1V8/@E&5DO_?6]5A5;/HD,YWTK?1X,&UY@]M]602`0`<['?+TD!Q'3Q6+11,O)D9VT!I16`;/M M.Y03Z*XPN7=CG11FU]$<#7#K([P9OS4>!(&QO]VZ[*X)HJM/[^C$WLJM'!R4 M*:$3I&(U),/16MK)1EQ.%H-F7AI0!ZG&/+ML'@597AKZ,1[.8[0$.1G7(@H+ MR&IPCF%`:G["HJ,0,^#6^4Y^R[;',PD$FO%"P?">X(*UD8L,P&C#,P4]/`>% M9-^C5]-\<8*KX(8\9K*FH^WT?$=-:#25U(S9!G5DPW-AS0]`]3U$A:)8*KH* M$)/+EA(.YZW@T*G09CMGR>[:-' M/W#_NY+D(E,"!F9E-:2OTEOPX)5L`),,1UAQ'8 MN0S#O3QNDJ\A,<-4D%WQL^V9&"],E"%8:6\7!R=BB\`P4@RP6GSD7&`$-JX. M5S;(MF*^""1*F$M4D,V?V<\'V<(K[ZN,O3#*HW[;&H,G%4-+%RX#HR4IN`K@:;6(S#X M"6,-?O']=7CC;\03J^)76G%2J%KV)NY1>I,<*4]P0"4@(@*J]^MLAYW909); M`G^]7T4HP$_8@UZKX\9.,>2K5L.%^8VSP>$GO+W#06TKY;_3'NJYRF5YUI@=\IPXJ@9]V7*HL"=;4ND;VC5-5?A,<]#GZY:]4,0: M3PXQS_96Z]X]US'>Z6[([&"(DS/D!-%;)J`#GA=!Y7BO6&Y"N#?<+R'\'##\ MV]ZKLYB.1#``OVE"A6UV$1GIF^6@%TXTA5D=-A1=.R'[6$IRV<4'-UPYF[]B M)WCOK2^R&*?G`Y*K29@D1$2A]^3%X%B8_K=55)AE M=S%+QZ,K3>&5OK]2ZX3^**!GDX(7AH3D'V4T)+_^[>)]J9%R?]`0Z8?:9`-@ M-D^.J%V@]WK#MYNN-%A_>7_]Z>SS7R'BLMK0)`I+MD",3M+G#=C*SZWSG/0) MY]C#]ZYHD-)42N-8I4$5V?7\Z3@Y,9"]WY&L6,82LZ?<$YDP`Q>%AMH%0\G+ M'?11R!#X++1D+.9',C).@835-5L=J+\N4?`Q`(B*&DBNCB!C'S"0=WOCY#+?MPU$[61MVT MT80^'H'4^D;)=7X7>.M?>C%-Q05>JF]PE=I.JHCNB_$:])&+H\F8K+J.&35L M?90)1)RWYO3>**?0/@O0OOK+V!0::6=&NIF13O4!/;"+SR0AE]U.)N,:F&'% M+L`KUTDN/,IK)J1\<0FM@PFA&I*=SGANVRF8#K+H6GM>&M0(0HEY=L4\LMSN M-)BGKU=M#+YBAUKO$S5]:7:R[VRU"O:X:==)LI#V_K1)(ZDHFHW&L\4XZ5$/ MAUI/42)4VZ:4N%]5::=5LE.WE0V]JTI3[;Y-JJ>7E07CH9^5#9O+A-N$PR$$XR07*B3>`2A0:7J:4G-E76LV6Y1:% MMEP.2#\W-E+MN2&YE4\ M&;Q@[YY_QA';R/SHAX='O:7YKYM86#KLI+-\X,\$[)B^74VN!R<5TX6%I&IZ M2"G9_2>UYQZU-H,Q!_<9CT!SKWTSCYV9X+$VI#JXV_@<.TBH`?!N+](2T'#W M)E',RN0P$'F1Y&P5N4]N]")'NL)2<)PJ4DD^CN<VYFIFG2906J,8EJ5+E!S#L@+FC-0JK\4$-)'<,!BJ)D.*".KQH]JIB\LH19 M'/;@+VDIAR4PVA#?*9%;PA=F$-H0[JIRF(C@T\UI; M>N!06RO?*F>WP^9%'W:3E`+);G(J2@?PI9A-5@@< ML4EJ*!^\%H?7#I6@0RTH5XT!I#:`(\J7#V^9P7F['R0_*FTX&#^Z&]E29%'-^ MNJKXR>R1W]"NJG+F$$&EF4?[4!&'5#NW`<@QFDSMJ_M\'LPUWI`72^AU051] MFBGSQ7FA'4/3\UI]I>H\CM-/5Y-/J+DHTH.PWT^(\:T!2.""EP*S1_'/0K9-0%0=S2F.I[_E*QX>R[$ZS; M\(F*6H#X18'JTOBQJBG\)`,V1RH%[LDK@.R#J":&49!FEZ;W_DNDSYI" M4`I1*2(L58V@>(IY@Q]H1=[ZO1<'U2YP0_P7=XT/7_39(N@M'6[JV5=U^1D# M[PAF4CN[63:K'Q$%<@^0&KW=H-.!919/W7?6X#ZS)ZHZ/5B=M`X<@IKGKZIX MCC.75=),JFF=?W"C!Y-W$`A(WNVUE0<+[\"K\'R0R00]K),JG"PZ6&8X"0_K M)0[O*@XEW43;G7EXW-K1^UKH]!JO_`>//%_6AT,Y4DPCSJJ*\B'..X`K#/%# M1<;R8S]?2).B/D_T(\)^[FC!?M(.,8+OQ-0@37("SZIFMOUVZP0O5_?7.*[$ M745X3=6)1[.EWWSUW"AL=P"LKW!`'NRGN3P&>"=PD\K)PMFALH0JR&RL\DNJ M@TF'SS2ZK\*HB?.N.,X[@W>>--OJ\R"'A`<-0-T$K8;A>+RMH(V&HG-:[=6. M#HR[<7:=!`.(N48]^>#G'>;-!3\+;E:)D?2JR`DU'`KB@M8DJ<@/M4S8Q1-0 M5">!_CH^:W*G8M+Z"W8?'F.J/'O"@?.`S\)POZ65AU_C,?&M_\[9K/9DB_^# MXP;TZ>JK>Z9=^$O@>)'L_%MA/7`$J,X(>63P#B:G>J!$$933!!%54.2C3!E$ MM&$/V1,L)0JA1",#*!7&K67B;7;JK<"I5]J=*DO2,)ZM4KG&@-5,^^KYD],Y M*&Y&-5U(0IOI?QVZ!1?W5K+;6VW*:Z?\%LK)(R,]G9T(C7&1_9AL]))1C1$; M50/9;Q7LSTD',+Z!0P?R@*TT`O2070>D'TBLK1^'?^,U586]KLF>B?@0_Z[\ MVG?]MYI>>14J(/O$Y'PZ+<$N>1"5R4)4F/YG7I7897>Q2\<[KXTAEC[T6N\& MW5@@+\W*(>'P)0@.LNJE7P4>V7P4T&>!C=BETCZ[LWTZT5$7 M>&6("#VB#R>L=RJ]6,YIO.)WFI%1J%R:2:UY"1+)(*+NO7@]2.ALC]W6'IV1 MSPVEQV)I6H7_6'-FD3OD`*`]W2&FX*&ZKNRVEN\Z(S0=$.5`S MZR`..+YW`L_U'K)CW/2ZZE)3U'^K\;`A5P'IIVQ3EDZEY`[R4T$PI_UZVT2# MG=V_[N$(N>RR@A\W?AC^1%[C1"$1"_40^W2 M=!(=[%KFF_S$WP,. MUUM>!3>RQI.)$$SP]^,I,2^;]![!H+SVHKIZ;X!@YOX>KZ*K^_?/JT=R0]ZU M$^$K[YT3/IYY:_*?]W_?NT_.AER<)VKB-B)T(JN%7I)COO%LEER"QH23XR"I M>$3DHRL/$='T"#3](5<)$`(' M$S]<+,.RF^B]V:+5L*%J`8"O(M6E^Z+T*:$,`(D"-1=,9TJPZTNR&X^2U#EV MZ3W<2I4!'K7%'CV]JWCT).]2O[M+=5.38BSSB$QEVQTO[5WCG1]$Q)H+?^NX MY?6S@2L[.A(L6R`Y&)@LQ^-AN)`IA"A\OS&=CIH3^SAX$&H\D7;Q<7&D"/CJ MJ9+;I,8RYF>?/FV'U_3I@?#6CYQ-_N_$I,]^]%<<'8SM@XA.]9G&FUV,D$2V M/9I,VU)GI@Y[C21$5*'B-T2E^,,(Q4KEL&\P=P[M9$J?7[W@P(,AO8N446=^ M\HKP,_D9=GEW:#"W)L+.[?.JN#`]/ATDOR+?6;K#GJ_$:V!-KF6R)P&L]`"V M%BH]7`(0H)RVR'IE'-N[2=H3[PGZGMQ&=.HDESD%.0_OJ$:ODIUKZ44+98N; M6TV^3:HW"8$O,0H>8Z6_Q$'T"6_O<%`*;JDBVO-MZO61@\;8&DV3AT8.;$5O MH$PE(B(2?6-"=>?;J#/1@C6Q(=]&G9UVDYUP:39RD#NDV4@X9?A3TO0&)Q>' MO#2\ZM\UG9,N5"I]682=;A0DI6$2S'KI;\OJK^.\-#K+N[C3 M",B3-6O\_!_X1>3^RG7N:B^$7E(A!5`Z*!0'%@[BMZ@KI14&-)M*T.%\4(4%E M)CT_DXIR8L$`HLA46V#JB:2M&L$C$9LE)#7Y2!>LN)N4E3]KA4J+?2H2*JQM87/MTQ>@'=X.#=TZ$'_Q`/,@I?J4U8@M52S?]V"H$ M+A6"4BE0X=O9%+N5*?IBF1L\Q9"NVJPKLJ_Q@TO.IWK19V"^R`%$3%0T=W=&+N=,?KBFQ]"Q0#GF*UF:74?^#MRI2@7^75H%=\F9"5#>9.N^C.D]2? MCLB??MZ?3C=_ZMK*'03!^9U:] M+'%:ZBXRAJ4YT4+V`MS[&@R+JND*]CJ&D@5M=&ZZN4&):#B"ZJ2OY.FMT70V M%7%3*RZBM1MP@X1NWU%&^N0$O^.(>N"&R&5@042Y?>;A^%%-P6=X]!I@0$CJIJ MR-[/.T]?D\V%%Y.6=%86T,*^8ALIA/YS[Y-C,%\"=Q43A.NALU7D/L5XHB/2 M$/V8F/R3$:`21R,74@+_@`(J3U357K3VNH)V,B!`)Z.8[$U\5OIT@(#E^<-) MV-L"!G-$94197+AJ[0KMR&T3]EPL2WL4`MV_^/[ZN[L1A47V9XV83.N4W?$9 MI2E\:<%!$+1+']ZK0U$7U2?L!9OXPQ5&3H3^?>]A-!Z=(-)B`YIR$SE!I-J8 M:Z._>FT-4E!/)TPC.5MN0GL M185AS&]+2<`/+;2'=3LF@MWO3U7,Z=.PV%]7`F!FQE%#^LI4:UG"8B'LH%?Y M%5EHW/2A)M1X,PJ1^9!H$4T[Q-\!(*/E>'%D6Y-Q"0_P>;N]C+%;&:,;!]P1 M;+W=D#%_&SA>N&'7>J[_MD]2:AJ:35`(``U\362C:6R7UO503A[*"81%27\C MV]=[N-KA M@"H9GN-[/\#LNUOG&8>?7,\/W.@E'D#B.'8B.I;,2R$OF40OGW#TZ*]SN6Z" M2-&I@4:4:S1+]O:^67HH.GG_BHA%1"XZJ(<.^B&F8/I:%E41I3JB5,EDME@2 MR#1%3-6FA,?^;$1NPJMC(T,;8Y9KC.0%[COF\^19[LAY1KO`?W)#X$=8`&@B M3YZZVP^.B6^BN(,CBC2\%"[Z6CO#5520!,#2GHP*;)0)`G\/7(%A=@?#]&)9 M&&A5W/$]`8>1&-]G^QBV!-XUV=B"C[4CI*R!;"[7;%'LKF,Y*!,$FEG=WRZ[ M@UUZ\2$*LBH\N'XP`QVU:6?"ST$1TBJ':C%)3R3P8PDT:4R%;34X,2`+K"G@ MZK$"G-N5*22_T5!;!`(UW1?B1]9H5D&.49L-JHPL00B#'B.0"3HN:M3L.0CR M!'+3)M$^@O@[W7O_/"6D\T_L)=OE+ZQIP&4;];7%TF]+_?Y\7X,J8`7?(VD$ M2+:W+K1=-4:%&3N5;P"QV2H)8SE;\'`)D6#3QP0.',$R9?K8P4$A<,J+*/IY MX(--7\D4><\>OSG''KYWZY?QJE]##":+*D@G=(PK<8\222@1!3Q^[&Y7'@>& M+<4+`XP[>N2X``@;`79"?('9?R^]L]7*WWM1^,5YJ;E-JKF<7KS4*R-[;]'4 M.@S@J"24BD27Y+PF$XH2J6`@4F^BAYQD.Q8>P^YO[6)AS9BH?':0E?9!;V% MW8!E4F?AXD22GD*K15F]^;\;U*T.Y*ZTUZ6>25[D9)>]^M0M&]][.(TUWJ)- MO5M`.:(#G!KYHZW#S>"6"WR/@P"OK_$3]O;R'7JY'"@[E)21[-:FH_3E`R[\ M4Z$HD6H*MGL82\&;V16([8(#IR`>Z]''+2H6^HY#$P3\29D0`[@`=J9O:/G..B59,[AW8'.NTQXY62I.!\/L;+!TF$@)`X6RC(:203V;U\Y&DYH.P])T M6^0P)675&=.SJO8-[7)3-W"FGH[0?#B\MX%#/?:EO0G#`\73_Y]Q]/YYM=F3 M-U(;;CV3*JH5X\WZ2-_)E>OGG&S&H![ M1ODP;<`>WT&*LN+B%O-H/IJS$;^5R?M,?VY<10?)!QRM\6B:IL?E9``]H-G3 M#DNS'4U9"U\_V3 M$T>5ZVQ('NS-?K?;U&7`-12#0*I`%\GXF2P/.W\I>F.)*!-)=^U3H<"@5F`J M!3HQ<)L92#8?PAH#M2.G(2BY:*IS#2C"_N('OY.<`'^%PT9<%3^&0%-!`^G` MFE?F140.2X:ADH"!T]DJ"A=2^M3U3G>!_Q`(C-$.$FY<<:%1-1X6$($;X0O_ MN_AZLLJ'($!(:Y=-?!I/JB`@,A`1`AW_78QAL4]*GJ[CHLB_1VXJT`P(E".) M'_X%VZ%"G]TRRP[FUT][RE]J#OY2];(WML_'N4D0DY'>#@TZ&>IACETRY\T:NPP%\0_EX(]_]=M'_.!LWGL1 M_[Y6WA<:@IU3K63BSGP^3N8*M#QB`D!N9.UIA-W"B*&CN2902!2++(4@\N:S MVT#'L%L?$1[-1FG>W>"'HIM6?3HJ3Q=];HEP4PXP-YQ%-N%8=`"'!B]+>6CA:W]Y`3_ M$\)"@P%@5!NC`FR)764BX!H.2DH7-PB`+8\(6E-[(@U$\!.20QC/1F.79^>7 M'R]O+]_?H+//%^CF]NK=?_S;U<>+]]_^?7R]N_FHS*NO.1K9P&C-)W M^R"(ITK-S9]^"(.\I';9K([EE-/9)3+`.[<.MN2ZLQ4K;>`@L!1*`D3DK3>&&/]V`V.R8AU<^+GB61+:\22I$J28YK1(CTT0.4B*AA=W2,B MF@[LDK'<03KHJT8#6&^7K?<3ZYV6UNO"9,N0S@.TC?L,16OM[WW+OBN!_ MHQ4FN8HE.78RFHY38-#20/9`+GRC,Y#S M%,7\KC2&J_/7[Z& M>'WI?7`]QUNYWL/9*G*?Z@;\+01HA("\5K+[]Z-E@@]R(1:1C5+AZ/P%$?$D MTSZK`!UJ@`'0,!ZP4P^LB`=VJ0?N7M!]9KE3:[DN_+4/[#PX6WK/;.0V;"5U M$&0DDMO>BFS-)QT1#;XQ-:Q3TB/6%3R#[EAUC_=NP`;?X1*HRC+)>W3-/`'P M@.9H);MH;*-?_=@&UJOYR]-M&U M7^8)@`VE%3J&]]!4'SR;VTA+QW@W8)O32[*3U M1U]XY4OQ&[VP/%0LN[L1A]#$3=3,B6D-D!?O3C)A;P$UB/W\V( MF;01&@%>C?<2=DNV@L#2][*Q#E,G>9I)U$+"[W7"5:2$=,C,TREM3E**X406 M$`)4F#83F?9C(NRG$T3/"8$"I"GR"F"I=8M1P&D:GS:6,P%(+0=:D]ELW@@H M^'&F2FO9L)*^W%>^`P=V8"D;EU+P@A\V[DDZQM5]-J2]P0_DUA[A$%+XO4Y8 MB920SG],GR!@DLB9@\,,)A4&!"(5MMDYV_Q[=+2]]DT%!()SIJ-9&]L2\[P):\L,SD M(6WW'31U)NJL/`S'0'$B%70%R#1[``X][,W*V&P)T)2_U8Z5D@*R)Y-MNPB1 MY)753`XD,'J8E)N>;'SO@1VA@7]BO#:NJKC@.0`,#N_\[2[`C_&TR'W"AQ[N M@Q]@]\%CB%V]W`:.%Y)-!M\[\];T7QO:@9^M_[9G-XY^QM'5_:WS7-?VZBO3 M#4CE%DB&_WPZ+2"ZH$=^G(@255"J"\HI0X]WY]1!!WWH$\SQC"Q6"9`<0-W+ M,E(3]ZU2]T4Y=]$Q+(Y'L0^."SQV'12[%%&8:(;6-_\5H)DM^7F'D=,$7)H:DL@$EX& MHY?#*Z%XZ]=%4O%#W?`OU"Z[1C2=%^"<>ZLV%@((RL[&4)"10F:\/R,.H`I" MJB:#17QNQ4UNF8M?0#<"N%K(/A.PF%MY).37@HU8]>IM''?IRY"+<)NCK@(7 ML3_`8-,V::RAD&[X],RQ&L4U%::`VI/(I'"DQ,H![K;BH6(+`9`0%6HEF\JUL!=BG*;2$16?79=+*S`%KDH\0#%+.Y.U M&^UCS>DY_UUJ/KDE%]<9#H;6QK"NA6R][]KAUKG;KBD:1[/QB&*1_.:W+S@. M`2]R'O#5/5E7<;P7MB5<:M^&CQ5C;.VO]L1.NE_32A.YJ"+W_RU_&U-<99)( M5Y#(2G(4!AE:\OA#G4U6R:8K+38)A\OJ#+.KC16Q=UA\+_0W[IJ0$F#ZA1R: M"-PE?*(1#SJWWFW9Z M5<)H7#KNWR[#T/'O.4D@JUNO+@)%RCG&2H6_9LPN-9%NI!(E_`M,`L MJLAZ(5&F\OE4:0(/*O*`D.KBN>)ZOXK2.#"'PB10+6:I)J^I(J)XMKUU8L/. MG1"OKW$8!>XJ[C/HBYHQ_Y5^\]5SHY![3WA_>0!$U5E9N<`=CV>+649<:66( MUH8.PMFKM+0KKOR2UCGL[>5U7*;%09:D@\Z`'-3(=UJ\9/<.(TAF[$TS>:;L MYV^01?&#TC>/3AR$M6\MB+[6N=S-5T$VDV`\&55AS00!/\6@P+`*$ID@T-7I M^O@J+$77.``$&K$L'`0)6+\XP55P$Y%IZZ_.9H]C;:F6HM:4*ZP3.%(:R;Y2 M,$L?%,[$)H0>"T97`6*B$95-$FA9*`(A2[GE[*WAC1/&LQM4\L`)VL4N>"*B M08'7*GH+.)1W%SPL&5.<[:-'/W#_6[Q%6%\(#(9E360/;HP68S[\DJ[L(-$$ MR/6QLAYJ]7;"8$T4DF*,-(;!\DAHJAUX2?G$],P<[5/@JC>-[K>@\M&C=?"AA%.55D@VVRG-1"*2?2 M'#QUM+,>5'Z]I9#(X@1F$[S*+H+'&!V/2C4R^Q(,2[1Z:;*V1WS\_"J:4NB& M3&MSZF'RCV]&UF'.E!O2H5-DG8Q&(_+_**1!^,])3T47$W/XBC_U?,^@"5'A0TB,[OFE"SR M%RX3`KUB2['%=M[BY$A(R$#&#OPRD09<-=0B9DNPD_(7#`S]%<;K\$-LZ(VS M(=I]'"UBUC^%PY6 M;EBS"M-4#@KH/&5DWTA=6A87V'0PG`A%F50#4-S76`%J<2*+@I4:[^_`KXZ5 M#E4A$H7>4I-`E%1U%:0G7#[X`9D[D.W%J^`:[Y+3>#05?NM[5)_/N#S@[2E, M>^I05TWEXG1N+4=I8GD:IU8EM MV:#(>89,">_++8>4H5XN!QJB\(\'5JE3JHC>@8E0#\G!]624&Y,(C\$.QFTR MPQ$E)MH%$PM'7<$OBI")P-*@H]XG0#!Z9LM?+WXB=0 M:HOHA9%0#]F;KL:C`XR8,-H_IN)0*@\,14HLI"@Z=]9HC>^B=%4-&#J-45>" M3KTC(*!S'?L=GSV[(IP<_JX1%%FELF]-+:?)JA4MB;Z1LD")IYUTMV5TUQ77 ME9#(!W'1/+"(KHR'3Q?X"6]\.H"JOQVNOHS.**]31#85<3E)$L12:73(GY,' M>S6<,AOM@HUDY+\^R`-%B4P(%G#3Z!+CD%3?1TB4-`55[8ZNS-/[%IJP!=W= MJ#7Y.*%6TU%)ND?)^G[?`\%&'P`>X*2F/9DF!W[-/]X[E/D6UWPS#^\.Y0.[ M90B`+;+W.HI[%$=O2RHU=?Z<;_5V]U4%9%-2K#1%IQ)CX!UZ/Z.X:`+NNL4Q M5>JL!:8;``6*SNN;KVT@42H#!XVB(I+1-%J.I@*(L*[H&MV@KV;!I;NA9=BP MC=X]5'_3*@IK0,1Q"`R8(L?U\/J]$WBN]Q">K>+AYGY#MOTO\+V[)1*E,E!.*$JE0V%)I+058WK:UV#9]Z)(-RR+$I/P"@S-Z M$19)9OLE<,0;M]7OM**H5+GL0OG2RB9,5`)+OF0RH"#2PQ3VM.G>6\=@"(Q< MP]TM*(H%3L3" M!VK#?(0I?-"#K/4G]YL*J4Q^!M4D1WT3J;)%A*5Q](QJ43V@"N3"7MB4Z&E M]L%2L$SHEA&81X^,)\#`E$";W+0=BG.:N9_JADVI?LGA\-*:3O-82@;EV6"J0(&GMU*MDEO5H]XO=_@J_MXXASL\3KW[.3'>%Y]&>$M M]R9WN8*Z-T:EM)(<22\6]HCMB*92R=&31&[A_=1O1#2BLC7OA"JWURK8>P5D M;_W6IW*C;16-K&73LQ58<-SBFWI!]OVZBLD$E<0C62?`/`)@=FY'B$ MBC6(0EJ;*44%Z!RJ2VLENX4ZM^9R2*3BXQB-*T"T!J!UH6%AOTN1.Z*Y+XZ6[V$5ZWA&L[:2#8;:6B[,;4?+JH`CG;F\YN M34>T,I84S:HS$-F#.8A='NAO=WLVEB-=,7.(DW-(/&M&[/UWY`?HHQ^&];?. MZ^>$3I#A$T1[7P.SQ7:W\5\POL'!DYN\[D"?2"'-&M,V;=>S#=4E_NGJ_AJO M_`>/W`$9F^CZ\71CO&N_\(")3FIKSGX-7"\,_@]@BCT.;0U2)2BC1Z4!6 M,1[S:JJ3<03/$5$-4-_).'-,.T:DXY)%8D_Q>F8?P_7YZ5_'[2=[QOM#Q M]'E".<\#L.:@U"&@U^':_#7P,&^-9]BZCIAQ6RP[C.;S)6>)137-@BS/&./> MP=D46AGE=%?I)S\@%:!98$T\?FY<9[Q:]!"*B@@N2@8#F9<7;%4TFF#)8Z6U89 M[LA8IA^IW%#CXZSJ"D-0(MW95TO`HJ5=1S":C-*K<`2(,:>G[&4BA4YFUMDJ MEBPNF0,M%I M#K.!.T#JS,^V?'R/7A/M'QP`_"!%V_CEXU'"4XHSM;(:/\HE?7*^A\O/JBHC MF_TW7W!2/`]8,B&QLY]Q-41A3!9G/PLK(UAY"S5G8(DQQDF^$CAE*-A+Y&66 MOC4`[FU2]JPFJ,/F7G:WJ0[A!B1:=C>L#MC&9%7R`52'9U/FI3?X@>"-[4&Z MWL.E=^\'6PJ_\Y?DCW(K._*20$;=TNK)+G0N>>*5"F1KO4+S"B3\F&HHY_2LJM)TP4GS5.\(96KGA)+[L-$!41U,(9J]'FQ2D""S?JB M%^]>"A]*>Q&`F=3`5,!7"AK*`!:[*UL@=]MGNH+;\CRU_.F:AFX%@KK;4:3^^W6"5Y8JI+\E<]F;70,!_@:BE3?;@:P M9H7W\P^P]N'&+H(-&NTU:RN;7FC/>?-&T3"O^(RQZ50VL-O*A)5WCHF,U`-, M;89FDDXVA5WR(\:\ZK\ZFST;:H;A?LM^UYEI>E0"S#K=-9=>HUG.ZAFH./,I M4E"F!LKI830?Z7$HY::_8/?A,>[M3\^><.`\X(*/OA+71CYZYVQ6]&I:],%Q M`^I0.DE-/4SO[#0E.5(E;)LXK6=#@?`;6[[[!?L/@;-[=%?.ACT5)XI/X?DA.Q%C*/I)"&09-DV+ZKVL3P-#*#".#MGW(F\==K@V11U!:35.@00--F" M^(4;KC9^N`^:>WJ)DOJ!5*>.[#,A]F16A-1AK^0@U80.5JW)>:#1Y8;W<=<7 M[`)R)>=?W#7.&0^;T"4?LASL-7K+!!3FMJ4JF2D-0<`M"HA#GCZ2]+]83"T1 M$/-;N7!I4T,9;?ARV#PN(EE/OR"O7CJL#GSUF?KK>NYY.;H M>$J/ZU_1E2RL%9,R&LG.L,;C;,1)Q:)$+EWW+TJ&?6%7O=EVSNP3])#83?I* MIR`:%I!M8K<(26E_F0M*_@.BW608!]%6KT>.IJ/LH)PT4J%>T!S<#Z\'NIP7 M-+M[#P3(W)5S44#P/]8)3:X&DK%G3:P4@X)M)2"<]38J=["<)06L&HS2AJ+: M\"K`1>P$C5XNO1CG-&,_O(H><7#[Z'C)JNT'/[C';H37 MEQX[N=XJ*H;1`!S!@Y@EG?.1+=M*)!76YQ0R)5%.2T351$3/;"':YU52+5DD37<@ MDPU(NI=X$0.#;#72G48H@,@I]YH(6LIBV5LZ%DL;A+N)$2BU`J7;VM0.=%'< MPS9I4&ER,]I_'-)OQ4A:^P/Y5GU=705[$!9L2%ZJ_E70?=$F2288S:VE7D)G M:JH:B9M'U]V;@5WA(\ZZZNV5F%_N_./SBV5G\4DO5W%HM#T8D)ZFF1[U]$R< MAGK-?8]Y,Y6V^KW"WDO50'<^FFF>KY2[MS_HI&7`YOPC=9-J<5#(#4=.$H^T M(SU=DWB\)_'X1!/![_T`!8&Z11ZM,6$ MM$6L.$F!.7?B[U?#C#68AVXB)XB.SD=3XJ-S_.!Z7H.;CK\K$W"EGJZ*UT9J M[A`<3.6X5Z7)N7&3W3K!`X[.5H\N?JKL\(*IH?WF0_TVRF%YN1S-TZ>M9?J> MNYJ^YT3<^42YSN<$Y71&3&F4:JWY\D:SFT7KD$!WHS3_+MV1W)NEU%>M'`4^#U=(X9:I^8K3R[NW`\TM9\5? MYXH:'_5Z%M0XS?*:*?76CYP-7&)&K3*OD&Z+%DH_B:4[H[!,OHCJ_8J3*U2U M$LL`/^SYQ^/?-EO^R;:;ZZ&=L--[;?3.9R`(LNS^:#(F(8+Q>6 MK79D_D'[36-FT%_C-$(3!*$ MO%I_H-%)ZWWAR20_2KF3S".\ZY%'*-?_O<)LBD$:S\"ARVM-OQBD_8H'U5H/ M"5][7PV0P-&NF8]J(?I@PN%9%W);*-GON'"?W#7VUM>QJ:H7YZ3K/8:%8UEC M9.]]6&2OJ=%Q=OCG,EMRW` ME:S0MFH9,+Z\:[;LKHUEMSC86G5!/DR%NAER$"MD'X9:%&Y5;IB(<+@&>34CQE_]32QF M$X^F=8\92S4?^ZBQ:([TQ98+91L73?1X4/"UC1R[N[Y(F$^9''">U`/SP4>. MG):!72?G*?L)1X_^FCPS^U'P@)N>.H]FA5O2(-D5M/EDJFSYFD^")XBIQ]X2 M'OP-.O7+T@-X?-A>1ZN_!UI+'L#IMD%A;O:J[#Z`O?&G'` MZGLE?1^8XC'0M2G'K/=8E*9XQ4OB?+!?65-E]F`*N M)=HAHAY*]7LMZU%]_4YYEP@YO2?N<5/W!`+W'.6*5!W"!UN/$K;,41&F:'E* MH>!CH+R6,^_1;*KN>@VXM0P8MQV&@J>20\%3WM8M]%J$>N@IH2J35A62Q+FS MAX>`WMD24V7@>J&[&BX[7++*HUE;D+-'.K%TM,@M+_2!W\DA;SO3#67*'6NJ MMGIO*^HCTD1K,%\/M,J@WN&T=Q&ZZ?C6!-IQ:/]E@18MU?I+C(.5FY( M5C>*EBE/V6NN\!A2]AJMD!SYV;&>:E+V4BK,J50APV/+V%/JY20!Y>`=)T+_ MOH_'RN/1"2*P`A\M#XI?)1E[<@UR5#/]JDG#/!4DK.<8U@%$RLL>'IA-E6TK M\7ANP.=]AELD4.%3\SEM"$@J61"H=?^1,UCI2%[R%_PE<%?*MWA:UGZ<;%=G MDO2I@?EX2`ZLG(E-E414RZ,G1U5-\$>A3!D.&(A(&YOJR&?()?NN\=9QR24Q M[WR/K@+LGJ@F/>$2,P\+%R,45BV$'+O55']]8N-8>V?R;A3748@`.*U>]2VQT M',TP6)GW2YM!;N:C[+)W/W$L3FH^]KO<.S#"`(/CY@8\1IK]X`?WV(WVP<&\ M@7#`J^F(2)2CON3,=;&8*+L%/>7,G#;'^SJ1&L_2AXC>D?L]-YO87^1A"_R\ M6N:OXOJ.B*Z$1LCN%RS' MRIZG3YDKI]/KF)LJ<3+EL[QKC%OY&Q*[*OFNOCF.G/H&S6D@.C_R]*2<)=?^9O.!/?D^ M?*CF*SM.0L]9(#FFLD8S92\=\%C]&U$))3H=V^%,90YF@U8F[940&0>9`[%9 MV>='3FD`&9>RM1\GZ2E(]YO/AAW;0F1.BNSQ'U3IV-E)PGCT93Y2<$DL?,8Z5S MCS?X]->%OJS5R7#S!_=:FBH__D=/S-%)Z@!S=.337[^JQ>S>S*.2YOLU\^LD M_D'7R*6K?U6TWFJU<[2TE5V!U9;%C_D<[!#-\#\,+4$1>@GYR%>QFPT$6`GJ MJ=2KXNK^TW%K,ILI7S>29?!7>8I77ZO]#^%WYB2]W8"YJS)WS6;?J3);]\EA MA0H>T8%B=5;+[@Y:JB_UZMQ]O+XSR#"M>;P=BQ&N'N(DL^)`.-[92)KMU\8,@+T:7J/;9;T66,DK\[>J;^:O2&58ZCO2!=M>,5 M]S7`;A_VKG35OJ>=4"KT5'XY[BBN36]#M\KN3I=N(1-[)-'D06/GU*C"D?=3 M3?;)HW>NH#:PVMO9K*)N%W<#6._/$%.T'XTVOI]&09 M?:C^3ZHMC5R5"D6&TO^YC?4[\]9?X@C\[&SQA4_,[+K8T*4JD]:C.N@O>V/F M;-0BSRBLYU7VOT0=NL=`%$)$(_2-Z63J&:^!W`W1)J/6B6.@@:[6":Y;S=M=;5!`T'6731ZG#D[8$V2O^79\-NK M!F$%-23;N96.DGXY=PQ"$'!;-8Z)@EO:)IL\,5NV6,:6)&'NS:6OE(8';!;[ M.&\]'8@KE-)REU8[2F(N7J\(PUE=*PL,T MQM%!)22;+">+PF9C$ZMF MNXT<5LWM-N84;K7UR$TW!MQP!&X8U=U=UU3[89JE]BZ@HV@?0VX%.@I?F7,_ M$'@'*+\C.U2;@FMNF7ZK&,B%25B42H7)8)1(AEH'J+::);"D8@!G4*TB5'H&Q$&E1&@ MPC@V\98S22."ZD.MA)H:+X`BY:/KX"M'"I(A!XX.@AF4MJ MV5D>6A9*5_>(B$-4'E@"KFHC2WCQ6QBI'3LUH2WTM"4D@*#4AG59!\VFRR6',`R633-NE!' M^@>#T*O:&54@7T6/..CB!P!`MXE]`;:E'0H*\UOG;B-,URA^!`%26K-DV"VG MRW%EVD8%0*.KM17EV9K8"NW8*`0,-_0/UL)$MK_Z_='?K./6>?_WO1N]"%NG M\J'6""_7+AD?H\5A:'@0@9B,8>+@T1ZVB1!K8B_&U7`/S8GW#N;8%7,,"?A0*N)#Z)#? M[W8;NM+@;-*-K$OOW@^VCLRND61IG>"04TEVLC";I!U$3NYA^Q+E1,-/C=2; M;E=,7[OA:N.'Y(`>[%RI7>`6X-?"3Q"8O,7/T7DL__<&]%6_TXBS2N6RZ9=6 M^LH7D8"H"'#D]#+&;F6,+GP(@RB/!+[=W6,^Q*LW#_[3VS5V6;C'/Y2C//[5 M;[>!0S+';UZV=WZY3:I_UQ#5E4HE`V`^'R4CJJ0T8L7UAG$O[6TY[8>.6V%8 MD'CE&PC"S0%VXL[OA0[AV'Q=Q"F<+W7R<[5ZZ1WGT2*-:28C66MB4H`8NI\Y M=L$?XAA_1&,+_J4> M<3@*`:3B'>-TH+/R]UX4O##X)/\H(R?Y]6^D?0JMF_N#!F0<:I,='4P623_P M%=WH9?UNNE*2__KY\O;]!;JY/;M]S]5ZZ,BL-C>)Q))%$,S]]2:#`5[M`S=R M/Y9)S%,3JP>B8->/U3C8$L^+GV0?)S<]#E>;K!%1"H M*9UN9J\P7[B;??P[-A3+'84^6_]M'T9;\7'BKM(TXJVCBK*Q&H])&!@KUT"P MFE!25;K-G;\YXE`;#%(UN(;=\7E_CU8-PKL85%-^IO=]3ESB)2Y(9EC^T M`YJ24`=TP*P0"R7#]R%[HG#E;W$H_@,]W_#CQ@_#G\@SAJR8 M<838S`J-1-C@:X,(L*+@N1.ZJW9Q)9`!3WY\Q63[\]&BF?HXHQQ:AU'$U]\- ME/9H*3#2BVN[\X',M^QVK'='/75?&_XW_%/Y"W MQ^)__']02P,$%`````@`NH`&0:Q]D4,6*0``][(#`!4`'`!A8FUD+3(P,3(P M-C,P7W!R92YX;6Q55`D``Z`C(%"@(R!0=7@+``$$)0X```0Y`0``[5U;<]LX MEGZ?JOD/VLS+;M4XCIV>GNE4]TS)MZQK$\LE.YV9?4G1)"1SFR(U`.E8_>L7 M("7>1(``"1(0A'[H)"(N!Q]NWSDX./CY'Z^K8/("(/*C\)?00S]U\D_ M71``Z,1@\NB\1F&TVDSN(4`@C)T8ESOYY(>_/3D(_'E"_N]-\$__O)A_FIR_ M/9M,GN-X_>'T]/OW[V^!MW3@2926_M:-5J>3DY-=S;]F,GZ8_/CV[*]O?RQ] MF4=)Z'V8_%#ZZ1*"K&8/"_5A';VX8?S#^_/_[><.EIO MH+]\CB?_Z?X73OSN+RW(;NV\DT""9SDA1-YKB!\`5X;[!O!Y2DN^_WI+N&;/_YADB7^\(K\2H;O[W?)ST[_^?G3 M@_L,5LZ)'Z+8"=U*1E)84]:SGW[ZZ33]FJ5&_@>4EO(IT9@L4O M;YRGE4?@/G_WX_MW)/^?KB(W6>&QL_O3";WK,/;CS6VXB.`JE?[-A)3_97Y; M:8;SY$7[P3W$?)) M%9>!@Y"_\($GV@#.4L=LPKT#@7!'"!0=/X/8=YU`?J/P5,;B38,8P!!W_0OH MT8K]LJ2+.\-(P,MHM8;@&80(UY%5VD-J:I'2A;]TT/--$'U'MZ'G0^#&/:3> M+ZNWN%<^'8@S?#Y%"-T#^/",!ZCP M&M2C*HGMS"N8P7(54\]+)Z$3]%EFN]4BL76?'?@;B)VG`#P`-X&X,H!'RPM` M,1E"J'N#V@J6/!*CD)1*EI<7_)<(XMKZC;>F`B7*7"I6\DAJ+5EB*SY&D??= M#P+)36`7.X3\+MZ),+N1(/*N)(E23ET7)L"[?EWCK:?/N*X7)%'&ASAR?[L@ MV@J9/+CXM*_FP(V6H?^[.'\3*'F@E:2Y7CF+"J5LF?V1K%8.W&RKFJU)^?U' M.;/4P4>3Y%5&I!*);?L*B#X,O.D+@,X23!%*5BF0Z`L6Y3&Z=`(W"3"'NW%\ M^*L3)`#3SRS!1^B$<9^Y)*'N(<;H'+,"Z+NX^+1/,+FK_?(E]&,D&X=F#H MA\M<@1F@U?0JE#7ND>@YPL2L>T5#-S1?_DO3:X">9%>CM)&R>Y2GLJ$;O-,, M-X4,`W0JLQ:5393=I1QU#=WR*E'80-G=V5[5T(VMJ>=X*T_-SI]\ MW)P@-:`-VL_=JM<2%-ECHX\00P-4U#Q;5"TD1)'#NBV*44HB4E7WWMFDN088 M/WT%T1PHV6-*CCC#;ZA;K7)@SL"H9>@F8O!7?G8J@2?V913&F'H#G&C@]5:P MWJ%AV&K8<[".()%DT+;S5+9M\+JDQQ+'F$K+<6(0>L0DEOU*JI7IXI"*@(7` M`E7J#8A72`2KD&^K35T_$'#?+J.74P_XIZ07R%].,K^:LZWCQY_P3]^FN&J/ M5'\3.,M=<8'S!()?WNQ_/QU"&]P?3O`OX,#KT+O"O=8@&C6IF)3[ M`Y7\\HVG>Z9/*(8..2*O"">>?WA<=V)D:&&]WH^\&_P;:@"6GG9L.4FO\DE9 MI!Q/QE)/XH4!W.*UA25H8_+QI,WZD3Z=FM.-)]\C+I8A5OIY>&G2.8IWP)3> M-(A3_3Z2/)M+#``D=F4/O/X/V-#DVDLWFGR82D1A>G*14D8T2V+B^TC<4NG" MLC*-)?E5M'+\D"KC]O-8TMSX`8"7>-XM(TCOY6JJL62;@Z5/MJLPOG-6U*E1 M3S:\=)_`T@FRNJ>O?M,"7$\QO$R/T"&C^&&S>HJ"!HFJWW-YRE1S"JNR.=#= M%83_NLF0@,Q:91G4$[T]5X(^3GT_IAV+!'9)R7 M:#N;DKQ2-#)TG'6F4T'!#':_5(W[FQ__C9UW2@)8W3O;,C8W>Z(-4M/ M2^+N9JC^[U$LN M8&*,9XM'YY7>)J%2E+0T]X>_=WSO-KQTUG[LU,VA;:F52(X0B.N6Y-I'=7)1 M3ITIB=3)V3(K*VF42\D%:CVM"JG)G7KBKH/_N/YW@A?D('7@B2\="#>8.Z=. MWI16\.55TBJZ+Q*M+8P875!/ID+6JRU#G(,7$"8M[(626*7<>$9W4>ARM8":S93#YN[([IS/*0CFGU7(=DL.)I<^)I[9*HQ)S?6K&R3$4M`B M-U=6-6W:WMW`$E%E+R4QZQB].VZE^4N!K9Q"L81X7TH7^N',?.%D( M!+Q\KXGJ16_ZM)9P9%31GMPVOG?.5I._ M(:%2>1ML^2T[&5=6I6UJ\A:G)%(C)R<+U81W"C--S;CE(P0.2N"F=V#'ZCB!QW%3G`(2%#,'65`.`_%TL MD\/TWN0]G0.FZEE&`8O)6S@'+%QFH`(MDS=YGKE&PZ7+'J_OSJ:Q:`2)Z MQ%0>,ZPCD8(:F77_209N[6X4!7IF79.2@1[K0*7`S:P+5))G:QFH+DQ1_@6*D+I<;NHXR927%9*=#K0NH/:KH*Z(7URQ\%2F9=2^^, M$NV:1@&4\>2,`RB:-VZ!DO$DC`,E]CCJ0K?T7Y;H9_S[JG/35F>F38$/%?X- ML<#+S/,$$<^+*IVJ>C>8;HIH]N8XNHO9[7"P)J*Y][+YG5-J5N!]]T53XU]U M@VC_YI2I`;"ZX4.]1VMJ&*QN,/$X>)H:%:L;8DUN:GP!LE+YDMP/+L,G]6T[ M#?$^F;X1:`1$PK?U30VAU0T^IBVI4Q0M$:5-SW`E]RG&SR#V72RIVIO*6)89 M3,7VTOE?/)6>54N_O$S-J?CN=19+:IK$SWAL_%YT([TE>SFT:,$M0@F_]-O4 M6DA.#_W-E<64N]AFW;NMJC&"RP9G9O7MXEP\6C+IT@[F$L+(H(O\[0M)6RY[ M+\O>R]+Y7E9%`RH)DIG'"0;Y+$;PYK0Y27_E!$E/MY+34IAQ3]0EAN_-^N,$[4G9-*<%0S=8` MINL6N@"+"&Z])!Z=5X`^^V&Z5^#U#.#5G\3)J9:2^0A\!EBI\LBUG;=6-2)3*#("!!#S')@4Z`9]#46_EA M^@XO,5&P)QYG9NOX8HZ3R%?@+Y^QRCE]P5V^!'?)Z@G`V6*KB/*Z2HF6HE%+ M]X1CV1G$RE!IN6VS_%1/C6JV-],=143`:2$PIGN+B$#%N_>8[C\B@EF;_=YT M)Q+1=:IJ>>_G-Z)_B(86&]TQGM1:']':&.&VU-2CJNX9(OO%83(4J39#C.GQ M4#J!QH676;%7VPPNR2T\&^*(GC5Q2@BT#4>B[-RF.+*;EUH%3E!4H(BWF`5RU^&6;1V M=_,(G1!A+96L9Z&7_BO(5C?O_Y),G6H9Q`-5IAMN/5#0ODV8F?E$@7;)%5]P M!;(_6UP-)11L'>*$(D%M+TZ2UX?V4.`/,`F M9KJ3WOB]T82MF8?4_>R*AKKM<1XA21B6ICOU<0>KH>N9IGOV=:1#Q^CQ9^UI MUIXF:D^[=-#S31!]1[>AYT.`)Y"*V"PY:T./T1RX4>CZ`:CLJH\1D?0>1B\^ M;O/%Y@L">-_(W12FF`N^9*^,L?6B0:I2$K$D>WXF/>CU_#@A(=ZR%Y"]BR2^ MB^)_@9@\5$.S1/)F5],V1*Z1D#_(@?^+$Y#^FL:7#H0;W`7;1U(H#>/):V2K MOIUKU*YF:B?4/$H1*MJX>QQ4+*)&6RXU+<&[BNL[6]VY?*V&V@IZ#B61@Q8+ MO$_-%M>O[K,3+L$<;V:SL'D(49HD5(0I!S.]XLA4IN!M6'M[F0)S>SZ]6H/Y M`,#=WJ5!I:S:M*GV[C,>VJE.GC.9TC>1]HH4JP<6M:>=N1M;SZ=':XC?8XAK M$^FV3A1EULF-AJN)TD7&U M^8H57'`5?:>1B(:$UL4@MQXW*9S;\,-EA9/N?\!;@-[M:PN9)5Z01NW-W-5[ M]&=3`7JWKUM_L@K2J+T-!B&Q=C85H'?[NO6G;I:SPW#IPAK2UDHY=;$R"L%G M!_X&8J)A/``W@:P!QY=7BU;AP8*'1[RY#YR07/.E=)7)Y&0OTV8D)XIO90J0'AIA.27O)H9W(V:FPB2=U`P70`S.`?K!+K/F&#/%J7W0/9CU_4L M3%'/O/@(8XJ%O(J2IWB1!#M3!;U3Z%F4N(=M;R.!]+P7*SPL(R4EL74X%'(X MS$\#^;T+][,M@]YEEL^LV>> M8Y@>;&XLD-G;B.E^;F.A3-OH3/=^&PO?)B.EZ0\ICK<,MQR,FQZL:;Q!S'^" M8GHD*/'3)#:23>>_?#%W+$$Q9VVD(EDYZZ_U(0*P<2_*%8['H"1X7 M\H5QL;#2_53ZQ7PYRJ51R(W$]+`QLO'=!- MC[K3#\B^)P5\P7D.>$N6,TY%G%R,#Z_=V8&B,O/Y#HCYXN":-SY%T10_N#4] MDNY`PY1QXL\7>_?HQZJ(@YGI,7N[.R_Q7.`W]:D"*:`-8_GL]^S!L6`OXI-8 M('K,H9&[X%X@9^8!7"_DF)M6@9R99K9>R#%5IP(Y,PUHG"&$A>YX%IB993,3 MPTSL'G:!V3&_C\)Y)S\'ZWT'56^=]@"6!\9'`]FW\S)H' M?P5D9BH>/*ZF-G)3W8W51F[2-G*3(ES$O(BKJS=OV*#QPF:.'?[JRD=N$"'< M=N)OF<3;-X73-SS(Z]790PP50\;N*0NQZ%B4>RD]ZJ2RS/7YYL`\O7 M='N&*XLI,9*,BRQQ`#>=&]]#HKV&5!PZ4-K3M31M6LYZ"8J_Q8Q2-&HI[1TU MD792RE#!SV6SN]P_J77%-ET3Y&);7"'9S;2J"^/3]6'#+C=*7=\8-$BL*\N6:CF6;.#@AUGH\=O"1,'66=B:3I%YGEC4>.1TH[75;6_SRQ M`X;M[^!VN7RL]>P5M7^T;J@-9V.&N=O*A&QO4/)YU!H'VG$?GXF"PS\"S3U: MT_AZFKKCL9RVSV#%3.%Y?B9AZ=!1R;LQN$<\LN3Y+Z6;&=>O;I#@II.K'!43 M3'V(3U?D;C#%VB2G;!6VMIZ27VR:"VBP,=L&)LLZ:&JU1(NFTY]E]C'V2M%U3#]^L25`B.*.PG-R:>.QH6P.L-<`V M&F";`L]D]Z[3L`N2;R.TU,9G0N(MQ!3K1W?-]\;Q87I9,HON.0W+418_`X>@ MZ133CV#!U'"I*K$`$!PVS/F5EINVY#S"Y0*LP9TSS$RJ&T!=LQE$45W(.9>:`@5H:UX&:H M?7;^+X*/N!8T6UR!IUV,L7C#=9;%FUO3EC''$W]^-:WC?AY-FQ?0OCP\PG1N MEB!D+E.,#!H8=P098%E3E+A/FZJ$#TK\RGW1%@G4+,//8$SQZ*Q$@R(I2EF- MM0Z-@C(W"=K!;`=SK\$L9RDWU[S736%MA)I/H3J:-5I$OVS$LTG%-O5\7&,K MLYIA)*@L"VXQ%D6*8E[&D:5#CN=_H38(4Q22Y6NV*#\B)C_44D,M_`&56)GM M84;^QN:-'_KH&7@?H\BCF6\HB97*O?_L>V,2I3+.G>^?'3RK?2<@5#,-`TK!Q7,A"4"QR&QH!WSMZ8>2B.KO M3DVK@6&3<_7/G3'H[3:5REAF7!XY/#.Q\8EIZA)MJO6U'URU79?BB)J)H*-:U: MC1@O&N`J^D[SWFE(>/B:L"S7H5=_E:R8GC?5-$JDQ#RN5^BEU*H8&E1'1OS/D5?0$VFG_R[(3-JF^Q MW!MM&^`%B(\[&FTA$!U+34NUT=:!-I)WG"HP#RH-NZ6Q#G;&P4A426O%\:>JQY@:^((7C:KNV2NV[X&8$HXROBD*UTEW=*Z-WBP1HN?;PY9U[4G#9%P1+& MDYIJ=Q3(K;5E3YUU0F@UR"F>2*^9NK?WF'3EW:Y8(XPV6HC/\^-4/;OAU&DL M6DWLJ$+?Y,/#C?T7+.)0M');O""3K.>RY'$8\CBJ;-_.E4I'([OT="JE?81. MB()L>:3EE=*V%G:8TVE3BUSOL! M^/8Z/3Y[B!T8&P0*;0TR]9"P$TAX5^MW*)B-G>O0TQ,4C=FSFM'1LHLYA MM``(I9UZ`SB;0,LDQ7*]K6..1Q">,L_D)7(2\2%:DSUSV]_-4@IGE^RM71N3 M?)HZ+9.*,7&]6@?1!H`YP%Q%8&2WYS/%[&"6&I>Z98DN8RV9E*BC3@#()<;K M5]='X-%YO7;VPF! MT:>KPL"),UA334#]!E[KCFZT]WAWV/BV/U,=(?N!UZ81C^

4BHM>D0!6I_ MM:AQV()*@/W-Y-`0+:K&T1E_Q>$1&8''811.G[F\K:UNE\ M9ECN4E3:91\`?/&W+P3OR;H=*SYYWK"0.[N.2CJA]0DNV;4<+E)SL(Y@3%K" M?*5FH,JLK5Q'6SE3FV][PKXUIUHG+CD#^6)3#&5&F(O!JS4!2SYW.IEU*4$- M!+C,Y4<0`N@0__JIMR(A!/%.2Y[AW1FXF;-+K`PEK6SL%EISFA-K<.H@RK.: M72>E3@]3=<&!>5_%$,&IGIAJ,AP1:MHZ8*I=<1Q.7D:X02RYC:;G-C'T76+A(OW6=E+3D%8#J;^$/N;/ M#U]$I*_EL:?;[8%&GNG0WY+=W&B[T\],B">N>L MV"?O@U2EYKX*GJFSE`VR3[GVTJED]8W\K-W4W7WT2D+!;559ZSQ,TR%!S7/]IMSE[`,WM+K.7"TO@)_ M^8S9[/0%0&<)ME_`/>:XU!5]I-H/?![7VC8'A';XX?(R"M-U*G&"1P!7(TQP M;DD.<2S?1'`!_!B34'2;OY([R+AMJND0$?M(@O<,#5:MDD/$:9;$B`0^PC.E MND4.!!F]O@-';]`=>;\>BY9`/8K>?)'8CGD4!'AI)A^'!ZUW],2(_E1I-L0D,A'9W>0PR+84PY5 M>C'QEKE%*`'>58+5Q&4V6]+6H9(K3;X]4"UY)#S%")I(R_:VLFSZ_5YH4[%O.9(H)\9/MC=;>&-&ZDG?,F9TF M:CJFW:A3]-&9[:-Q^JC5I;7H$[.N*HWI$#S0QE,__BNZRL1GHA1UU4!^SD5? M=7FARO:5[&G5X]2]Z$I+^<3=EP9:&W>G]+UNVJXSPU+LP-AVT3#^N$=_55=> MSW2PK_+=X$W;GN0&W@S[U"A[&J8KHF?A'\:UG^_NK^T?%7O+M_.>88>RW>4Z M].P*-MB].%-?SCV\SN%WK.SW>*^^?3:Z*]E`RQ_;PR+OO?,.=E;M";?>?2C3 M4Z;H1[-LL8?=@X+^>T4G6N.M/ITH[!Q8=*-92K+>W2CM%E*I_SH$RM)<33CH M/N2.#5'TH%E/-QYT[_6]3U1TJEE!@U7>R.`_F![$P[8XB^FP4QZE]G$0'5O9 M1,_L)BJ[8Y5&!"HZUNZM.G:JS.NB15\/O>4J#&;:_-Z$Y_F9@+?A(H*K],ABNRQRX_G>"N_@VQ&,[27>66?P,X..S$VZ')E:>4RQ#%SPZ<`GB8HA>@"F> MD^!E[QJ):FDD/[,G,-HXP]MV*%#;A_?NHO`E6[Y(#Z+'*':"\G<2]?XNBO\% MXB(>/F5.#%>?4>AE]JR;"&Y_(NEH<0)&%L+&9*X+U"\F,V5M*BV#:6?6HLAC M(M$45Y[^9F2O\E3,K9+`F?<-\UDR6FHI?=$7>^VQMA&]Q>_6"UV#UTAN&1QM MV'B@HM6;C&U-*4P_7CDQN'%\.$B\,NGRJ8V,(ZYNL!0>%6*8-;HS,\AN]*0T M5-U09@IS4+CG8D\12E8[,V*F-U_Y+[X',.?`TU(VQ-SU'A2:GW1[B4./R(-[ M;C/IC!DE?"97U8>(:74)&FPI;*E-2^3L(]VL1[K9ZG!#0OM,MUEG8E*,US9& MDHV1I%UD'QLC21:2E/7WB!Z,'@!,&6J%#3BE)N`4GPIS]`]+*^D;JBID;[=W MZ8X!3_:/_LEJO3J$XBPPWI/7)O72"";87O?=;<%_L4V2X<\UC) MU+OPA]I;]/!%'6)_'>%\4G32I=M&PI6WL)G;A#7,4[D]F*LU4ZQ M>ETYM-A*\/'M=S70=D$'5U]C+^V-O:)0?<6/X:9<36$MF1^^($((+IW`38*R M!CM;E(DXKE[N9:K^`O'=L9)8C[W44A>HWZ46Q4^TLFQQ@SRYVEZAEBY676R9 MOT9X2OD!'A=C.Y36:E;K6-XDZ&<0/T<>67SV]`LI7N2\=>J,3-,UH>'K._C9 M-_?1;S<0D+#Y`#.*>*RYUUBO!CYO\CE&?\,:U\`WU8_)NL9)"5@BN*T,=G+9 MO-Z8ZABCML\&8KBFNLV8,<%H=-I4WYK1..71>1"/BNQ(DV],_UB%,:YVKUGS M68UW#UT?4;RKWEAQ1FOJ6;@U'\HU']HX+)+N+1Q!'!89[A3;6/*%!]GHH0CV M)3`281*M7[^0)D+"F=4O-I*/1G[%2L$_MI&?W[38O9@U,OKU^BVZ`];_[5SW M.%3DX;A%]G`<2V<95P"SQF3UDL#H0[)6O4L71 M?S]K;8*:78Y?K(-:GVG^1J9'K#N4&&$VYI81IVS2CR-L_"WK9*1=H*.C.CVW M\;<.#4P9),G<^%OJS%3CQ`[8,RSV"G-C^&.5^G@XNU_,E]+4R$HZ]KUJ MF2H,KTL8)\T9WD&&4VQ4`TR]G'F0/20PUTV]GGD(0=(&OW2N[B;@;8B_@D?G M%:#&=YND1.B:KB(8^[^G!>8QXZ^V:%X^DSBBC?%JN/+UOW3F1DD8PTWF';+] M1]TQ9/OSMZOKFJ"E#RH<579HX![\Y.,.#W`7`F)_<1-(IAS%Z:0UF^1+E&W# MC.^V)'HB:7,GY+XXWFYT9/)UL" M:ORJO31*^XV$EP@1N``A6/BTY8>6^O`O$/?=7[X\4/87_$$#[S/1=3QG7OL# MV72_'O8*7#;8T->\X\-HG[B7F9?I+PN)X$%6"J.=%EB[;WGZM%/@7HJ\&*(PP M!I:I@3;TKDD@3RPI`E]]#Q0I!K0W]A>#,WI7W](/V4Y%P?XZ@=$:T$-A5;ZK ML53$3KCT\,4*$L\/EQ^CR/ON!P'5;,&159+=!X^GT,E&#AW, MIF1FV5"Z]W/F>DB";P.($0J7V]E*,X+2TTOI4`2Z-!HM>= MOL.!AXNJE],ND+69ALQ]4"R[Q#CLV*:>F`I;;3UM'Z9[H\B!U^F MQHQL_=$+7=X(<,721(#S*$+H"R(5^*B6> M@1<.\M%L<5\2YQ%7?Q%$[F\J7BCJ(&6S5:Q#08=\@&CNT5,^@EL-NOL)EKP65RH6GK8BQZV+$N6!%H2:$F@)8%22*!9UD4)5#!SM_X,'(*3-POG M@`1JPSHZULKOHA#N_IFZ_'"9]:04;8FE)9:66%IB*8=8]EKD+/^T_-/R3\L_ M>?GG;?B"_XC@IN"?U@99"OC&0*=Y#V9FL431$D5+%"U1[$44V8N2)8"6`%H" M:`F@#`)HEOW1,`J5NRGE/7B9/5HAZ,[8DMW20TL/+3W48D\3]5]L6Q@L5;14 MT5)%2Q5YJ>(NE)4U%3;LK2QPFG=95@[+3)"Y)%GR9\F?)7^6 M_$D@?]9,J#&!RJT!NP[DMPSNY[`4T%)`2P&UV+A$C8$-T]]20$L!+06T%)"7 M`DY=%R;`VSYMCJ:A-XN?`?SDX\("/_8!ZFT9I+S$V*WFZG[6HR`;'%%+:FN) MH26&EAB*$<,^RZGEBY8O6KYH^>*@?-$:$S5F7+DU8=NUI:X4]#IL+<`R2LLH M+:/48L,3-36V+PZ625HF:9FD99*\3++@B=DKKYA/IK7/08"3>)<1BM$N1"OP M[IU-FDOITRQ]16[>(?N6:BV96O)JRSLM[[2\LQOO[+W06C)JR:@EHY:,CD1& M^QHXY5#20L!R$Z80.N%R^X+V9J\1T^\.]$0HJHQ:+&75DK(6KV2LUD&T`>`! MP!??!90N#U)9\-]FBSEPHV7H_XX['.!9GTT8@>=W)->G%KU4_*>Z^'.`EV#? MQ:O)0TQ6Y-"K_?(E],GY2NR_X$$@:'H?H$H-,-P;`JG0LW03Z854EX)UP:.\ MHI;%)G$FLWF"4++*?NN,38]*K+)ME6VK;&M!_X4?QY*][1^-&LYMS9#"T0M8 MWQ\QK#+(0H'D#Q9):32C0/4O%M6!%(("XQ_-QMA:.*V%TUHX>ULX;T.<&CPZ MKS;23V-0<`8ZS3H/,XLU*5K%W"KF5C'O&12.^$2X$02KGC+V=0$)6S>\00+L2?1EC9:VFAIXT'L=7RT4709 MM432$DE+)"V1Y"62#V!)_IR#=03)TF*P0=$P5L71<13JPI'3\D3+$RU/U&(K MXSR?YED.+#FTY-"2PX,DAS^?$@F)VPG^Q_\#4$L#!!0````(`+J`!D&E7E`G M\0P``-J,```1`!P`86)M9"TR,#$R,#8S,"YX^&(P:/WZR_??G?ZOW4;]R\^]$1H&'@T(&K1O MB.3T&?WI$(]P+`F:X&<6,'^!QLZ,^/A'=(\%<1$+T)_GHVMT=-!%:";E_*33 M>7IZ.B#N%/,VT^(.'.9W4+N=J/H],NH$?3SH_G3PT;@S8F'@GJ#WQJ4+3K`$ M:N2"%2?HZ+![U#[\N7WX?M+MGKP_.CD^^K])S>8+3J;[G'EWC4%<2GN,.#83$@4,,%K#H;PN'NJTB;2K)L,1F=3]] M^M31=PWJ4+2G&,^7]`]8W&OJ^$8GBFBW?=Q=YY*+.1&Y;/I./A^^]]TUT_`] M93Y$5J6`XCC\>'QHT`Z:5`[D(V2+];)!7$.INRQ$]_,#X-+:#X7W,CGH,$C$3*?*;J7YI.83XF\ MQ3X1<^R08E&'UNR30%XQ[E^2!QQZH/*?$'OT@1*WA;"$5G\?2K)&$`8KDE^4 ME%,6/P5+J@T/.',(Q.``JD/7T:#C4;*N'?I*,+.)7-" M96;R'P=N/Y!4+@:@@OM:<0M1R+1"E$NC$K-<\D`#JLWO'G91&R7LYD<0A2)9 MR!!VVDE+2`L/H5L MCH?7@\O>I'^)SGO7O=N+/AK_UN]/Q@UTNT%WASF0S(BD$)O2.&KN+6"^+PXF M>K=FS@\-N`7`A7D/$/4\27@`+CR2?!2S9';8/MA@&T_@WTW_%B`;7J'A77_4 MFPR`H`&L`&!#R&]^P7SP8D8"`5!$V.3CMI':#M_'XO!=#&_N1OW?^K?CP>]] M-+B%[WWT[GHX'C<-L`B>%UC,KCSV)`:!2SEQ9#Z063([@C^50+`W_@U=70__ M:!K@1L!NF21BPI:#V3*TXCP4L(`4XI((A].YLJT7N.=84#%\N#,\G9!G>>XQ MYV\#X+V*M2?$SVHB2X7C,1%R`E]NL50?V`-*=.GYK5:AKH*2.>;-#+=B7O0Q M#V@P%7>$CV60'P2/\8WRQ"G`Y8*T"[+AV MT[@FLBAIL*R`Y6?&W"?J>56AM/';D3Q*(YF(:F`L#V//<7A(W/[S')8N1,#\ M1R]GKBD(\\!4(JH"7$VR'?KC-/2Q$I1H:5*@?`JL`@I+(%C&0B"U8R,"H2'N M!1-2Z,G,N7KT=(<7FJM<,NRJPYX6[]-I,9;`U-:RD*FN28\J@[::V4[P<_5! MVR+`#NR'[*"MI]D@K&GK5<"$QN!3&?7/`32[0,(*B`!1]7Z^I$@[X!_3@!O2 M]=)Y37Z3`>4S8$RFZO^(S!E7D:P*>Q$Y=JQ_RO3:DK[K)1,\+U'Q&[UDEB&'>UL;6QSU02]BT0VU>U]ET]*P%U$CAWR3*%L0RFE M@?N%:BHET"X@Q@KV4:9N9M17&H!?IM!2`M_M4NSP9LIGB<`&V]>NOI1`?1?Y M]GS(%.'2E9@F+]ZN)%,B0_:CR9XKF:K=IO),DS/;]V@NXZ@"%T:V#Q_4$V4' MFO;6T=1:3:R3^7J\=7,'`7:8,U4X0X%^!*Y4Z,5=K,1<`B@]Y@+@ MDDA,F_UE11)AB=60FVCU7%?;A;WL]MUJO';X,[4Z`UW&TP##@+'486[T;9`O M@?P-YG]#M*#+'!,GY'I`'^A=Z[J73H.]C=R.;Z8TMQ*'5O*0(;#!LF1WS@(5 M-K43=+ETRNNT\\CLV&5*;2LQJF=>6ZHUF!7&S(A;H=YV*[T=Q4P)S<2MZ5#W M`&BRJ"V$IIW8#F6F-+9<3C:FVL_#:S%FVGH^Y@O8H2&T:L+&\8Z*ZT= MRNR^JDC6$D<4B6N&P?WUM86FGF58[1!GJC8;VVHC8G/'`CG5.(6JU+;<9*/;2UJ.] MD#U]L$J\$U)MA#0V8Q6;*5258\^`3/VJX-[-)CG@LOJC#I<:D0>DSXTZ4><>:<77,'<4O_W$J)MNY@6/VL?=@V?AQB:6L6`5Z7(6 M)'QE+<@]$*ZH[H1!*?U02)WU4+U-:K7*W%/\.L238BFKO9)5/OJ9,_0*!2'- MI2+Q286_^W$7$XSC_TJ:P8+;:I;83DG<`1AUI2PNVTX=M)J3QY=\V-2'G91G#T0LI-]@BS]OL"(^)5&;<=;:X=9ZP)X>C-3AHRW`P6\WE'`=337*^R&S![3UA[O;_ M"?69FV"H/CQ3Z`R?S'`0E]G`=;W"`C0F^MQ2!;TJN4S8.>DY,PI)X1IA>TLC M3#"$TB3>KM%=$I\MWXC)YI(1L:V4:SD6V_B&CFUZRMZ+#3%=VTZ[AIGD-)CF MN199^VJ>;=@B9_5P*T_M/=WP2*BHT]O8:^M_J1WL6\-145HMHY/>Y&1U?C-Q MO7W+JUT6<]3.64NOMY7MK8X79ZZI[_:]LUM\+\I<2]^W;-RWNEZ8MY:>EWD_ MQ1J&:H)J&9.JCW2L\=E=:#UC57RCC#T\5>1\11%9;:^L$(8\YGKZ7FWG@STD MN\JL=Z1R-@T6"X>5L98^[[Z3RAJ9?8JO4_P*_!1,7EQ*L=7(W_0I2"N`KVE` ME%EF';(0]5?AG7XSOY!G,>4K>^7*DQEP\UW'=X)\_]]B"1`/972)%7H,JRUBCME7(]'0S*\-4RQ9GE!WR\,R_72/4#`/3V&1OU12!^!>% MU$(ETT?DWJU35Y%S,EE^(MG(:I50V9/6,HFUB:26"093`$=-X:;Q&4(X6$0] ME.&2A29.-LBT>43T9L]@32,G3&(O,O%\\9FP*PI%6^#?F(S.,9LV[M/@NT.[?$7`+N(&/G'2NK8*2VK+CD M?D\[5BKFR->;$^IGF=W0`[CB_0+&5JN\$;L@?8V&;IO%Z3&\`&TM!_.5WIFKRNLU^:)?A7B7\!*];FPEK-F\W]WS`.K]HJ2ECS+;25E5NK M!U,W1,Z8JQY/Y4X!7ES5MQ_7S%3D1=5\6].9N)WVIE-.IM`P!X%R25!G[WU% M44W?0K[F]W[]9X"1"G('"]&7"&TQ==]N?$=$+=W!(?7[5LJ-$'L3POV7#_5V MS5]3U,46YX>A5#,A564M&(>C,J%_$?5F_"N]0;+#[.^T$[WA!Q__`U!+`0(> M`Q0````(`+J`!D%6QM9QD&@``#]Y!0`1`!@```````$```"D@0````!A8FUD M+3(P,3(P-C,P+GAM;%54!0`#H",@4'5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`+J`!D%AU?J&F`X``)/"```5`!@```````$```"D@=MH``!A8FUD+3(P M,3(P-C,P7V-A;"YX;6Q55`4``Z`C(%!U>`L``00E#@``!#D!``!02P$"'@,4 M````"`"Z@`9!5#D1.6DF```?&`,`%0`8```````!````I('"=P``86)M9"TR M,#$R,#8S,%]D968N>&UL550%``.@(R!0=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`NH`&06-)Y#VZ2P``_G0$`!4`&````````0```*2!>IX``&%B;60M M,C`Q,C`V,S!?;&%B+GAM;%54!0`#H",@4'5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`+J`!D&L?9%#%BD``/>R`P`5`!@```````$```"D@8/J``!A8FUD M+3(P,3(P-C,P7W!R92YX;6Q55`4``Z`C(%!U>`L``00E#@``!#D!``!02P$" M'@,4````"`"Z@`9!I5Y0)_$,``#:C```$0`8```````!````I('H$P$`86)M M9"TR,#$R,#8S,"YX`L``00E#@``!#D!``!02P4&```` /``8`!@`:`@``)"$!```` ` end XML 20 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accrued Expenses (Detail) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Mar. 31, 2012
Schedule of Accrued Liabilities [Line Items]    
Employee compensation $ 5,861 $ 9,272
Research and development 1,238 519
Sales taxes 1,108 948
Warranty 800 726
Professional, accounting and auditing fees 383 427
Other 744 588
Accrued expenses $ 10,134 $ 12,480

XML 21 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation Recognized (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation $ 2,679 $ 2,332
Cost of product revenue
   
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation 146 76
Research and development
   
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation 563 500
Selling, general and administrative
   
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation $ 1,970 $ 1,756
XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Net Income (Loss) Per Share
3 Months Ended
Jun. 30, 2012
Net Income (Loss) Per Share

Note 2. Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted average shares outstanding any potential dilutive securities outstanding for the period. Potential dilutive securities include stock options, restricted stock awards, restricted stock units, performance-based stock awards and shares to be purchased under the employee stock purchase plan. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. The Company’s basic and diluted net income (loss) per share for the three months ended June 30, 2012 and 2011 were as follows (in thousands, except per share data):

 

     Three Months Ended
June 30,
 
     2012      2011  

Basic Net Income (Loss) Per Share

     

Net income (loss)

   $ 3,119       $ (4,594
  

 

 

    

 

 

 

Weighted average shares used in computing basic net income (loss) per share

     39,144         38,268   
  

 

 

    

 

 

 

Net income (loss) per share - basic

   $ 0.08       $ (0.12
  

 

 

    

 

 

 

 

     Three Months Ended
June 30,
 
     2012      2011  

Diluted Net Income (Loss) Per Share

     

Net income (loss)

   $ 3,119       $ (4,594
  

 

 

    

 

 

 

Weighted average shares used in computing basic net income (loss) per share

     39,144         38,268   

Effect of dilutive securities

     2,405         —     
  

 

 

    

 

 

 

Weighted average shares used in computing diluted net income (loss) per share

     41,549         38,268   

Net income (loss) per share - diluted

   $ 0.08       $ (0.12
  

 

 

    

 

 

 

For the three months ended June 30, 2012, approximately 490,000 shares underlying outstanding securities were not included in the computation of diluted earnings per share primarily related to out-of-the-money stock options and performance-based awards where milestones were not met. For the three months ended June 30, 2011, approximately 3,565,000 shares underlying stock options and approximately 837,000 restricted shares were excluded from the calculation of diluted weighted average shares outstanding because the Company incurred a loss in the period, and to include them would have been anti-dilutive.

XML 23 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
Components of Stock-Based Compensation (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation $ 2,679 $ 2,332
Stock options
   
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation 970 903
Restricted Stock
   
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation 338 1,156
Restricted stock units
   
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation 1,323 256
Employee Stock Purchase Plan
   
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation $ 48 $ 17
XML 24 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Mar. 31, 2012
Current assets:    
Cash and cash equivalents $ 3,989 $ 5,990
Short-term marketable securities 77,233 71,233
Accounts receivable, net 18,343 20,458
Inventories 12,477 11,142
Prepaid expenses and other current assets 1,749 1,716
Total current assets 113,791 110,539
Property and equipment, net 6,337 6,378
Intangible assets, net   115
Goodwill 34,741 36,846
Other long-term assets 33 33
Total assets 154,902 153,911
Current liabilities:    
Accounts payable 6,294 6,910
Accrued expenses 10,134 12,480
Deferred revenue 2,687 3,025
Total current liabilities 19,115 22,415
Long-term deferred tax liability 4,890 4,799
Other long-term liabilities 377 400
Total liabilities 24,382 27,614
Commitments and contingencies (Note 9)      
Stockholders' equity:    
Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none      
Common stock, $.01 par value Authorized - 100,000,000 shares; Issued - 39,559,821 shares at June 30, 2012 and 39,323,708 shares at March 31, 2012; Outstanding - 39,497,477 shares at June 30, 2012 and 39,272,754 shares at March 31, 2012 395 393
Additional paid in capital 405,688 401,771
Accumulated deficit (270,156) (273,275)
Treasury stock at cost - 62,344 shares at June 30, 2012 and 50,954 shares at March 31, 2012 (1,065) (827)
Accumulated other comprehensive loss (4,342) (1,765)
Total stockholders' equity 130,520 126,297
Total liabilities and stockholders' equity $ 154,902 $ 153,911
XML 25 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Operating activities:    
Net income (loss) $ 3,119 $ (4,594)
Adjustments required to reconcile net income (loss) to net cash provided by (used for) operating activities:    
Depreciation and amortization 842 1,046
Bad debt expense 8 15
Stock-based compensation 2,679 2,332
Write-down of inventory 252 156
Deferred tax provision 90 96
Changes in assets and liabilities:    
Accounts receivable 2,032 847
Inventories (1,982) (1,601)
Prepaid expenses and other assets (65) 220
Accounts payable (300) (1,360)
Accrued expenses and other long-term liabilities (2,024) (5,443)
Deferred revenue (333) (270)
Net cash provided by (used for) operating activities 4,318 (8,556)
Investing activities:    
Purchases of short-term marketable securities (11,500) (5,001)
Proceeds from the sale and maturity of short-term marketable securities 5,500 4,500
Expenditures for property and equipment (470) (472)
Net cash used for investing activities (6,470) (973)
Financing activities:    
Proceeds from the exercise of stock options 1,228 7,629
Payments in lieu of issuance of common stock for minimum payroll taxes (238)  
Net cash provided by financing activities 990 7,629
Effect of exchange rate changes on cash (839) 220
Net decrease in cash and cash equivalents (2,001) (1,680)
Cash and cash equivalents at beginning of period 5,990 5,831
Cash and cash equivalents at end of period 3,989 4,151
Supplemental disclosures:    
Fixed asset additions included in accounts payable $ 92 $ 44
XML 26 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Detail)
3 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]    
Risk-free interest rate 0.78% 1.83%
Expected option life (years) 4 years 3 months 29 days 5 years 3 months 18 days
Expected volatility 56.30% 51.60%
XML 27 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation (Tables)
3 Months Ended
Jun. 30, 2012
Stock-Based Compensation Recognized

The following table summarizes stock-based compensation expense by financial statement line item in the Company’s consolidated statements of operations for the three months ended June 30, 2012 and 2011 (in thousands):

 

     Three Months Ended
June 30,
 
     2012      2011  

Cost of product revenue

   $ 146       $ 76   

Research and development

     563         500   

Selling, general and administrative

     1,970         1,756   
  

 

 

    

 

 

 
   $ 2,679       $ 2,332   
  

 

 

    

 

 

 
Components of Stock-Based Compensation

The components of stock-based compensation for the three months ended June 30, 2012 and 2011 were as follows (in thousands):

 

     Three Months Ended
June 30,
 
     2012      2011  

Stock options

   $ 970       $ 903   

Restricted stock

     338         1,156   

Restricted stock units

     1,323         256   

Employee stock purchase plan

     48         17   
  

 

 

    

 

 

 
   $ 2,679       $ 2,332   
  

 

 

    

 

 

 
Summary of Stock Option Activity

The following table summarizes the stock option activity for the three months ended June 30, 2012:

 

     Shares
Underlying
Options

(in  thousands)
    Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Term (years)
     Aggregate
Intrinsic
Value

(in  thousands)
 

Outstanding at April 1, 2012

     4,268      $ 10.42         6.03      

Granted

     303        22.44         

Exercised

     (161     7.62         

Cancelled and expired

     (31     9.21         
  

 

 

   

 

 

       

Outstanding at June 30, 2012

     4,379      $ 11.34         6.01       $ 50,278   
  

 

 

   

 

 

       

Exercisable at June 30, 2012

     3,327      $ 10.72         5.29       $ 40,249   
  

 

 

   

 

 

       

Options vested and expected to vest at June 30, 2012

     4,133      $ 11.33         5.89       $ 47,479   
  

 

 

   

 

 

       
Weighted-Average Assumptions Used to Calculate Fair Value of Options Granted

The fair value of options granted during the three months ended June 30, 2012 and 2011 were calculated using the following weighted average assumptions:

 

     Three Months Ended
June 30,
 
     2012     2011  

Risk-free interest rate

     0.78     1.83

Expected option life (years)

     4.33        5.30   

Expected volatility

     56.3     51.6
Summary of Restricted Stock and Restricted Stock Units Activity

The following table summarizes the activity for the three months ended June 30, 2012:

 

     Three Months Ended
June 30, 2012
 
     Number of
Share (in 000’s)
    Weighted Average
Grant Date

Fair Value
 

Outstanding at April 1, 2012

     871      $ 15.76   

Granted

     361        22.40   

Vested

     (209     13.76   

Forfeited

     (18     20.48   
  

 

 

   

 

 

 

Outstanding at June 30, 2012

     1,005      $ 18.47   
  

 

 

   

 

 

 
XML 28 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary of Restricted Stock and Restricted Stock Units Activity (Detail) (Restricted Stock and Restricted Stock Units, USD $)
3 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Restricted Stock and Restricted Stock Units
   
Number of Shares    
Beginning Balance 871,000  
Granted 361,000  
Vested (209,000)  
Forfeited (18,000)  
Ending Balance 1,005,000  
Weighted Average Grant Date Fair Value    
Beginning Balance $ 15.76  
Granted $ 22.40 $ 18.49
Vested $ 13.76  
Forfeited $ 20.48  
Ending Balance $ 18.47  
XML 29 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Net Income or Loss Per Share - Additional Information (Detail)
3 Months Ended
Jun. 30, 2012
Performance Shares
Jun. 30, 2011
Stock Options
Jun. 30, 2011
Restricted Stock
Earnings Per Share Disclosure [Line Items]      
Shares excluded from the calculation of diluted weighted average shares outstanding 490,000 3,565,000 837,000
XML 30 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 31 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Nature of Business and Basis of Preparation
3 Months Ended
Jun. 30, 2012
Nature of Business and Basis of Preparation

Note 1. Nature of Business and Basis of Preparation

Abiomed, Inc. (the “Company” or “Abiomed”) is a leading provider of mechanical circulatory support devices and offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company’s products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial reporting and in accordance with Article 10 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by GAAP for complete financial statements. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2012 that has been filed with the Securities and Exchange Commission, or SEC.

In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair presentation of results for the interim periods presented. The results of operations for any interim period may not be indicative of results for the full fiscal year.

There have been no changes in the Company’s significant accounting policies for the three months ended June 30, 2012 as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2012 that has been filed with the SEC.

Recently Adopted Accounting Standards

During the first quarter of fiscal 2013, the Company adopted Accounting Standards Update, or ASU, No ASU 2011-05, Presentation of Comprehensive Income. ASU 2011-05 requires entities to present net income and other comprehensive income in either a single continuous statement of comprehensive income or in two separate, but consecutive, statements of net income and other comprehensive income. In December 2011, the Financial Accounting Standards Board, or FASB, issued ASU No. 2011-12, Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05. ASU 2011-12 amended ASU 2011-05 by indefinitely deferring the requirement under ASU 2011-05 to present reclassification adjustments out of accumulated other comprehensive income by a component in both the statement in which net income is presented and the statement in which other comprehensive income is presented. The Company has adopted ASU 2011-05 with retrospective application as required, except for the components of ASU 2011-05 which were indefinitely deferred by ASU 2011-12 and has included in these condensed consolidated financial statements separate unaudited statements of comprehensive income. The adoption of this standard did not impact the Company’s condensed consolidated financial statements other than this change in presentation

In September 2011, the FASB issued ASU No. 2011-08, Testing for Goodwill Impairment. ASU 2011-08 amended current goodwill impairment testing guidance by providing entities with an option to perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. The Company adopted ASU 2011-08 during the first quarter of fiscal 2013 and will apply the provisions to its annual impairment assessment to be conducted during the third quarter of fiscal 2013.

XML 32 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
Jun. 30, 2012
Mar. 31, 2012
Class B Preferred Stock, par value $ 0.01 $ 0.01
Class B Preferred Stock, Authorized 1,000,000 1,000,000
Class B Preferred Stock, Issued      
Class B Preferred Stock, outstanding      
Common stock, par value $ 0.01 $ 0.01
Common stock, Authorized 100,000,000 100,000,000
Common stock, Issued 39,559,821 39,323,708
Common stock, Outstanding 39,497,477 39,272,754
Treasury stock, shares 62,344 50,954
XML 33 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Net Income (Loss) Per Share (Tables)
3 Months Ended
Jun. 30, 2012
Computation of Basic and Diluted Net Income or Loss Per Share

The Company’s basic and diluted net income (loss) per share for the three months ended June 30, 2012 and 2011 were as follows (in thousands, except per share data):

 

     Three Months Ended
June 30,
 
     2012      2011  

Basic Net Income (Loss) Per Share

     

Net income (loss)

   $ 3,119       $ (4,594
  

 

 

    

 

 

 

Weighted average shares used in computing basic net income (loss) per share

     39,144         38,268   
  

 

 

    

 

 

 

Net income (loss) per share - basic

   $ 0.08       $ (0.12
  

 

 

    

 

 

 

 

     Three Months Ended
June 30,
 
     2012      2011  

Diluted Net Income (Loss) Per Share

     

Net income (loss)

   $ 3,119       $ (4,594
  

 

 

    

 

 

 

Weighted average shares used in computing basic net income (loss) per share

     39,144         38,268   

Effect of dilutive securities

     2,405         —     
  

 

 

    

 

 

 

Weighted average shares used in computing diluted net income (loss) per share

     41,549         38,268   

Net income (loss) per share - diluted

   $ 0.08       $ (0.12
  

 

 

    

 

 

 
XML 34 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information
3 Months Ended
Jun. 30, 2012
Jul. 31, 2012
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2012  
Document Fiscal Year Focus 2012  
Document Fiscal Period Focus Q1  
Trading Symbol ABMD  
Entity Registrant Name ABIOMED INC  
Entity Central Index Key 0000815094  
Current Fiscal Year End Date --03-31  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   39,527,727
XML 35 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements (Tables)
3 Months Ended
Jun. 30, 2012
Marketable Securities Investments

The following table presents the Company’s financial instruments recorded at fair value in the consolidated balance sheet, classified according to the three categories described above (in thousands):

 

     Quoted
Prices in
Active
Markets
(Level 1)
     Using
Significant
Other
Observable
Inputs
(Level 2)
     Using
Significant
Unobservable
Inputs

(Level 3)
     Total
Carrying
Value
 

At June 30, 2012:

           

U.S. Treasury securities

   $ 77,233         —           —         $ 77,233   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     Quoted
Prices in
Active
Markets
(Level 1)
     Using
Significant
Other
Observable
Inputs

(Level 2)
     Using
Significant
Unobservable
Inputs

(Level 3)
     Total
Carrying
Value
 

At March 31, 2012:

           

U.S. Treasury securities

   $ 71,233         —           —         $ 71,233   
  

 

 

    

 

 

    

 

 

    

 

 

 
XML 36 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Revenue:    
Product revenue $ 38,647 $ 27,166
Funded research and development 136 189
Total Revenue 38,783 27,355
Costs and expenses:    
Cost of product revenue 7,446 5,891
Research and development 6,712 7,324
Selling, general and administrative 20,953 18,176
Amortization of intangible assets 111 385
Costs and Expenses, Total 35,222 31,776
Income (loss) from operations 3,561 (4,421)
Other (expense) income:    
Investment (expense) income, net (2) 4
Other expense, net (4) (81)
Nonoperating Income (Expense), Total (6) (77)
Income (loss) before income tax provision 3,555 (4,498)
Income tax provision 436 96
Net income (loss) $ 3,119 $ (4,594)
Basic net income (loss) per share $ 0.08 $ (0.12)
Basic weighted average shares outstanding 39,144 38,268
Diluted net income (loss) per share $ 0.08 $ (0.12)
Diluted weighted average shares outstanding 41,549 38,268
XML 37 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accrued Expenses
3 Months Ended
Jun. 30, 2012
Accrued Expenses

Note 6. Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

     June 30,
2012
     March 31,
2012
 

Employee compensation

   $ 5,861       $ 9,272   

Research and development

     1,238         519   

Sales taxes

     1,108         948   

Warranty

     800         726   

Professional, accounting and auditing fees

     383         427   

Other

     744         588   
  

 

 

    

 

 

 
   $ 10,134       $ 12,480   
  

 

 

    

 

 

 

Employee compensation consists primarily of accrued bonuses, accrued commissions and accrued employee benefits at June 30, 2012 and March 31, 2012.

XML 38 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Goodwill
3 Months Ended
Jun. 30, 2012
Goodwill

Note 5. Goodwill

The carrying amount of goodwill at June 30, 2012 and March 31, 2012 was $34.7 million and $36.8 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, or Impella, in 2005. The goodwill activity for the three months ended June 30, 2012 is as follows (in thousands):

 

Balance at March 31, 2012

   $ 36,846   

Exchange rate impact

     (2,105
  

 

 

 

Balance at June 30, 2012

   $ 34,741   
  

 

 

 
XML 39 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Computation of Basic and Diluted Net Income Loss Per Share (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Basic Net Income (Loss) Per Share    
Net income (loss) $ 3,119 $ (4,594)
Weighted average shares used in computing basic net income (loss) per share 39,144 38,268
Net income (loss) per share - basic $ 0.08 $ (0.12)
Diluted Net Income (Loss) Per Share    
Net income (loss) $ 3,119 $ (4,594)
Weighted average shares used in computing basic net income (loss) per share 39,144 38,268
Effect of dilutive securities 2,405  
Weighted average shares used in computing diluted net income (loss) per share 41,549 38,268
Net income (loss) per share - diluted $ 0.08 $ (0.12)
XML 40 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Inventories (Tables)
3 Months Ended
Jun. 30, 2012
Components of Inventories

The components of inventories are as follows (in thousands):

 

     June 30,
2012
     March 31,
2012
 

Raw materials and supplies

   $ 4,390       $ 3,586   

Work-in-progress

     3,946         4,098   

Finished goods

     4,141         3,458   
  

 

 

    

 

 

 
   $ 12,477       $ 11,142   
  

 

 

    

 

 

 
XML 41 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies
3 Months Ended
Jun. 30, 2012
Commitments and Contingencies

Note 9. Commitments and Contingencies

Litigation

From time to time, the Company is involved in legal and administrative proceedings and claims of various types. While any litigation contains an element of uncertainty, management presently believes that the outcome of each such proceedings or claims which are pending or known to be threatened, or all of them combined, is not expected to have a material effect on the Company’s financial position, and results of operations or cash flows. At June 30, 2012, the Company did not have any material pending litigation.

XML 42 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation
3 Months Ended
Jun. 30, 2012
Stock-Based Compensation

Note 7. Stock-Based Compensation

The following table summarizes stock-based compensation expense by financial statement line item in the Company’s consolidated statements of operations for the three months ended June 30, 2012 and 2011 (in thousands):

 

     Three Months Ended
June 30,
 
     2012      2011  

Cost of product revenue

   $ 146       $ 76   

Research and development

     563         500   

Selling, general and administrative

     1,970         1,756   
  

 

 

    

 

 

 
   $ 2,679       $ 2,332   
  

 

 

    

 

 

 

The components of stock-based compensation for the three months ended June 30, 2012 and 2011 were as follows (in thousands):

 

     Three Months Ended
June 30,
 
     2012      2011  

Stock options

   $ 970       $ 903   

Restricted stock

     338         1,156   

Restricted stock units

     1,323         256   

Employee stock purchase plan

     48         17   
  

 

 

    

 

 

 
   $ 2,679       $ 2,332   
  

 

 

    

 

 

 

Stock Options

The following table summarizes the stock option activity for the three months ended June 30, 2012:

 

     Shares
Underlying
Options

(in  thousands)
    Weighted
Average
Exercise
Price
     Weighted
Average
Remaining
Contractual
Term (years)
     Aggregate
Intrinsic
Value

(in  thousands)
 

Outstanding at April 1, 2012

     4,268      $ 10.42         6.03      

Granted

     303        22.44         

Exercised

     (161     7.62         

Cancelled and expired

     (31     9.21         
  

 

 

   

 

 

       

Outstanding at June 30, 2012

     4,379      $ 11.34         6.01       $ 50,278   
  

 

 

   

 

 

       

Exercisable at June 30, 2012

     3,327      $ 10.72         5.29       $ 40,249   
  

 

 

   

 

 

       

Options vested and expected to vest at June 30, 2012

     4,133      $ 11.33         5.89       $ 47,479   
  

 

 

   

 

 

       

The aggregate intrinsic value of options exercised was $2.5 million for the three months ended June 30, 2012. The total fair value of options vested during the three months ended June 30, 2012 was $2.0 million.

The remaining unrecognized stock-based compensation expense for unvested stock option awards at June 30, 2012 was approximately $5.0 million, net of forfeitures, and the weighted-average period over which this cost will be recognized is 2.9 years.

 

The Company estimates the fair value of each stock option granted at the grant date using the Black-Scholes option valuation model. The fair value of options granted during the three months ended June 30, 2012 and 2011 were calculated using the following weighted average assumptions:

 

     Three Months Ended
June 30,
 
     2012     2011  

Risk-free interest rate

     0.78     1.83

Expected option life (years)

     4.33        5.30   

Expected volatility

     56.3     51.6

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for a term consistent with the expected life of the stock options. Volatility assumptions are calculated based on the historical volatility of the Company’s stock and adjusted for factors not reflected in historical volatility that may be more indicative of future volatility. The Company estimates the expected term of options based on historical exercise trends and estimates of future exercises of unexercised options.

The calculation of the fair value of the options is net of estimated forfeitures. Forfeitures are estimated based on an analysis of actual option forfeitures, adjusted to the extent historic forfeitures may not be indicative of forfeitures in the future. In addition, an expected dividend yield of zero is used in the option valuation model, because the Company does not pay cash dividends and does not expect to pay any cash dividends in the foreseeable future.

Restricted Stock and Restricted Stock Units

In addition to stock option grants, the Company also has the ability to grant restricted stock and restricted stock units. Similar to stock options, these restricted stock and restricted stock unit grants are subject to certain vesting criteria. The following table summarizes the activity for the three months ended June 30, 2012:

 

     Three Months Ended
June 30, 2012
 
     Number of
Share (in 000’s)
    Weighted Average
Grant Date

Fair Value
 

Outstanding at April 1, 2012

     871      $ 15.76   

Granted

     361        22.40   

Vested

     (209     13.76   

Forfeited

     (18     20.48   
  

 

 

   

 

 

 

Outstanding at June 30, 2012

     1,005      $ 18.47   
  

 

 

   

 

 

 

The remaining unrecognized compensation expense for outstanding restricted stock awards and restricted stock units, including performance-based awards, as of June 30, 2012 was $12.6 million and the weighted-average period over which this cost will be recognized is 2.4 years.

The weighted average grant-date fair value for restricted stock and restricted stock units granted during the three months ended June 30, 2012 and 2011 was $22.40 and $18.49 per share, respectively. The total fair value of restricted stock and restricted stock units vested during the three months ended June 30, 2012 and 2011 was $2.9 million and $1.5 million, respectively.

Performance Based Awards

Included in the restricted stock and restricted stock units activity discussed above are certain awards granted in fiscal years 2012, 2011 and 2010 that vest subject to certain performance-based criteria.

During the three months ended June 30, 2012, performance-based awards of restricted stock units for the potential issuance of 195,188 shares of common stock were issued to certain executive officers and employees, all of which would vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. As of June 30, 2012, the Company believes it is probable that the prescribed performance targets will be met for these awards and the compensation expense is being recognized accordingly.

During the three months ended June 30, 2011, performance-based awards of restricted stock units for the potential issuance of 284,000 shares of common stock were issued to certain executive officers and members of the senior management of the Company, all of which would vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. During the year ended March 31, 2012, the Company determined that it met the prescribed targets for 184,000 shares underlying these awards. As of June 30, 2012, the Company believes it is probable that the prescribed performance targets will be met for the remaining 100,000 shares, and the compensation expense is being recognized accordingly.

In June 2010, 311,000 shares of restricted stock and a performance-based award for the potential issuance of 45,000 shares of common stock were issued to certain executive officers and members of the senior management of the Company, all of which would vest upon achievement of prescribed service milestones by the award recipients and performance milestones by the Company. During the year ended March 31, 2011, the Company determined that it met the prescribed performance targets and a portion of these shares and stock options vested. The remaining shares will vest upon satisfaction of prescribed service conditions by the award recipients.

During the three months ended June 30, 2012, the Company recorded $0.9 million in stock-based compensation expense for equity awards in which the prescribed performance milestones have been achieved or are probable of being achieved. The remaining unrecognized compensation expense related to these equity awards at June 30, 2012 is $6.8 million based on the Company’s current assessment of probability of achieving the performance milestones. The weighted-average period over which this cost will be recognized is 2.4 years.

XML 43 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes
3 Months Ended
Jun. 30, 2012
Income Taxes

Note 8. Income Taxes

Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to tax benefit carryforwards and to differences between the financial statement amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates. A valuation reserve is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The tax benefit associated with the stock option compensation deductions will be credited to equity when realized.

The Company regularly assesses its ability to realize its deferred tax assets. Assessments of the realization of deferred tax assets require that management consider all available evidence, both positive and negative, and make significant judgments about many factors, including the amount and likelihood of future taxable income. Based on the available evidence and uncertainties surrounding the Company’s ability to continue to generate future taxable income, the Company has recorded valuation allowances to reduce its deferred tax assets to the amount that is more likely than not to be realizable as of June 30, 2012 and March 31, 2012.

As of June 30, 2012, the Company has accumulated a net deferred tax liability of $4.9 million which is the result of the difference in accounting for the Company’s goodwill, which is amortizable over 15 years for tax purposes but not amortizable for book purposes. The net deferred tax liability cannot be offset against the Company’s deferred tax assets since it relates to an indefinite-lived asset and is not anticipated to reverse in the same period.

The Company and its subsidiaries are subject to U.S. federal income tax, as well as income tax of multiple state and foreign jurisdictions. The Company has accumulated significant losses since its inception in 1981. All tax years remain subject to examination by major tax jurisdictions, including the federal government and the Commonwealth of Massachusetts. However, because the Company has net operating loss and tax credit carryforwards which may be utilized in future years to offset taxable income, those years may also be subject to review by relevant taxing authorities if the carryforwards are utilized.

During three months ended June 30, 2012 and 2011, the Company recorded a provision for income taxes of $0.4 million and $0.1 million, respectively. The income tax provision for the three months ended June 30, 2012 is primarily due to $0.2 million of income taxes in Germany that the Company does not expect will be offset by the Company’s net operating loss carryforwards in Germany and therefore expects to pay in cash. The Company also recorded $0.2 million in income taxes related to its deferred tax liability on goodwill and alternative minimum tax in the U.S.

XML 44 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segment and Enterprise Wide Disclosures
3 Months Ended
Jun. 30, 2012
Segment and Enterprise Wide Disclosures

Note 10. Segment and Enterprise Wide Disclosures

The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 70% and 68% of the Company’s total consolidated assets are located within the U.S. as of June 30, 2012 and March 31, 2012, respectively. The remaining assets are located in Europe and are primarily related to the Company’s Impella production facility in Germany, and include goodwill and intangibles of $34.7 million and $37.0 million at June 30, 2012 and March 31, 2012, respectively, associated with the Impella acquisition in May 2005. Total assets in Europe excluding goodwill and intangibles amounted to 7% and 8% of total consolidated assets at June 30, 2012 and March 31, 2012, respectively. International sales (sales outside the U.S. and primarily in Europe) accounted for 5% and 7% of total revenue for the three months ended June 30, 2012 and 2011, respectively.

XML 45 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation - Additional Information (Detail) (USD $)
3 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Aggregate intrinsic value of options exercised in period $ 2,500,000    
Fair value of options vested in period 2,000,000    
Expected dividend yield 0.00%    
Stock-based compensation 2,679,000 2,332,000  
Stock Options
     
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized stock-based compensation expense 5,000,000    
Unrecognized stock-based compensation expense, weighted-average recognition period 2 years 10 months 24 days    
Performance Based Restricted Stock and Restricted Stock Units
     
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized stock-based compensation expense 6,800,000    
Unrecognized stock-based compensation expense, weighted-average recognition period 2 years 4 months 24 days    
Shares of award granted 195,188 284,000 311,000
Shares of award granted, performance target met 184,000    
Shares of award granted, it is probable that the prescribed performance targets will be met 100,000    
Stock-based compensation 900,000    
Restricted Stock and Restricted Stock Units
     
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized stock-based compensation expense 12,600,000    
Unrecognized stock-based compensation expense, weighted-average recognition period 2 years 4 months 24 days    
Weighted average grant-date fair value for restricted stock and restricted stock units granted $ 22.40 18.49  
Fair value of restricted stock and restricted stock units vested in period $ 2,900,000 1,500,000  
Shares of award granted 361,000    
Performance Shares
     
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares of award granted     45,000
XML 46 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accrued Expenses (Tables)
3 Months Ended
Jun. 30, 2012
Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

     June 30,
2012
     March 31,
2012
 

Employee compensation

   $ 5,861       $ 9,272   

Research and development

     1,238         519   

Sales taxes

     1,108         948   

Warranty

     800         726   

Professional, accounting and auditing fees

     383         427   

Other

     744         588   
  

 

 

    

 

 

 
   $ 10,134       $ 12,480   
  

 

 

    

 

 

 
XML 47 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Components of Inventories (Detail) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Mar. 31, 2012
Schedule of Inventory [Line Items]    
Raw materials and supplies $ 4,390 $ 3,586
Work-in-progress 3,946 4,098
Finished goods 4,141 3,458
Inventories $ 12,477 $ 11,142
XML 48 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Net income (loss) $ 3,119 $ (4,594)
Other comprehensive (loss) income    
Foreign currency translation (losses) gains (2,577) 1,026
Total other comprehensive (loss) income (2,577) 1,026
Comprehensive income (loss) $ 542 $ (3,568)
XML 49 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Inventories
3 Months Ended
Jun. 30, 2012
Inventories

Note 4. Inventories

The components of inventories are as follows (in thousands):

 

     June 30,
2012
     March 31,
2012
 

Raw materials and supplies

   $ 4,390       $ 3,586   

Work-in-progress

     3,946         4,098   

Finished goods

     4,141         3,458   
  

 

 

    

 

 

 
   $ 12,477       $ 11,142   
  

 

 

    

 

 

 

The Company’s inventories relate to its circulatory care product lines, primarily the AB5000, BVS 5000 and Impella product platforms. Finished goods and work-in-process inventories consist of direct material, labor and overhead. During each of the three months ended June 30, 2012 and 2011, the Company recorded $0.3 million and $0.2 million, respectively, in write-downs of inventory.

From time to time, the Company loans finished goods inventory on a short-term basis to customers for demonstration purposes and this inventory is amortized over a one to five-year life. The Company had $0.3 million and $0.4 million in demo inventory at June 30, 2012 and March 31, 2012, respectively.

XML 50 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Inventories - Additional Information (Detail) (USD $)
3 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Mar. 31, 2012
Inventory Disclosure [Line Items]      
Write-down of inventory $ 252,000 $ 156,000  
Demo inventory $ 300,000   $ 400,000
Minimum
     
Inventory Disclosure [Line Items]      
Demo inventory amortization period 1 year    
Maximum
     
Inventory Disclosure [Line Items]      
Demo inventory amortization period 5 years    
XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 49 170 1 false 23 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.abiomed.com/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.abiomed.com/taxonomy/role/StatementOfFinancialPositionClassified CONSOLIDATED BALANCE SHEETS false false R3.htm 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.abiomed.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.abiomed.com/taxonomy/role/StatementOfIncomeAlternative CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 106 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.abiomed.com/taxonomy/role/StatementOfOtherComprehensiveIncome CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) false false R6.htm 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.abiomed.com/taxonomy/role/StatementOfCashFlowsIndirect CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 108 - Disclosure - Nature of Business and Basis of Preparation Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock Nature of Business and Basis of Preparation false false R8.htm 109 - Disclosure - Net Income (Loss) Per Share Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Income (Loss) Per Share false false R9.htm 110 - Disclosure - Fair Value Measurements Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements false false R10.htm 111 - Disclosure - Inventories Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock Inventories false false R11.htm 112 - Disclosure - Goodwill Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsGoodwillDisclosureTextBlock Goodwill false false R12.htm 113 - Disclosure - Accrued Expenses Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherLiabilitiesDisclosureTextBlock Accrued Expenses false false R13.htm 114 - Disclosure - Stock-Based Compensation Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation false false R14.htm 115 - Disclosure - Income Taxes Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R15.htm 116 - Disclosure - Commitments and Contingencies Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R16.htm 117 - Disclosure - Segment and Enterprise Wide Disclosures Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Segment and Enterprise Wide Disclosures false false R17.htm 118 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net Income (Loss) Per Share (Tables) false false R18.htm 119 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) false false R19.htm 120 - Disclosure - Inventories (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables Inventories (Tables) false false R20.htm 121 - Disclosure - Goodwill (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsGoodwillDisclosureTextBlockTables Goodwill (Tables) false false R21.htm 122 - Disclosure - Accrued Expenses (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsAccruedExpensesAndOtherLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) false false R22.htm 123 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.abiomed.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) false false R23.htm 124 - Disclosure - Computation of Basic and Diluted Net Income Loss Per Share (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureComputationOfBasicAndDilutedNetIncomeLossPerShare Computation of Basic and Diluted Net Income Loss Per Share (Detail) false false R24.htm 125 - Disclosure - Net Income or Loss Per Share - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureNetIncomeOrLossPerShareAdditionalInformation Net Income or Loss Per Share - Additional Information (Detail) false false R25.htm 126 - Disclosure - Marketable Securities Investments (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureMarketableSecuritiesInvestments Marketable Securities Investments (Detail) false false R26.htm 127 - Disclosure - Components of Inventories (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureComponentsOfInventories Components of Inventories (Detail) false false R27.htm 128 - Disclosure - Inventories - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureInventoriesAdditionalInformation Inventories - Additional Information (Detail) false false R28.htm 129 - Disclosure - Goodwill - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureGoodwillAdditionalInformation Goodwill - Additional Information (Detail) false false R29.htm 130 - Disclosure - Goodwill Activity (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureGoodwillActivity Goodwill Activity (Detail) false false R30.htm 131 - Disclosure - Accrued Expenses (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses (Detail) false false R31.htm 132 - Disclosure - Stock-Based Compensation Recognized (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureStockBasedCompensationRecognized Stock-Based Compensation Recognized (Detail) false false R32.htm 133 - Disclosure - Components of Stock-Based Compensation (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureComponentsOfStockBasedCompensation Components of Stock-Based Compensation (Detail) false false R33.htm 134 - Disclosure - Summary of Stock Option Activity (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureSummaryOfStockOptionActivity Summary of Stock Option Activity (Detail) false false R34.htm 135 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) false false R35.htm 136 - Disclosure - Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureWeightedAverageAssumptionsUsedToCalculateFairValueOfOptionsGranted Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Detail) false false R36.htm 137 - Disclosure - Summary of Restricted Stock and Restricted Stock Units Activity (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureSummaryOfRestrictedStockAndRestrictedStockUnitsActivity Summary of Restricted Stock and Restricted Stock Units Activity (Detail) false false R37.htm 138 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) false false R38.htm 139 - Disclosure - Segment and Enterprise Wide Disclosures - Additional Information (Detail) Sheet http://www.abiomed.com/taxonomy/role/DisclosureSegmentAndEnterpriseWideDisclosuresAdditionalInformation Segment and Enterprise Wide Disclosures - Additional Information (Detail) false false All Reports Book All Reports Element us-gaap_IncomeTaxExpenseBenefit had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '128 - Disclosure - Inventories - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '135 - Disclosure - Stock-Based Compensation - Additional Information (Detail)' had a mix of different decimal attribute values. 'Shares' elements on report '137 - Disclosure - Summary of Restricted Stock and Restricted Stock Units Activity (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2011' Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Process Flow-Through: 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS abmd-20120630.xml abmd-20120630.xsd abmd-20120630_cal.xml abmd-20120630_def.xml abmd-20120630_lab.xml abmd-20120630_pre.xml true true XML 52 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segment and Enterprise Wide Disclosures - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
3 Months Ended 3 Months Ended
Jun. 30, 2012
Segment
Jun. 30, 2012
UNITED STATES
Mar. 31, 2012
UNITED STATES
Jun. 30, 2012
Europe
Mar. 31, 2012
Europe
Jun. 30, 2012
International
Jun. 30, 2011
International
Segment Reporting Information [Line Items]              
Number of business segments 1            
Percentage of total consolidated assets   70.00% 68.00%        
Goodwill and intangibles       $ 34.7 $ 37.0    
Percentage of total consolidated assets, excluding goodwill and intangibles       7.00% 8.00%    
Percentage of total product revenue           5.00% 7.00%
XML 53 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Goodwill (Tables)
3 Months Ended
Jun. 30, 2012
Goodwill Activity

The goodwill activity for the three months ended June 30, 2012 is as follows (in thousands):

 

Balance at March 31, 2012

   $ 36,846   

Exchange rate impact

     (2,105
  

 

 

 

Balance at June 30, 2012

   $ 34,741